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ABSTRACT
A diastereoselective synthesis of 2,3-methanophenylaIanine methyl ester afforded 
both the (Z)-(2S,3S)-form (253) and (E)-(2S,3R)-form (259), as major diastereomers. 
Each of these were incorporated, in turn, into a dipeptide analogue of CCK-4, (260) 
and (262) respectively. The (E)-dipeptide ester (262) was found to possess an 
excellent binding affinity for the CCK-B receptor site, IC5o= 6.5nM. A 
(Z)-dehydrophenylalanine dipeptide analogue of CCK-4 (219Z) was also prepared.
Conformational studies on the (Z)-dehydrophenylalanine dipeptide ester (219Z), and 
(E)- and (Z)-2,3-methanophenylalanine dipeptide esters (262) and (260), indicated 
the presence of a p-tum in which there was no preference in type. The phenyl and 
indole rings, however, did prefer to be situated on the same side of the p-tum, and 




















CNS central nervous system












EDU - l-(3-dimethylaminopropyl)-3-ethyl urea
E.I. - electron ionisation
Enz - enzyme
Et - ethyl
FAB - Fast Atom Bombardment
Glu - glutamine
Gly - glycine
GMP - guanosine monophosphate
h - hour
IC50 - half maximal inhibition
lie - isoleucine
i-pr - wopropyl
J  - coupling constant
Kj - binding affinity
Leu - leucine




Ms - 2-mesitylenesulfonyl chloride
NBS - N-bromosuccinimide
NMM - N-methyl morpholine
NMR - nuclear magnetic resonance





ppm - parts per million
Pro - proline
Rf - retention factor
RT - room temperature
Ser - serine
t- - tert-
TFA - trifluoroacetic acid
THF - tetrahydrofuran
Thr - threonine








Examples of the nomenclature and numbering system used throughout this thesis 
are illustrated below, designated by an asterix, together with examples of 






e N7 (IS, 3S, 6S)-7 (H)-6-/s<9-propyl-5-methoxy-l-phenyl-4,7-
diazaspiro[2,5]oct-4-en-8-one *
5
'n / = N iMeO 3 i  (IS, 3S, 6S)-7 (H)-4 ,5-dehydro-6-W(9-propyl-5-methoxy-l-
ph phenyl-4,7-diazaspiro[2,5]oct-4-an-8-one
H2N . 2 ^C02Me 2,3-methanophenylalanine methyl ester *








In the case of the dipeptides made, the locants are numbered by treating each 
individual amino acid in turn, thus applying the amino acid numbering 
convention (IUPAC). The residue number, which is obtained by numbering the 
residues from the N-terminus, is placed after the atom number and separated by a 
full stop. For example, in Structure I, the H attached to C-3 of the valine residue 
in 2,3-methanophenylalanine-S-valine methyl ester is defined as 3-H.2, i.e. H on 
C-3 of residue 2.
Structure I
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Over the last twenty years there has been increased interest in the preparation of
2,3-methanoamino acids and their incorporation into various sized peptides for 
conformational and biological purposes. Meanwhile, a peptide mimetic of 
cholecystokinin (CCK), a gut hormonal regulator and neurotransmitter, was still being 
sought, possessing similar binding properties to CCK..
The aim of the project described in this thesis was to establish a diastereoselective 
synthesis of 2,3-methanophenylalanine, and to incorporate each diastereomer into a 
dipeptide analogue of CCK-4. The analogous dehydrophenylalanine dipeptides could 
then be prepared, and their binding affinities compared. These dipeptides would then 
be modelled in an attempt to determine their preferred conformations and thus, as a 
result of binding data, probe the CCK receptor requirements.
1.2 Peptide Conformation
In a peptide it is generally found that each amide bond in the backbone adopts a trans 
configuration [1]. Thus, to a first approximation, only two angles are required to 
define the backbone configuraton of the peptide chain: namely <j), which defines the 
torsional angle about the Na -Ca  bond and y, which defines the angle about the Ca -C 
(carbonyl) bond. The side chain can be characterised by the torsional angle about the 
Ca -Cp bond, X
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Fig. 2 Conformational energy contour map of N-acetyl-Gly-N’-methylamide
3The conformational constraints on the overall configuration of a peptide can thus be usefully 
expressed in terms of configuration (<J>,y) versus potential energy maps. These maps were 
first introduced by Ramachandran in 1963 [2] and are called Ramachandran, or <j>,\j/, maps. 
Figure 2 illustrates the calculated conformational energy versus map for 
N-acetylglycine-N'-methylamide [3].
Both p-tums and y-tums are well known secondary structures in peptides and proteins, and 
cause a reversal of a peptide chain over a sequence of four and three residues, respectively. 
These turns may or may not be stabilised by an intra-turn hydrogen bond. In the case of the 
p-tum it may occur between the carbonyl of residue 1 and the NH of residue 4, whilst in 
y-tums it may occur between the carbonyl of residue 1 and the NH of residue 3. Figure 3 
shows a schematic representation of both a p- and y-tum, with the conformational parameters 
defined.
H2—
Fig.3 A Schematic Representation of (A) a p-Tum , And (B) a y- Turn.
Conformationally, a P-tum is fully defined by the (<}>,y) torsions of the middle two residues: 
Oh. ¥ 2) an<3 (<J>3 > ¥ 3); whereas for the y-tum only the single torsion (4>2, ¥ 2) 1S necessary for 
definition. The formal definitions of types I-III P-tums and their mirror images, and normal 
and inverse y-tums are given in Table 1.
4Table 1 Characteristic torsions of type I-III and T-IIT B-turns T41 and
7  and inverse 7 -tums f5I
Turn 4>, ¥  values in (°) at position 2 and 3
*2 *2 *3 *3
8-tums 
Type I -60 -30 -90 0
Type II -60 + 120 + 80 0
Type III -60 -30 -60 -30
Type I ’ +60 +30 +90 0
Type II’ +60 -120 -80 0




+ 70 to +85 
-70 to -85
-60 to -70 
+60 to +70
It should be noted that type I and III p-tums are very similar; they occupy contiguous 
regions of <j>, \y space and are not distinct types [6]. However, it is convenient to 
distinguish type HI as a separate category since it describes a helical turn - actually 
one loop of a 310 helix - and may form part of a larger repeating structure.
51.3 <x,p-Dehydroamino Acids and Peptides
Definition and Nomenclature
Dehydroamino acids are defined as those a-amino acids containing one or more double 
bonds not involved in an aromatic nucleus such as a benzene or imidazole ring. Most 
these are a,p- or p/y-unsaturated amino acids (1,2 ) that occur naturally and/or have 
some interesting biological activity.
H2N ^ ^ C 0 2H 
a
R
H2N C 0 2H
R
The following is concerned only with the a,p-unsaturated variety. The nomenclature 
used is as follows: a capital delta (A) is prefixed to the three letter symbol for each 
amino acid residue to designate the presence of a double bond in the carbon chain, e.g. 
ALeu = dehydroleucine. Both structural and stereoisomers are possible in 
dehydroamino acids. A superscript a,p,y, etc. is therefore used to designate the first 
carbon atom of the double bond when proceeding from the carboxyl group down the 
chain, e.g. A^Leu indicates a dehydroleucine residue with the double bond between the 
p- and y- carbon atoms. However, in the case of a,p-unsaturated amino acids this 
position designation is unnecessary since only the a-position is available for the double 
bond. Should the unsaturation appear between the Ca  and the amino nitrogen, a 
superscript N will be used e.g., ANAla is an imine, whereas AAla is an enamine.
6The configuration of the unsaturated site can be conveniently designated by a 
superscript E or Z [7] following the position descriptor, e.g. Aa,zLeu = 
(Z)-a-dehydroleucine; AEPhe =(E)-dehydrophenylalanine. In general, the 
(Z)-a-dehydroamino acids will have the larger p-substituents cis to the amino group 
and the (E)-compounds will have that group cis to the carboxyl function.
History
The chemistry of a,p-dehydroamino acids was studied extensively during the 1930’s, 
notably by Bergmann and co-workers [8] and by Greenstein [9]. For a long time after 
that they received little attention, until the early 1960’s when various investigations 
[10-12] reported their synthesis via non-enzymatic p-fragmentation, involving cysteine 
or serine residues in peptides and proteins. During the past decade, numerous 
a,p-dehydropeptides, many of them possessing biological activity, have been isolated 
from natural sources and characterized. This rapid progress was as a result of improved 
isolation techniques and the development of new methods of analysis. Chemical 
synthesis of dehydropeptides has also become possible through the recent development 
of new methods. These peptides have aroused interest among researchers throughout 
the field of peptide chemistry.
Naturally Occurring Dehydroamino Acids and Dipeptides 
Free a,p-unsaturated dehydroamino acids (1) are unknown in nature since they are 
enamines and consequendy might be expected to undergo ready hydrolysis, liberating 
ammonia and the corresponding a-keto acids (3) (Scheme 1).
Scheme 1
It might be expected, also, that 1 will be weakly basic and exist in tautomeric 
equilibrium with the imine (4). The weak basicity and low nucleophilicity of 1 may be 
ascribed to resonance stabilization of the system, in which the non-bonded electrons of 
the nitrogen atom are delocalized into the carbon chain. The extent of such 
delocalization will be enhanced when R is aromatic, as in structure C (Scheme 2).
Scheme 2
A B C
Consequently, aromatic dehydroamino acids might be expected to have amino groups 
showing especially low reactivity towards electrophiles, i.e. activated acids used in the 
coupling reaction of peptide synthesis. The dehydro compounds (1) occur in nature 
primarily as N-acyl derivatives or in peptide sequences, and they will be discussed in 
terms of these derivatives.
8The majority of a,p-dehydroamino acids have been found in relatively low molecular 
weight peptides from microbial sources [13-15]. It was postulated that dehydroamino 
acids might be precursors in the biosynthesis of several heterocyclic metabolites e.g. 
penicillin and cephalosporin, which possess a variety of biological activities (Table 2).
The possibility that the tautomeric imine form (4) of 1 might be a key intermediate in 
the biosynthesis of D-amino acids from the L-isomers was also, discussed [13-15]. More 
recently this subject has been reviewed and it was concluded that further evidence is 
required before it can be claimed that dehydroamino acids are necessary intermediates 
in the biosynthesis of either the heterocyclic metabolites or D-amino acids[16,17].
Probably the best known natural occurrence of dehydroalanine and dehydrobutyrine are 
seen in the microbial metabolites nisin, subtilin, cinnamycin and duramycin [18,19]. 
The first two peptides, nisin and subtilin, contain the two dehydroamino acids 
mentioned, along with "masked" dehydro-compounds in the form of lanthionine (5) and 
(3-methyllanthionine (6). The last two peptides, cinnamycin and duramycin, contain 
only 5 and 6 .
9Table 2 Natural peptides containing a.ff-dehvdroamino acids*
Peptide N°. of 
amino











l APro deriv. Antibacterial 142
Primocarcin l AAla deriv. Antitumour 143 144
Thienamycin l APro deriv. Antibacterial 145
Piperazin-2.5-dione
Albonoursin 2 ALeu, APhe Antitumour 146 147
Isoechinulin A 2 ATrp deriv. Growth
inhibitor
33
Isoechinulin B and C 2 AAla, ATrp deriv. 33
Neochinulin 2 ATrp deriv. 26
Neochinulin A,D and E 2 ATrp deriv. 27, 31, 
32
156
Neochinulin B and C 2 AAla, ATrp deriv. 29, 30
Oligopeptides
Celenamides A and B 3 APhe deriv. Alkaloid 46
Cephalosporin C 3 AVal deriv. Antibacterial 148 149
AM-Toxin I 4 AAla Toxic 150 151
Tentoxin 4 AMePhe Toxic 152 120
Lavendomycin 6 AAbu Antibacterial 41
Cirratiomycin 7 Alle 39
Antrimycin 7 Alle Antibacterial 36
Polypeptides
Stendomycin 14 AAbu Antibacterial 153
Subtilin 32 2AAla, AAbu Antibacterial 154
Nisin 34 2AAla, AAbu Antibacterial 155
L-Histidine ammonia 
Lyase
> 100 AAla deriv. Enzyme 22
L-Phenylalanine 
ammonia Lyase
> 1 0 0 AAla deriv. Enzyme 21
1 AAbu, o,jS-dehydro-ot-aminobutyric acid; AAla, a,/3-dehydroalanine; Alle, c*,/?-dehydroisoleucine; ALeu, 
a,/?-dehydroleucine; AMePhe, a,/?-dehydro-N-methyl-phenylalanine; APhe, a,-dehydrophenylalanine, 
APro, a,j£?-dehydroproline; AVal, a,/?-dehydrovaline; ATrp, a,/?-dehydrotryptophan.
10
The formation of these compounds can be envisioned by an addition of the thiol group 
of cysteine to the electrophilic p-carbon atom of dehydroalanine or dehydrobutyrine. A 
third masked dehydroalanine appeared as lysinoalanine (7) in which the e-amino group 
of lysine has apparendy added similarly to the p-carbon of the unsaturated amino acid. 
The former mode leads to the complex amino acids and rings appearing in the 
metabolites discussed; whilst the latter mode gives a cross-linked system that may be 
responsible for various physical and chemical changes occurring during the heating or 
ageing of proteins [20].
Both of the enzymes phenylalanine ammonia lyase [21] and histidine ammonia lyase 
[22,23] have been shown to contain reducible electrophilic centres that appear to be at 
the active site. These are thought to contain dehydroalanine residues. In both cases the 
electrophilicity of the dehydroalanine P-carbon atom is thought to be enhanced by the 
existence of this residue as a Schiff base (8) in the enzyme, causing the amino group of 
the substrate to add rapidly to this site (Scheme 3).
Scheme 3 
H
2O C ^  ^ N :
H








Once the amino acid is covalently bound to the enzyme, elimination of ammonia occurs 
to give the unsaturated product (9). Thus, the presence of a dehydroamino acid residue 
incorporates an electrophilic site into the system and leads to the Michael addition of a 
nucleophile to the unsaturated system. It is well known that a-acylamino acrylic acids 
react rapidly with thiols and amines [24] and may serve as traps for these functional 
groups in natural systems.
The presence of a,p-unsaturated acids is, however, not necessarily restricted to peptides 
of microbial origin. Dehydroalanine, for instance, has been identified in histidine 
ammonia lyase of both bacterial [22,23] and mammalian [25] origin and also in 
phenylalanine lyase from a plant source [21].
Structure and activity o f afi-dehydropeptides
The discovery of a variety of biological activities has facilitated the isolation and 
characterisation of a,p-dehydropeptides from various sources. Some of these that are 
of particular interest because of their potential pharmacological and physiological 
usefulness are described here.
(a)Neoechinulins.- Neoechinulin is a microbial metabolite which has been isolated 
from Aspergillus amstelodami and identified as a cyclic compound (10a) containing a 
dehydrotryptophan (ATrp) unit with isoprenyl groups on the indole ring [26]. A number 
of analagous piperazindiones such as neoechinulin A (10b) [27,28], B (10c), C (lOd) 
[29,30], D (lOe) [31] and E (lOf) [32], have been isolated and characterized in recent 
years. Nagasawa et al [33], in 1976, also reported the isolation of isoechinulin A (lOg), 
B (lOh), and C (lOi), in which the isoprenyl group is linked to the indole ring at 





Neoechinulin (10a) H ) = V _ O
Neoechinulin A (10b) H H h ,c h 3
Neoechinulin B (10c) H
\ H
c h 2
Neoechinulin C (lOd) H ) = \ _ c h 2
Neoechinulin D (lOe) H
)= V _ 0
Neoechinulin E (lOf) H H o
Isoechinulin A (lOg)
) = \ _
H h ,c h 3
Isoechinulin B (lOh) )= V _ H c h 2
Isoechinulin C (lOi) / W - H c h 2
The geometry of the a,p-double bond of ATrp was determined to be of (Z)-type (i.e. the 
indole ring is cis to the amide nitrogen) by ^-N M R  study [26] and 13C-NMR studies 
[34].
(b)Antrimycins, cirratiomycins and lavendomycin.- These are all fungal metabolites. 
The antrimycins (11) and cirratiomycins (12) are closely related and have been isolated 
from Streptomyces xanthocidicus [35-37] and Streptomyces cirratus [38-40]
respectively. Their structures have been elucidated and have been found to be similar. 
These tuberculostatic peptides contain several non-ribosomal amino acids including the 









11 R*= CH3, C2H5, n-C3H7, 1-C4H9,
r 2= c h 3, c ^ ,
12 R '=C H 3, i-C4H<,









L a v e n d o m y c in  (13)
Lavendomycin (13) is also a fungal metabolite and was obtained from the culture 
filtrates of Streptomyces lavendulae [41]. It is active against gram-positive bacteria in 
vivo and in vitro while having an extremely low toxicity (LD5o>2g/kg). This antibiotic
14
contains various unusual amino acids, namely dehydroaminobutyric acid(AAbu), 
a-aminocrotonic acid and the strongly basic 5-guanidinoisoleucine.
(c)Tunichrome B-l and celenamides (A-D).- These two compounds are examples of 
marine metabolites. Tunichrome B-l (14) is a yellow blood pigment isolated from the 
tunicate Ascidia nigra [42-44]. It is an extraordinarily oxygen sensitive compound 
which is thought to effect the ability of the tunicate to bind vanadium (III) or vanadium 
(IV) at physiological pH. Its structure is derived from three 
(3,4,5-trihydroxyphenyl)-alanine units and its reductive properties are thought due to 
the presence of the pyrogallol moiety [45].
The celenamides A-D were isolated in the form of their peracetyl derivatives from the 
sponge cliona celata and their structures have been elucidated [46,47]. The compounds 
are closely related to cyclopeptide alkaloids of plant origin and belong to the "linear 





a styrylamine moiety, a 6-bromotryptophan unit; whereas peracetylcelenamide D 









15 i-C4H9 Ac OAc
16 /-C3H7 Ac OAc
17 /-C4H9 Ac H
The total synthesis of hexaacetylcelenamide A (15) has been reported [48,49]. The key 
step in this synthesis is the condensation of the triacetoxybenzaldehyde with the 
phosphoryltripeptide (18) to give the dehydropeptide (19). The (Z)-isomer was 
separated from the E/Z mixture and taken on to the desired product (15) via a 




Synthesis o f a fi-Dehydroamino Acid and Derivatives 
Use o f oxazolones.-a,p-Dehydroamino acids are labile substances prone to 
isomerisation and hydrolysis. As a consequence, they are generally prepared as their 
N-acyl derivatives and sometimes as carboxylic esters or amides. The earliest work 
leading to the synthesis of dehydroamino acid derivatives came from the discovery by 
Erlenmeyer that aldehydes and ketones condense with oxazolones(20)(old name 


















Reagents : (a) H+ , H20  ; (b) i) H2 /  c a t., ii) H20
Originally, the oxazolones (21) were hydrogenated to remove the double bond and the 
ring was opened hydrolytically to give the amino acid (22). This constituted a new 
synthesis of amino acids. If, however, 21 was carefully hydrolysed using either acidic 
or basic catalysis, a dehydroamino acid derivative (23) could be obtained (Scheme 6 ).
18
This method has been used extensively over the years. The Erlenmeyer condensation 
gives the best results when aromatic aldehydes are used; ketones and aliphatic 
aldehydes generally give poor yields of the unsaturated oxazolone. The N-acyl 
dehydroamino acid (23) can be coupled with other amino acids and peptides to form 
N-terminal dehydropeptides, but attempted hydrolytic deacylation yields the 
corresponding a-keto acid (24) and the amide (25). Thus 23 cannot be used to extend a 






Reagents : (a) H+ , H20
A second synthesis of oxazolones of the type 21 was reported by Bergmann [8,51], in 
which a phenylserine derivative (26) was oxazolonized in acetic anhydride to give 21 





In this case, the amino acid is already oxidised at the p position and elimination of the 
hydroxyl function, as the acetate, generated the double bond. If R in 26 corresponds to
19
an amino acid moiety, then 21 is a dipeptide oxazolone and can be used to synthesize 
dehydropeptides. This approach was used by Stoll et al [52]. In 1926 Bergmann [53] 
reported that halooxazolones of the type 27 undergo spontaneous dehydrohalogenation 
giving a "pseudo oxazolone" (28) that equilibrates with its tautomer (29) (Scheme 9).
Scheme 9
FT— ^  x  CHR’
X
ui-im
— _ < KR
H




Stammer, more recently, showed [54] that when a dibromooxazolone (30) is taken, 
instead of 27, a double dehydrohalogenation results giving an oxazolone (31) that has 
the desired double bond in the 4 position (Scheme 10).
Scheme 10
Oxazolones of the type 31 are, as in the case of 21, only useful in the preparation of 
N-terminal dehydropeptides. The aromatic dehydroamino acid derivatives prepared by 
this, or by any of the other methods discussed, all have the (Z)-configuration.
2 0
By the early 1960’s few dehydropeptides containing other dehydroamino acids had 
been prepared because of the instability of oxazolones with alkyl substituents. Since 
then, however, there has been a revival of interest in the synthesis of dehydroamino 
acids owing to the recent discovery of many natural products containing these 
unsaturated residues. As a consequence of this, more facile and effective methods of 
preparation have been developed.
p-Elimination reactions.- The elimination of water from both a- and 
p-hydroxy-a-amino acid derivatives is an important method for the preparation of 
dehydroamino acids and peptides. In the case of the a-hydroxy-a-amino derivatives 
(32) a wide variety of amino acids are accessible via the condensation of an a-keto acid 
(24) with an amide (Scheme 11).
Scheme 11
















Reagents : (a) PhCH2OCONH2 ,p  - TsOH
2 1
When benzyl carbamate was used as an amide component for the a-keto acid (33), the 
elimination of water was facilitated via the addition of a catalytic amount of 
p -toluenesulphonic acid to generate dehydroleucine having (Z)-stereochemistry [55] 
(Scheme 12).
Use of the dehydrating agents e.g. disuccinimido carbonate (DSC) [56,57], 
N,N-carbonyldiimidazole [58] or a base and acetic anhydride [59], has been 
recommended for the dehydration of natural p-hydroxy-a-amino acids, serine, 
threonine and phenylserine [60]. In the case of phenylserine it was found that the threo 
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34













(Z) - isomer 
where R= Ts , Z= CBZ
Lee et al [61] have similarly confirmed these stereochemical results with the O-tosyl
2 2
derivatives of threonine. They obtained the (Z)- and (E)- dehydrophenylanine isomers 
from the threo and erythro forms respectively. These eliminations are thought to go via 
a trans E2- type mechanism (Scheme 14).
It should be noted, however, that competitive side reactions such as aziridine formation 
may occur with certain O-tosylthreonine peptides on treatment with base [62]. Also, 
isourea-mediated p-elimination methods of threonine peptides [63] involving 
carbodiimide and copper(I)chloride catalysis have yielded a mixture of (Z)- and 
(E)-isomers in a 2:3 ratio.
Dehydration of the p-hydroxy-a-amino acid can also be accomplished by use of the 
Mitsonubu reagent, but the structure and reaction conditions are crucial in determining 
whether a dehydroamino acid or a aziridine results [64]. In the preparation of a 
dehydroalanine unit one of the simplest methods is the conversion of a cysteine moiety 
(35) to the S,S-dimethylsulfonium salt (36) with methyl iodide and subsequent 





RNH COR’ RNH COR’
35 36
37
Reagents : (a) M el, base.
Eliminations from the corresponding selenium derivatives of 36 [68,69] and 
S-phosphinothionylcysteines have also been suggested [70]. Similarly, Nomoto et al 
[71] reported the direct preparation of AAla residue from a a,|3-diaminopropionic acid 
residue, mediated by a Hofmann rearrangement, utilizing methyl iodide and potassium 
bicarbonate. Thiol elimination (S-benzyl) has also been achieved [72] on the attempted 
release of a C-terminal Cys peptide from the bound resin, with hydrofluoric acid, 
resulting in the formation of a AAla peptide (38) (Scheme 16).
Scheme 16
Reagents : (a) HF, 25°C .
The cleavage of water from N-hydroxylamino acids [73] proceeds almost quantitatively 
[74] and is to be recommended when the appropriate substrates are readily available.
N-Chlorination and dehydrochlorination.- The N-chlorination of amino acid esters and 
N-acylamino acid esters with f-butylhypochlorite and subsequent elimination of 
hydrogen chloride has been reported [75-77]. Initially a mixture of the imine (40) and 
the enamine (41) is obtained from the amino acid ester (39). Treatment of this mixture 
with hydrogen chloride in ether gives rise to the enamine hydrochloride.
The N-chloroamide (42), initially formed from the acyl amino acid ester, reacts 
depending on the solvent and base used, to give either the a-acylamino- 
a-alkoxycarboxylate (43) or the acylimino compound (44). Treatment of the former 







N-acyldehydroamino acid derivative (45). This reaction sequence has been employed 
frequently in the last few years [78-82] and can also be performed with peptides [79] 
(Scheme 17, see page 25).
An alternative preparation of the imine (46) was reported by Shin et al [55] who 
condensed an a-keto ester with triphenyl phosphine imine. The imine (46) was 
converted to the dehydroamino ester derivative (47) via subsequent acylation with 






Reagents : (a) Ph3P=NH ; (b) ClCI^COCl
CICH2C O N H ^ C 02Et 
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From azido compounds and aziridines.- a-Azidoacrylates (49) are easily accessible 
from bromocarboxylates (48) through treatment with sodium azide [83] (Scheme 19).
Scheme 19
R Br





Reagents : (a) NaN3 , DMF
In the presence of phosphites or phosphinites, phosphinimines (50) are formed, which 
rearrange to give the (Z)-phosphoric amides or -phosphinic amides respectively, of the 












Reagents : (a) i) t - BuOCl, ii) DBU ; (b) HC1 
Table 5
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R 1 R2 Yield (%)
42A c h 3 c h 3 80
B H i - C3H7 63
C c h 3 c 2h 5 75
R2 R2
C 02Me a










Reagents : (a) CH3ONa; (b) Et3N; (c) HC1; (d) DBU
Tab e 6
R1 R2 Yield(%)
45A c h 3 c h 3 70
B H * ■ c 3h 7 65








N3 C 02Et 
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where X= O, N
Reagents : (a) P(XR)3 , benzene
Various thiols and alcohols undergo addition to a-azidoacrylates in alkaline solution. 
The (3-phenylthio- and p-alkoxy-a-azidocarboxylates formed are not isolated, but 
undergo cleavage of nitrogen under the action of alkoxides, to give the corresponding 
p-substituted dehydroamino acid (52) [85] (Scheme 21).
Scheme 21
M ™  u  h 2n ^  ^ C 0 2Me3 .^ ^ C 0 2Me 2 2
T  ---------------------------- Y
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where Y= PhS , EtO
Reagents : (a) i) Y -H ; ii) NaOEt
It has been found that in the presence of tertiary amines, (Z)-Phe-Azy-OBzl dipeptides 









Reagents : (a) Et3N , CH2Cl2 
This reaction has been applied to peptides containing aziridinecarboxylic acids [87] and
catalyst [88].
From phosphorylglycine e s te r s N-acyldialkoxyphosphorylglycine esters (55) have 
been previously used in the synthesis of dehydroamino acid esters [89-90]. The glycine 
esters (55) can be prepared via the treatment of acylaminobromoacetates with 
phosphites [91] (Scheme 23).
Scheme 23
Reagents: (a) P(OMe)3
The dehydroamino acid esters are afforded via the condensation of 
N-acyldialkoxyphosphorylglycine esters (55) with aldehydes in the presence of base. If 
potassium r-butoxide is used as base, dehydroamino acid esters, having 
(Z)-stereochemistry, are preferentially formed (Scheme 24).












Dimethoxyphosphoryl glycine can also be incorporated into peptides without difficulty. 
The condensation of the dimethoxyphosphoryl peptide with aldehydes leads directly to 
dehydropeptides [91].
From glycine derivatives.-Aromatic and heterocyclic aldehydes have been condensed 
with trimethylsilyl(trifluroacetyl)amino ketene methyl trimethylsilyl acetal (56) to 
furnish 2-trifluroacetyl amino-3-trimethylsiloxycarboxylates (57). These were 
subsequently converted to the (Z)-dehydroamino acid esters (58) in 60-85% overall 










R 57 : Yield (%) 58 : Yield (%)
3,4-(CH30 )2C6H5 82 93








The synthesis of N-acyl-dehydroamino acid esters via the condensation of acetals with 
nitroacetates in acetic anhydride was reported by Kochetkov in 1982 [94]. Initially the 
p-alkoxy-a-nitroacetates were formed, then subsequent reduction and acylation, 
followed by dehydration, yielded the desired compound (59) (Scheme 26).
Scheme 26
From modified oxazolones.- Previous work [95] has shown that amino acids could be 
converted to pseudo-oxazolones (60) with trifluroacetic anhydride, and that these could





Reagents : (a) Ac20  ; (b) raney nickel; (c) NaOMe, MeOH
be readily brominated in the p-position to afford 61. It has since been found that these
60 61 62
Both aliphatic (Abu, Ala, Val, Leu, lie) and aromatic (Phe) amino acids readily formed 
the unsaturated oxazolone (62) with (Z)-configurations favoured. These compounds
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were found to be very reactive towards nucleophiles giving the acyl derivative (63) in 
good yield. The anilide (64) could readily be deblocked by ammonia to give the free 
dehydrophenylalanine anilide (65). Unfortunately the amino group in (65) was too 








Ph— 2 '' CONHPh
R
^  \  HR .  H
where X=Nu
63 64 65
More recently it has been shown [98,99] that the N-phthaloylglyclphenylalanine 
oxazolone, a dipeptide oxazolone, could be directly oxidised using 
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) to give the unsaturated oxazolone (67, 
R1 = H, R = Phth). This reaction was extended to include several N-terminal amino 
acids (Leu, Phe, Gly) and C-terminal amino acids (Phe,Tyr, Trp). Hence the difficult 
step of the coupling of the enamine nitrogen has been avoided in synthesising 
dehydrooligopeptides (68).
CONHCHCOoEt
The Erlenmeyer synthesis has recently been performed upon C-terminal glycine 
peptides via the condensation with aromatic aldehydes.
The (Z)-dehydrooxazolones formed (69), have been cleaved with amino acid salts to 
give rise to tripeptides possessing a central dehydroamino acid. Tri- and tetrapeptides, 
even with two dehydrophenylalanine units, have been synthesized [100-106]. The 
disadvantage of the Erlenmeyer synthesis is that drastic conditions are usually required.
From piperazin-2,5-dione.-PipeTazin-2,5-dione (70) containing glycine residues can be 
condensed with aldehydes at the a-methylene site [107,108]. This approach has been 
adapted by Gallina et al [109] via the advance activation of the a-methylene group by 









Reagents : (a) Ac20  ; (b) RCHO, t - BuOK
Utilizing this procedure for piperazin-2,5-dione containing L-glycine and L-amino 
acids, Kanmera et al [110] prepared a variety of dehydroamino acids (AAbu, AVal, 
APhe, AApp and ATrp).
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It should be noted that many dehydropiperazin-2,5-diones have been found in bacterial 
metabolites. Their preparation and incorporation into various metabolites has been 
reviewed by Schmidt et al [111].
The isomerisation of(Z) —* (E) alkenes.- The equilibration of (Z)-dehydrooxazolone to 
its (E)-geometrical isomer was generally performed either by the addition of hydrogen 
bromide or phosphoric acid, followed by elimination [112,113], or by 
photoequilibration. For other unsaturated compounds photoequilibration was usually 
employed.
Determination o f (Z)- and (E)- configurations.- When two geometric isomers of the 
a,p-double bond in dehydroamino acids are possible (AAbu, ALeu, APhe, etc.) it is 
important to determine which stereochemistry results: whether Z, E or Z/E mixed 
configuration. Such a structural examination can be made directly by X-ray analysis or 
by 1H- and 13C-NMR spectroscopy. The following empirical regularities have been 
developed in recent years:-
(a) A difference in the chemical shift (AS) of the (1-vinyl and amide protons [114] 
and the p-alkyl proton [115,116]. The (E)-isomer appears 0.2 - 0.7 ppm 
downfield from the (Z)-isomer.
(b) A change in the chemical shift (A8) of the vinyl proton when measured in 
CDC13 and trifluroacetic acid (TFA) [115]: (Z)-isomer A8 = 0.34 - 0.54 ppm 
downfield shift; (E)-isomer, AS = 0.18 - 0.32 ppm upfield shift.
(c) A comparison of the chemical shifts of the vinyl proton before and after 
N-methylation [115,117]; (Z)-isomer, almost no change; (E)-isomer, 0.7 - 0.9 
ppm upfield shift.
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(d) A difference in the vicinal coupling constant (Jch) between the carbonyl carbon 
and the vinyl proton in the coupled nuclear Overhauser enhanced (n.O.e.) 
13C-NMR spectrum [118]: (Z)-isomer, J « 5 Hz; (E)-isomer, J * 10 Hz.
(e) A differential nuclear Overhauser effect between the vinyl and amide protons 
[119]: (Z)-isomer, n.O,e.= 0%; (E)-isomer, n.0.e.= 26-37%.
Rich and Mathiaparanam [120], in 1974, reported the U.V. absorption peak of the APhe 
peptides in assigning the (Z)-configuration (e = 18,400 at X= 276 nm) and the 
(E)-configuration (e = 9080 at X= 282 nm). Such a difference in the intensity of the 
peak was not observed for the isomers of N-blocked APhe-OH and its esters [121,122]. 
Since spectroscopic pictures are often sensitive to local factors around the a,P~double 
bond, the use of general combined measurements is recommended for structural 
examinations.
Coupling Reactions o f a$-Dehydroamino Acid Derivatives 
When a,p-dehydroamino acid esters are used as the amine component in peptide 
couplings, the coupling tends to be low yielding. This is because the amine group of an 
enamino function is less nucleophilic than a normal amine, owing to it being in 
equilibrium with its tautomeric imino form. Even though such coupling methods as 
those involving an acid chloride [55,123] or mixed anhydrides [124] have been used in 
the acylation of enamino acid esters. Shin et al [125] has shown that the 
decyclohexylcarbodiimide (DCC) coupling of the dipeptides (Z)-Ser-OH and 
(Z)-Thr-OH with several a,p-dehydroamino acid esters gave only a 20-50% yield of the 
desired dipeptides. The water soluble carbodiimide (EDC)/HOBt, however, was found 
to be an effective method for the coupling of BOC-Phe-OH and H-ALeu-OBzl in 50% 
yield. [126,127].
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When N-blocked a,p-dehydroamino acids are used as acid components, the usual 
coupling procedures are applicable, for example, mixed anhydride [76,99],
N-carboxyanhydride (NCA) [128] or DCC [125] methods.
Peptides Containing a,$-Dehydroamino Acids
Over the years there has been increased interest in the synthesis of natural 
dehydropeptides and also of unsaturated analogues of peptide hormones.
Various natural products have been synthesised including the phytotoxic metabolite 
Tentoxin, achieved by Rich and co-workers [120,129,130], which causes chlorosis in 
germinating seedlings of many flowering plants [131]. It is a cyclotetrapeptide 
containing a single (Z)-N-methyldehydrophenylalanine unit.
A considerable number of these natural products are biologically active and most of 
them possess antibiotic properties. The presence of these dehydroamino acids within 
peptides is thought to be as intermediates in the interchange of natural L-amino acids 
into their D-enantiomeric form, since these D-isomers cannot be incorporated directly 
into the peptide chain [132]. This explains why a great number of microbial peptides 
having antibiotic activity contain both a,p-unsaturated and D-amino acid residues. 
Incorporation of a dehydroamino acid unit into the peptide decreases its conformational 
flexibility and has been found to have a stabilising influence upon a type II p-tum 
(Found <}> * 60°, « 0°; typical value <}> = 80°, \jj = 0°) [133,134]. This phenomenon has
been used in analogues of biologically active peptides to reduce their enzymatic 
degradation [135]. It has recently been found [136] that if a peptide possesses two 
dehydrophenylalanine moieties adjacent to each other as in N-Ac-APhe-APhe-Gly then 
a p-pleated sheet structure results. Whereas, if they are separated by either a glycine 
or the more hindered valine residue, as in Boc-Ala-APhe-Gly-APhe-Gly-OMe and 
Ac-APhe-L-Val-APhe-NHMe respectively, then a 310 helix is formed (Found <J> = -58°,
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\jr = -23°; typical value <{> = -60°, = -30°) [137].
Peptide mimetic studies have led to the synthesis of various biologically active 
peptides, in which an a-amino acid residue has been replaced by its unsaturated 
equivalent. In 1981, Fischer et al [138] synthesized the unsaturated analogues of the 
vasodilator peptide hormone bradykinin (Bk) (72). (APhe5)Bk showed a high biological 
activity in its blood pressure-lowering effects, being 23-fold more potent than Bk.
H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH
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Enkephalin (73), which is found in the brain as an opiate-like neuropeptide, has been 
synthesized in a derivatised form by English and Stammer [139]. They reported the 
synthesis of a highly potent (D-Ala2, APhe4, Met5)-enkephalin amide which was 5-fold 
more potent than the saturated analogue.
H-Tyr-Gly-Gly-Phe-Leu(or Met)-OH 
73
Also, a series of unsaturated (D-Ala2, Leu5)-enkephalin analogues (AAla2)-, (D-Ala2, 
AAla3)-, (D-Ala2, APhe4)- and (D-Ala2, ALeu5)-enkephalins were prepared. These 
analogues exhibited almost the full receptor activity [140]. It has been shown that for 
(APhe4)- and (ALeu5)-enkephalins the 5-enkephalin receptor selectivity has remained 
unchanged. Furthermore it has been suggested that the phenyl ring of APhe4, oriented 
in the (Z)-configuration, is important for the interaction with the 8-receptors [141].
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1.4 2,3-Methanoamino Acids and Peptides
Definition and Nomenclature
The nomenclature of the title compounds will be named and treated as modified amino 
acids. The carboxyl carbon atom is given the number one (1) rather than the quaternary 
ring carbon atom which is Ca  in the common nomenclature system. The individual 
amino acids will be referred to as 2 ,3-methano- or 3,4-methanoamino acids, depending 
upon the position of the cyclopropane ring on the amino and carbon chain. Here only 
the 2,3-methanoamino acid will be discussed.
The symbol Vz or VE prefixed to the abbreviation for an amino acid residue, as in 
VzPhe, means the (Z)-diastereomer of 2,3-methano- or cyclopropane-phenylalanine. It 
is used here only when the methanoamino acid appears in a peptide chain. The Az 
symbol indicates a dehydroamino acid as in AzPhe, meaning (Z)-2,3-dehydro- 
phenylalanine. The only exceptional case to this terminology will be the simplest 
cyclopropane amino acid, 1-aminocyclopropane-l-carboxylic acid (ACC) which might 
be called 2,3-methanoalanine, but is well known in the literature as ACC.
Z- isomer E- isomer
Except for the 2,3-methano analogues of proline and valine, each protein amino acid 
cyclopropane analogue exists in diastereomeric (E)- and (Z)- forms in which the 
characteristic functionality at the p-carbon atom of the specific amino acid is cis to the 
carboxyl or to the amino function respectively, Of course each of these diastereomers
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consists of an enantiomeric pair, as does 2,3-methanoproline and valine.
Naturally Occurring 2,3-Methanoamino Acids
(&)1 -Aminocyclopropane-1 -carboxylic acids.- 1-Aminocyclopropane-l-carboxylic acid 
(ACC) was first isolated in 1957 from ripe cider apples and perry pears by Burroughs 
[157] and from ripe cowberries by Vahatalo and Virtanen [158]. It was later found to 
be the key intermediate in the biosynthesis of ethylene from methionine [159] in plants. 
Subsequently it has been of considerable interest to both plant biologists and chemists 
alike.
There have been many different approaches to the synthesis of ACC. One of the 
earliest and most straightforward procedures involves the alkylation of a glycine 






74A , R= C 0 2R’ 75
B , R= NC 




Reagents : (a) BrCH2CH2B r, base
The first synthesis, by Ingold [160], started with the diester (74A, R'=Et), followed by 
the conversion of one ester function into an amino group. This was achieved by base
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rearrangement of the bis-N-bromoamide into a spirohydantoin which was hydrolysed to 
give the free amino acid (76). This method has been repeated by others [161-163]. The 
more elegant use of the isonitrile (74B) prepared from N-formylglycine ester, obviates 
the need for the amide rearrangement, since simple hydrolysis of the isonitrile affords 
the amino group directly [164]. This approach was used to prepare specific ring 
deuterated ACC isomers for use in biological studies [165,166]. The process is 
simplified even further by the use of the benzophenone Schiff base (74C, R"=Ph) [167] 
and its conversion into 76 is accomplished by phase-transfer catalysed cycloalkylation, 
followed by hydrolysis [168]. The synthesis of 2-methyl-ACC and various deuterated 
isomers was achieved on the starting material (74A, R'-t-butyl) for use in enzyme 
studies [169-170]. A second synthetic approach to 76 is the "diazo addition" method in 
which diazomethane is added to an a-substituted acrylic acid derivative (77A, R"=H) 
forming a pyrazoline (78A, R"=H) which can be converted into the desired 




c o 2r *
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77A , Y= NHCOR’









This method was first carried out by Bregovec and Jakovac [171], with R=R'=Me, 
who applied thermolysis conditions to convert the pyrazoline (78A, R"=H) into the 
cyclopropane (79A, R"=H). Alkyl and aryl substituted diazomethane give 
5-substituted pyrazolines and, subsequently, 2-substituted-ACC derivatives [172]. It 
has been found that the final removal of the N-acyl group by vigorous acidic
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hydrolysis, or hydrogenolysis in the case of the benzyloxycarbonyl blocking group, has 
been successful only when the 2-substituent is hydrogen or alkyl [173-174]. Although, 
when Y is an azido group (77B), the final step requires the reduction of the azido 
function [175] and is reported to be successful when R"=H, Me, Et and Ph.
A third type of ACC synthesis proceeds through the intramolecular cyclisation of a 





80A , X= B r , R= NHCOR’ ’
B , X =N +(CH3)3 ,R= NHCOR”
C , X =S+(CH3)2 ,R =  NHCOR”
Reagents: (a) base
Use of a strong base on 80A, R"=OBzl gave the cyclopropane (81A R"=OBzl) which 
was converted to 76 by hydrolysis [176-178]. Since the y-carboxyl group of glutamic 
acid can be converted into a leaving group, glutamic acid can serve as the ultimate 
starting material for ACC [179]. The quaternary ammonium function [180] of 80B and 
the dimethylsulfonium group [181] of 80C can also replace the bromide as a leaving 
group in this cyclisation, giving good yields of various cyclopropane intermediates 
(81). Similarly, the cyclisation of y-chloro-a-aminobutyronitrile with base gave ACC 
after hydrolysis [182].
ACC can also be prepared via the nitration of the a-carbanion formed from 





the intermediate nitro compound [183]. Interestingly, the intermediate nitro ester, 
having geminal electron accepting groups on the ring, is quite susceptible to ring 
opening by various nucleophiles [184], with the formation of y-substituted a-nitro acids 
convertible into special amino acids. It has been recently demonstrated [185] that 
cyclopropanone acetals undergo conversion to 1,1-aminocyanocyclopropanes via the 
Strecker synthesis [186]. The subsequent hydrolysis and hydrogenolysis of which 
afforded ACC in good yield.
Optically active 2,2-dideutero-ACC were prepared via alkylation of the chiral 
intermediate, (R)-(-)-2,5-dimethoxy-3-benzyl-3-methyl-3,6-dihydropyrazine, used 
previously for the asymmetric synthesis of a-amino acids [187,188]. Their absolute 
configurations were determined via NMR studies [189-191].
The stereochemistry of the enzymatic decomposition of ACC to ethylene and its 
synthesis from S-adenosylmethionine (SAM) in plants has been studied in considerable 
detail. An early paper [192] showed that postclimateric apple slices and mungbean 
hypocotyls converted the (1R, 2S)-2-ethyl-ACC into but-l-ene 50-200 fold faster than 
they decomposed the other three stereoisomers of 2-ethyl-ACC. Further work with 
[1-14C] ACC led to the conclusion that, in mungbeans [193], the carboxyl group 
yielded carbon dioxide and the quaternary carbon (Ca ) was released as hydrogen 
cyanide: work with 1-azidocyclopropanecarboxylic acid and 13C and 2H labelled ACC 
led to the same conclusion [194-196]. A detailed mechanism [197] has been proposed 
and the reaction pathway has been subjected to semi-empirical molecular orbital 
calculations [198], which support the formation of radical intermediates. Surprisingly, 
it was found that enzymatic decomposition of stereospecifically deuterated ACC 
derivatives occurred non-stereospecifically; whilst chemical decomposition, using 
sodium hypochlorite, took place with reproducible retention of configuration [169,199]. 
These stereochemical results can be explained by involving cation radical and nitrene
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intermediates in the enzymatic and chemical decompositions respectively [200]. In 
these studies the required deutero compounds were prepared by alkylation of a glycine 
Schiff base with meso- and racemic dideuterodibromoethylenes; whilst the 2-methyl- 
and 2-ethyl-ACCs were also prepared [170] by condensing meso- and racemic
1.2-dibromopropanes with di-r-butyl malonate as described in Scheme 29. The racemic 
amino acid esters were then resolved and their absolute configurations determined 
[201].
The deamination of ACC by the microorganism Pseudomonas sp., to generate 
a-ketobutyrate and ammonia, was reported in 1978 [202] and since then mechanistic 
studies of this conversion have appeared [203,204]. The preparation of optically active
2.2-dideutero-ACC, used in these studies [188-191], was achieved separately by two 
unique syntheses. One method uses a benzene ring as precursor of the required 
carboxyl function, and the other proceeding through a chiral epoxide [205].
Studies upon the stereochemistry of the enzymatic formation of ACC from 
S-adenosylmethionine in plants have also appeared [206-208]. The results indicate that 
inversion occurs at the y-carbon atom of the methionine residue with direct 
intramolecular nucleophilic displacement of adenosyl methyl sulfide by a a-carbanion, 
to form the cyclopropane ring. Attempts to find alternate substrates and inhibitors of 
ACC synthetase from tomato plants showed that the enzyme accepts only very specific 
substrates [209]. Whilst in the rat brain ACC has been found to mimic the effects of 
glycine on the NMD A receptor [210].
(b)Coronamic acid (82).- Coronatine (83) is a toxin produced by Pseudomonas 
corona-facience which induces chlorosis in Italian ryegrass. It consists of a coronamic 
acid residue, i.e. (+)-(E)-2-ethyl-1-amino-1-cyclopropanecarboxylic acid, which has 
been N-acylated by coronafacic acid [211], a hydrinanonecarboxylic acid.
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The first synthesis by Ichihara et al [212] of 82 (Scheme 31), began with the diester 
(84) prepared by dialkylation of dimethyl malonate with 1,4-dibromo-2-butene, 
followed by hydrogenation of the remaining vinyl group. Aminolysis of the less 
hindered ester function gave the amide (85), which was converted into the urethane
(86) by Hofmann degradation. Hydrolysis of 86  gave racemic 82, which was resolved 
as the brucine salt of the N-formyl derivative and by L-acylase hydrolysis of the 
N-acetyl derivative. Surprisingly, application of the sector rule [213] to this 
cyclopropane amino acid led to the conclusion that the (+)-form, obtained directly from 
the enzymatic hydrolysis, had the unlikely (1R, 2R)-configuration, i.e. unlikely if one 
assumes that the S-configuration of the a-carbon atom of a cyclopropane amino acid 
corresponds to that of a natural L-amino acid. This assignment was later revised [214] 
to the (IS, 2S)-configuration based on enzymatic oxidation experiments and X-ray 
crystallography. Thus indicating that the sector rule may not be applicable in the case 
of cyclopropane amino acids.
A synthesis of the optically active forms of allocoronamic acid was also reported by the 
same research group [215] in which the dimethylsulfoxonium methylide was used to 
cyclopropanate propylidenecyanoacetic acid ester, followed by resolution of the free 
amino acid via the quinine salt. A chiral synthesis of allocoronamic acid has been 
reported [216], but in poor yield. Later, a synthesis of racemic coronamic acid was
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reported [171] via the addition of diazoethane to a dehydroalanine derivative (see 
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Reagents : (a) NH3 , MeOH ; (b) Br2 , NaOH; (c) H20
Norcoronatine, a minor component of the phytotoxic fraction of Pseudomonas syringae 
pw. glycinea has been shown to contain norcoronamic acid, E-(1S, 2S)-2-methyl-l- 
aminocyclopropanecarboxylic acid [219] and a diastereoselective synthesis has been 
recently reported [220]. Studies of the biosynthesis [221], enzymatic deamination 
[222] and the bioactivity of a series of coronatine analogues [223] have also been 
published.
(c)Carnosadine.~ In 1984, the isolation of a new 2,3-methanoamino acid, camosadine
(87) was reported [224] from a red alga, Grateloupia carmosa. This was followed by a 
report of its synthesis, by Wakamiya et al [225] (Scheme 32), which proceeded using 
the 2,3-methanoglutamic acid derivative (88), also synthetised for the first time. 
Conversion of the y-ester function of 88  into an amino group by Hofmann degradation 
of the corresponding amide gave 89, which was coupled with (R)-(+)-oc-methyl
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benzylamine, to give the amides (90), separable into the expected diastereomers. The 
y-amino group was the deprotected, guanidated (3,5-dimethyl-1-nitroguanylpyrazole) 
and deblocked by hydrogenolysis, followed by hydrolysis to give 87. The natural 


















91A , (IS ,2S)
B , (1R , 2R)
Reagents : (a) i )  NHX , MeOH , i i )  Bra . NaOH : (b) i )  ZC1, NaOH . i i )  (+) - PhCH(CH,)NH, 
D C C ,h 6 6 T ; ( c )  i )  H2 /  Pd , i i )  DfiG ; (d) i )  /  Pd , i i )  6M HC1.
Synthetic 2,3-Methanoamino Acids
Mono- and di-substituted ACCs provide a significant challenge to synthetic chemists 
due to the difficulty in controlling the relative and absolute stereochemistry around the 
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(a) Tandem dialkylation of a glycine equivalent with a 1,2-dibromoalkane or a 
similar 1,2-disubstituted electrophile (Eq. 1).
(b) Via Curtius or Hofmann rearrangements of cyclopropane-1,1 -dicarboxylates 
(Eq.2).
(c) Diazoalkane or dimethylsulfoxonium methylide addition to dehydroamino acid
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derivatives, followed by extrusion of N2 gas or elimination of DMSO 
respectively (Eq. 3).
(d) Lewis acid activated ring opening of a substituted epoxide with a lithiated 
glycine equivalent followed by subsequent cyclisation (Eq. 1).
(e) Cyanide addition to a-chloroketimines or base-induced cyclisation of 
p-chloroimines (Eq. 4).
(a.)Via treatment o f a glycine equivalent with a 1 2 -disubstituted electrophile.- In 1973, 
Schollkopf reported [164] the synthesis of ACC via the subsequent treatment of an 
a-isocyanoester (92A) with base and the 1-substituted-1,2-dibromoethane (93, R2=H) 




<  + > - ^
R1 Br Br
93
92A , R = C 0 2R ,R 1=NC 
B , R= C 02R , Rx= C 02R
Reagents : (a) base ; (b) H30 +
The methodology has since been repeated by Pirrung et al [226] who prepared a 
2-cyclopropyl derivative (95A) as a mixture of diastereomers (>7:1). Alternatively, 
Baldwin [227] reported the cyclisation of the ester (92B) to the cyclopropane and then 
selectively hydrolysed the less hindered ester function with base. After acidification, 
the carboxylic acid obtained was activated to the mixed anhydride with ethyl 
chloroformate, treated with sodium azide at 0°C, refluxed in toluene and hydrolysed 





The preparation of allocoronamic acid has been achieved by using epihalohydrins 
[216,228,229] or by other a-substituted epoxides [230]. The glycine equivalent (96) 
has been shown [228] to dialkylate at the aminonitrile function via treatment with 
strong base and epibromohydrin, to produce all four possible cyclopropyl diastereomers 
(97) through cyclisation, two of which predominated (Scheme 34).
Careful chromatography of 97 allowed the separation of approximate equal quantities 
of two pairs of components, each of which contained one major and one minor product, 
in a ratio of approximately 6 :1 for both pairs. It transpired that in the first pair the 
major component had a cw-relative configuration of the nitrile and hydroxymethyl 
substituent, whilst in the second pair the major component had a trans configuration. 
The difference in substituent geometry within each pair was exploited and allowed 
further separation via sequential treatment with aqueous base, acid and thionyl 
chloride/methanol mix to effect esterification. The cyclopropane possessing the cis 
configuration underwent exclusive y-lactone formation to give 98, while those with the 
trans configuration yielded the monocyclic methyl esters (99). Separation of the cis 
and trans derivatives was achieved, once the chiral auxiliary had been removed, by 
hydrogenolysis to give the primary amino compounds(+)-(100) and (-)-(101) 
respectively.
(b)Via Curtius or Hofmann rearrangements o f cyclopropane-1,1 -dicarboxylates.- The 
Curtius and Hofmann rearrangements [231,232] are invaluable procedures for the 
conversion of azides (103) and primary amides (104) through to isonitriles. In the case 
of the Hofmann rearrangement, the isonitrile formed is usually hydrolysed under the 
reaction conditions to afford the primary amine. Whereas the isonitrile can be isolated 
in the Curtius procedure, or subsequently transformed into amines, carbamates, etc. 
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(-) -101 (IS , 2R) 
( and (-) - 1 0 0 )
Reagents : (a) i) LDA , HM PT, 2.1 eq ., TH F, -70° C , 45 m in.., ii) epibromohydrin, THF, -70°C, l h .;
(b) Chromatography (silica, 40:60 EtOAc : hexane ) ;  (c) i) NaOH, A , 20 h , ii) H30 + , pH 2-3 , 
room tem p., iii) SOCl2 , M eOH, A , 3 h ; (d) i) 3 atm. H2 , 10 % Pd /  C , M eOH, 20h , ii) 
Chromatography (silica ,10 : 90 MeOH : EtOAc) ;  (e) HC1, EtOH .
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The initial cyclopropane- 1,1-dicarboxylates (102) can be readily transformed into the 
primary amides or azides via treatment with methanolic ammonia or potassium 
hydroxide/sodium azide, respectively. This takes place through the selective hydrolysis 
of the less hindered ester function (Scheme 35).
Scheme 35
These methods have been frequendy used [212,227,233,234] in the preparation of
2,3-methanoamino acids providing stereochemical retention and good yields of the 
desired products. For example, Ichihara et al [212] used a Hofmann rearrangement in 










c h3o 2c H<
CH30 2HN
Reagents : (a) Br2 , NaOH , MeOH ; (b) H30  +
5 0
Whereas, in the preparation of 2,3-methanotyrosine, Stammer et al [233] have 
transformed the monoester (106), (prepared through selective hydrolysis of 105 with 
potassium hydroxide), to the silyl carbamate (107) via a Curtius rearrangement. This 
involved the treatment of 106 with diphenylphosphazidate (DPPA) with reflux, 
followed by esterification of the resulting isocyanate with 2 -(trimethylsilyl)ethanol, to 






Reagents : (a) aq. KOH ; (b) DPPA , Et3N , PhCH3 ; (c) (CH3)3SiCH2CH2OH , A .
(c)Diazoalkane or dimethylsulfoxonium methylide addition to dehydroamino acids.- 
The substrates used in these methylene insertions fall into five types, namely:-
(i) Oxazolone derivatives
(ii) Dehydroamino acid derivatives
(iii) Piperazin-2,5-dione derivatives





(V ) l,4-Oxazin-2-one derivatives
(\)Oxazolone derivatives.- Oxazolone derivatives of the structure (108) have been 
prepared since the 1930’s.
R
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They are generally prepared by the Erlenmeyer-Ploch reaction [200] via the 
condensation of aldehydes or ketones with oxazolones (old name azlactones) (See 
section 1.3). The stable isomer in all cases has the (Z)-configuration in which the aryl 
group and the carboxyl function have the trans orientation.
Initially the isolation of 2 ,3 -methanoamino acids, as indeed for dehydroamino acids, 
was hampered by the inability to remove the acyl group from the amino function of the 
newly assembled amino acid; as was found by Stammer [235] in the attempted 
preparation of 2,3-methano-3',4'-dihydroxyphenylalanine (109) as a potential 
3',4'-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor.
This was overcome by Stammer [173] in the first synthesis of the (E)- and (Z)- isomers 
of racemic 2,3-methanophenylalanine (113) from the oxazolone (110) via methylation 























Reagents : (a) CH2N2 ; (b) i) MeOH , DM AP, ii) Et30 +BF4*; (c) i) IN HC1, room temp., 
ii) NaOH , iii) AcOH ; (d) H B r.
The instability of the cyclopropane ring to strong acid hydrolysis and to hydrogenolysis 
[235] was circumvented during the synthesis of some twenty-four aromatic 
ring-substituted 3-aryl-2,3-methanoamino acids by the use of the sulfur-containing 
heterocycles, 4-arylidene-2-benzylthio-5(4H)-thiazolones [236], which are cleavable to 
the amino acids by strong aqueous base. A number of these
2,3-methanophenylalanines prepared by this method were shown to be reversible 
time-dependent inhibitors of both DOPA decarboxylase [237] and tyrosine 
aminotransferase [238]. Further work concerning the reaction of diazomethane with 
oxazolones [239-240], thiazolones [241] and (E)- and (Z)-2-acylaminocinnamates 
[242] have been reported.
Reports have been made of the preparation of the cyclopropane analogues of
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(Z)-2,3-methanothyronine, its 3',5'-dibromine derivative [243] and 
(Z)-2,3-methanohistidine [244], through treatment of the corresponding oxazolones 
with diazomethane. These spirooxazolones were reportedly converted into the desired
2.3-methanoamino acids by acid catalysed hydrolysis without apparent decomposition. 
The thyronine derivatives showed little thyroxine-like activity whilst the histidine 
analogue had a weak inhibitory effect on histidine carboxylase.Both
2.3-methanohomoserine (115) and 2,3-methanomethionine (116) were prepared in the 
process of investigating the cyclopropanation of heteromethylidine-oxazolones (117) 
















Reagents : (a) CH2N2 ; (b) HC1, H2Q
The treatment of 117, X=C1, with diazomethane yielded a 1:1 mixture of (E)- and 
(Z)-isomers of the cyclopropanes (118), which in turn were taken through to the (E)- 
and (Z)-diastereomers of 2-chloro-l-aminocyclopropane-carboxylic acid (119 E/Z). 
The bromo derivatives of 117, X=Br, however, gave five compounds upon methylene 
insertion, separable by chromatography, of which the insertion products predominated 
(120 E/Z). These (E)- and (Z)-isomers of 120 were separately converted into the
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methylthio derivatives (121 E/Z) and then hydrolysed to give the diasteromers of 








h o c h :
122 123
Reagents : (a) CH3SNa , CH3OH ; (b) HC1, H20  ; (c) KOAc , H20 ; (d) HC1;
(e) i) PhCOCl, NaOH, ii) HC1.
In order to prove the configurations of these compounds, the presumed (E)-isomer (by 
NMR) of 120 was converted into the lactone (123), prepared also from 
(E)-2,3-methanohomoserine (115). Comparison of this with an independent synthesis 
of 115, verified that it had the (E)-configuration.
(ii)Dehydroamino acid derivatives - The malonate method, first reported in a patent 
[247], has been used for the synthesis of aromatic 2,3-methanoamino acids. This is the 
cyclopropanation of an arylidene malonic acid diester with a dimethylsulfoxonium 
methylide [248], followed by the introduction of the amino group via an azide and 
consequent Curtius rearrangement. This method (Scheme 41) has two advantages: 
firstly, either diastereomer of the target amino acid can be synthesized at will; and 
secondly, diazo compounds are not used. This method is, however, longer than the 
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Ar a  N H C 02R Ar a Q 0 2Et
H C 0 2R' H NHCOoR
127Z 127E
Reagents : (a) (CH3)3S+(0)CH2- ; (b) NaOH, H20  ; (c)
(PhO)2PON3 ,ROH; (d) i )  KHC03 , E tO H , H20  ,
i i )  NH2NH2 , H20  , EtOH , A ; (e) i )  1M H2S04 , 
NaN02 , Et20 , i i )  CH2N2 , Et20  , i i i )  R’OH , 
PhCH3 , A
Both diastereomers of 2,3-methanotyrosine have recently been synthesized by this 
method [233]. The cyclopropane (125) is easily saponified to give the less sterically 
hindered acid (126) which is rearranged to the isocyanate with diphenylphosphoryl 
azide. Conversion to the urethane (127E) was achieved in situ by isocyanate 
alcoholysis, and the final deblocking steps depend upon the alcohol used. The 
(Z)-isomer (127Z) was obtained from 126 via hydrazinolysis of the ester function 
followed by nitrosation, rearrangement and alcoholysis as before. Resolution of the 
racemic amino acids obtained by this method is necessary if the optical isomers are 
desired.
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In the case of aliphatic 2,3-methanoamino acids, several different approaches have 
been used. Racemic 2,3-methanovaline (129A) and both (Z)- and 
(E)-2,3-methanoleucines (129B and 129C) were prepared by the additon of a 








130A , R” = r - Bu 
B , R” = PhCH2
131A , R= R’= CHo , R” = t - But \ k iv c n i iv i u
B , R= / - P r , R’= H , R” = PhCH2
NHCOoR” NHCOoR"
C 02pNB
132A , R= R’= CH3 , R ” = t - Bu 
B , R= i - P r , R ’= H , R” = PhCH 
C , R= H , R’= / - P r , R’ ’= PhCF
133A , R= R’= CH3 , R” = t - Bu 
B , / - P r , R’= H , R” = PhCH2 
C , R= H , R’= i - Pr, R” = PhCH2
129A , R= R’= CH3 
B , R= / - Pr , R’= H 
C , R= H , R’= / - Pr
Reagents : (a) RR’CN2 ; (b) A or hv ; (c) NaOH , H20  ; (d) HC1 or H2 , 5% Pd /  C .
Photolylic conversion, which is preferable to pyrolysis, of the pyrazolines (131) to the 
cyclopropanes (132), followed by standard deblocking procedures, allowed the final
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isolation of the amino acids. The aliphatic 2,3-methanoamino acids are stable to both 
hot aqueous acid and hydrogenolysis (5% Pd/C) at atmospheric pressure. Thus, 
compound 129A was prepared on the removal of the N-t-butyl group by strong 
hydrolysis of 1-N-t-butyl-l-cyano-2,2-dimethylcyclopropane (133A).
The synthesis of racemic (Z)-2,3-methanoglutamic acid (134) reported recently [225], 
has allowed the preparation of racemic 2,3-methanopyroglutamic acid to be achieved 








135A , R= OMe , 
B ,R =O H  
C , R= NHMe 
D , R= NHp- Naph.
Reagents : (a) i)CH2N2 , ii) hv ; (b) 6M HC1, A ; (c) i) H2 , Pd /C , ii) A ,
iii) NaOH , H20  .
Cyclopropanation of a (Z)-dehydroglutamic acid derivative (136), prepared by the 
reaction of benzyloxycarbonylamide with 2-ketoglutaric ester, was accomplished by 
the addition of diazomethane to 136, followed by photolysis of the resulting pyrazoline. 
Acidic hydrolysis of the cyclopropane 137 gave the free amino acid in good yield. 
Hydrogenolysis of the benzyloxycarbonyl group of 137, followed by ring closure in
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boiling sec-butyl alcohol, gave the 2,3-methanopyroglutamic acid ester (135A), which 
was readily hydrolysed to the desired 2,3-methanopyroglutamic acid (135B). An X-ray 
structure of the ester (135 A) and an NMR study of the conformation of N-methylamide 
(135C) have also appeared [250,251]. The p-naphthalimide (135D) was found to be 
stable to enzymatic hydrolysis by pyroglutamate aminopeptidase in vitro [250].
Scheme 44
139A, R=Z, R’=r-Bu 
B, R=Ac ,R’=NHMe
140A , R= Z , R’= t - Bu 
B , R= Ac , R’= NHMe
Z= PhCH9OCO
Reagents : (a) i) CH2N2 , ii) hv ; (b) CF3C 02H ; (c) H2 /  Pd .
The synthesis of racemic 2,3-methanoproline (138) has been accomplished recently 
[252] by diazomethane cyclopropanation of the 2,3-dehydroproline derivative (139) 
(Scheme 44), followed by deblocking. The racemic form (138) was found to be a weak 
inhibitor of the methylene forming enzyme in cucumber cotyledons and squash seeds. 
NMR studies performed on the N-acetyl-N-methylamide (140B) indicated that the
2,3-methano compound showed a slightly greater preference for the cis amide bond at 
the ring nitrogen atom than the same derivatives of proline. An X-ray crystal structure 
on 140B indicated a small \\r angle (7°) as compared to the same derivative of proline 



















Reagents : (a) NaOH , L-Proline, H20  , acetone ; (b) Ac20  ; (c) CH2N2 , benzene ; (d) hv , 
benzene ; (e) 6N HC1, AcOH .
(iii)Piperazin-2,5-dione derivatives.- A recent chiral synthesis [253] of 
(Z)-2,3-methanophenylalanine was reported in which the oxazolone (143) was 
converted into an optically active piperazin-2,5-dione (144) with L-proline, and to a 
chiral ester (148) with (-)-N-methylephredine, before diazomethane cyclopropanation 
was employed (Schemes 45 and 46 respectively); the first study (Scheme 45) producing 
















Reagents : (a) (-) -N- methylephredrine , NaH , THF ; (b) CH2N2 , benzene ; (c) 6N HC1, 
dioxane.
(iv)Meldrum’s acid derivative - The reaction of 5-arylidene Meldrum’s acid derivatives 
(150) with dimethylsulfoxonium methylide gave the racemic spirocyclopropanes (151) 
in good yield [254]. Treatment of 151 with sodium methoxide, followed by 
Curtius-type treatment, yielded the isocyanates (153), which on hydrolysis gave the 
corresponding (Z)-2,3-methanoamino acid salts (154Z). Whilst the addition of 
ammonium hydroxide to 151 gave the amide salt (155), which under Hofmann 
rearrangement conditions and subsequent hydrolysis of the generated carbamate (156), 















Reagents : (a) CH2"S+0(CH3)2 ; (b) NaOMe , MeOH ; (c) i) EtOCOCl, Et3N , acetone ,
ii) NaN3 , H20  ; (d) HC1; (e) NH4O H ; (f) i) Br2 , MeOH , ii) NaOMe , MeOH .
(v)7,4-Oxazin-2-one derivatives - Optically active l,4-oxazin-2-one derivatives (158) 
have been efficiently condensed with various aldehydes via the Emmons-Homer- 
Wadsworth procedure [255] to provide a,p-dehydrolactone adducts (159) in good yield 
[256]. It was found that the adducts (159) were cyclopropanated with the ylide of 
racemic {[(diethylamino)methyl]phenyl}oxosulphinium tetrafluroborate to furnish in 
high chemical and optical yields (>99% ee) the desired (E)-cyclopropanes (160). Final 
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Reagents : (a) i) NBS , CC14 , A , ii) (MeO)3P , TH F; (b) i) NaH , THF , ii) RCHO ; (c) L i , NH3 , 
THF , EtOH ; (d) i) HC1, MeOH , ii) propylene oxide , EtOH , A
X-ray studies upon 159 and the N-/?-bromobenzoyl derivative of 160 had indicated that 
the alkene geometry was preserved and that the sulfoxime ylide attack on the lactone 
(159) proceeded from the top (p) face of the double bond. The unusual (E)-selectivity 
of the olefination and the complete absence of the (Z)-alkene (159Z) was thought to be 
due to the steric interaction between the aldehyde R group and the bulky BOC 
























Reagents : (a) NaH , RCHO .
Also, the high degree of facial selectivity was thought to be due to 7i stacking
interactions of the two phenyl rings of the oxazinone with the phenyl ring of the ylide,






























Reagents : (a) B uL i, THF ;
(b) M sCl, Et3N , DCM ;
(c) r-BuOK, THF.





(d)Via Lewis acid activated ring opening o f a substituted epoxide with a lithiated 
glycine equivalent.- Lithiated f-butyl isocyanates (168) have been shown [257] to react 
with epoxides (169) in the presence of boron trifluoride ethers to give exclusively the 
r-butyl-4-hydroxy-2-isocyanoalkanoates (170) (Scheme 51). The substitution took 
place with inversion of configuration of the least hindered carbon centre of the epoxide. 
The y-hydroxy ester (170), upon mesylation, underwent base induced cyclisation giving 
the 1-isocyano-l-cyclopropane carboxylates (172) with trans configuration (C02r-Bu 
with respect to R1 and R2) with high diastereoselectivity (>95:5 trans:cis) when R2 = 
Me,Et. The trans configuration resulted as a consequence of the steric interactions
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between the large r-Bu group and R2 being reduced to a minimum. The hydrolysis of 
172 via heating with concentrated hydrochloric acid gave the 2,3-methanoamino acids 















Reagents : (a) KCN , MeOH , A ; (b) 6N HC1
(e)Via cyanide additon to a-chloroketimines or base-induced cyclisation o f
\
$-chloroimines.- As a result of early research [257] into the preparation of 
a-cyano-aziridines, Dekimpe et al developed a synthesis [258,259] of racemic 
l-(alkylamino)cyclopropane carbonitriles (176) (Scheme 52). This involved the 
treatment of tertiary a-chloroketimines (174) with potassium cyanide via the trapping
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out of the intermediate cyclopropylideneamine (175) with cyanide ion, generating 176 
in 90% yield, together with a small amount of aziridine by-product (177). The 
cyclopropanes (176) were hydrolysed under acidic conditions to generate the
2.2-dialkyl-2,3-methanoamino acid (178).
An alternative preparation of 178 was later reported by Dekimpe et al [260]. This 
involved a base-induced intramolecular cyclisation of a p-chloro-N-benzylimine (179), 
yielding the N-(benzylidene)cyclopropylamine (180) which can be readily hydrolysed 
into the corresponding cyclopropylamine (181). Thus, providing the R1 substituent is 
transformable into a carboxyl function, then 181 can be converted into the
2.3-methanoamino acid (178) (Scheme 53).
Scheme 53
Reagents : (a) f-BuOK, THF , A ; (b) H30 +
A similar cyclisation has more recently been reported by Salaun et al [220] in the 
preparation of norcoronamic acid. The 8-chloronitrile (185), resulting from the addition 
of TMSCN/benzylamine to the aldehyde (183), underwent Swem N-oxidation to give 
the racemic chloroimine (186A,B) in 70% yield. The treatment of 186A,B with base 
resulted in cyclisation to give the cyclopropanecarbonitrile (187A,B) as a mixture of
179 180 181
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diastereomers (IS, 2S):(1R, 2S) (84:16) respectively. The mix of diastereomers 
(187A,B) was hydrolysed to afford norcoronamic acid (189A,B) and resolved using 
porcine kidney acylase to give the (1S,2S) diastereomer of 189 in high enantiomeric 










N =  CHPh
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N zzC H P h





Reagents : (a) TBSC1, imidazole, DMF ; (b) DIBAH , D CM , -78C ;
(c) TMSCN , Znl2 . (d) PhCH2NH2 , MeOH ; (e) w-Bu4N F , 
T H F; (f) TsC l, Et3N , DM AP; (g) L iC l, N-methyl 
pyrrolidine; (h) DMSO , (COCl)2 , Et3N , DCM ;
(i) K2C 03 , D M F; (j) IN HC1; (k) NaOH , A .
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Peptides Containing 2,3-Methanoamino Acids
2 ,3-Methanoamino acids have been incorporated into several peptides and their 
properties studied. The first reported synthesis was that of Tyr-ACC-Gly-Phe-Leu, an 
analogue of Leu5-enkephalin [261], in which ACC replaced a glycine residue. In that 
investigation, the ease of coupling at the ACC amino and carboxyl functions was 
compared with that of 2-methylalanine (Aib). It was found that the ACC amino and 
carboxyl groups are more sterically hindered than those of normal a-amino acids, but 
less than those of Aib. ACC underwent blocking, deblocking and coupling reactions 
uneventfully.
Another bioactive peptide containing ACC, ACC7-oxytocin, was synthesised [262] 
with the finding that sodium/ammonia (liq) deblocking of the cysteine sulphur atoms 
led to reductive opening of the cyclopropane ring. Whereas, if anhydrous hydrogen 
fluoride was used, the ring remained intact. This peptide analogue was found to have 
lower bioactivity than oxytocin.
In 1987, it was reported [263] that the two dipeptide derivatives, 
N-benzoyl-ACC-Phe-OH (190) and N-benzoyl-ACC-Pro-OH (191) showed time 
dependent inhibition of carboxypeptidase A. Thus incubation of the phenylalanine 
peptide (190) caused complete inactivation of the enzyme (t1/2 = 4.5 min.) with an 
apparent Kj = 8.4 x lO^M. The inhibition occurred about 2.3 times faster than 
hydrolysis of the peptide. The proline peptide (191) was more potent, having a t1/2 for 
total inactivation of 3 min. and an apparent Kj of 5.5 x lO^M with no hydrolysis 
occurring, as expected. Using molecular graphics, it was postulated that the Zn2+ ion, 
known to be present at the active site of carboxypeptidase A, coordinated with the 
peptide carbonyl group; thus assisting the attack of the Glu270 carboxylate anion, an 
enzyme-situated nucleophile, on the cyclopropane ring leading to covalent bonding 
with the peptide and irreversible inactivation.
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The structural preferences of simple ACC containing peptides have been indicated 
through X-ray diffraction studies and conformational energy calculations. 
Semi-empirical potential energy calculations performed on a simple ACC dipeptide 
and a 2-substituted ACC dipeptide indicated that different types of helices are 
energetically favoured [264]. Potential energy maps showed that P-substituents may 
restrict either the (J) or y  values selectively. Using both empirical and ab initio 
methods, the conformational effects of introducing ACC into a peptide chain have been 
studied [265-267]. The concensus of this work indicated that the ACC residue is quite 
different from the aminoisobutyric acid (Aib) residue, since it favours folding of the 
peptide chain by formation of a C7-helix or y-tum, with formation of a p-tum being a 
close second energetically. More recently, tri- and tetra-ACC peptides have been 
shown to fold into distorted type I p bends and 310 helices, in contrast to the acyclic 
Aib, a,a-diethyl-and a,a-dipropylglycine residues which favour the formation of 
regular type III p-bends and 31o-helical structures [268-270].
The two amino acids (-)(2S, 3R)- and (+)-(2R,3S)-(E)-2,3-methanophenylalanine have 
been incorporated into anto an enkephalin analogue, forming [D-Ala2, Leu5, (-)-and 
(+)-VEPhe4]enkephalins. These peptides were reported to show reduced activity in the 
mouse vas deferens (MVD) and guinea pig ileum (GPI) muscle assays [271]; the 
peptide showing a strong preference for the 5-receptor of the GPI. It was later found 
that the peptide containing the (2R, 2S)-isomer showed a very high preference for the 
8-receptor in rat brain, while the other peptide was inactive [272]. Thus indicating aiii
possible differentiation between the peripheral and central nervous system receptors by 
these peptides.
During the synthesis of a series of aspartyl dipeptides containing a 1-amino-1- 
cyclopropanecarboxylic acid at the carboxyl terminus, it was found that
Asp-ACC-OMe had a distinct sweet smell [273]. Further work [274], on a series of 
esters Asp-ACC-OMe showed that the /z-propyl ester had 250-300 times the sweetness 
potency of sucrose. More recendy, all four diastereomers of Asp-VPhe-OMe were 
prepared [275] with the expectation that at least one of the four compounds would be 
sweet and allow the close mapping of the "sweet receptor". Surprisingly all of these 
compounds were tasteless. Molecular modelling, CD and NMR studies of these 
dipeptides led to the conclusion that the rigid positioning of the phenyl moiety by the 
cyclopropane ring prevented its necessary orthogonality [276] to the flat zwitterionic 
ring formed by the aspartic acid residue, thus prohibiting their binding to the taste 
receptor.
The incorporation of (Z)-2,3-methanophenylalanine into the natural chlorosis-causing 
peptide tentoxin, cyclo[N(Me)Ala-Leu-(Z)-N(Me)-AzPhe-Gly], by replacing the 
dehydrophenylalanine residue, led to a peptide with no bioactivity in the lettuce 
seedling assay [277]. Tentoxin, a secondary metabolite of Alternaria alternata, is of 




Enzyme Action and Inhibition
The function of enzymes is to act as catalysts in biological reactions, although often a 
further non-protein component called a cofactor is required before an enzyme has 
catalytic activity. Enzymes can catalyse reactions by virtue of the amino acid residues 
present in their chains. Every enzyme has a unique protein structure defined by a 
characteristic amino acid sequence. This makes them substrate specific.
Catalysis is the result of raising the ground state energy for the reaction. It is possible 
to make some generalizations concerning the methods by which enzymes catalyse 
reactions:
(a) Deforming a configuration of atoms away from their equilibrium position 
raises the energy of the system. If an enzyme can stretch a bond, the energy 
will become closer to the transition state energy and bond cleavage will be 
aided. In order to strain a system there must be some interaction of that 
system with the enzyme, equal in energy to the induced strain energy.
(b) Enzymes which can concentrate and orientate reactants will catalyse reactions. 
A simple bringing together of reactants can theoretically cause an 
acceleration, largely due to the change in concentration caused.
(c) Nucleophilic attack on an electrophile can be speeded up by making the 
electrophile more electrophilic and vice-versa. This is electronic activation.
Enzymes bind substrates at a region of the enzyme termed the active site. Binding sites 
link to specific groups in the substrate, fixing its relative orientation, so that reacting
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groups are in the vicinity of catalytic sites on the enzyme. Inhibitors are substances 
that tend to decrease the rate of an enzyme catalysed reaction. Some inhibitors act on 
the substrate or cofactor, but this discussion is concerned only with those which 
combine directly with the enzyme.
There are several forms of enzyme inhibition: competitive, uncompetitive, 
non-competitive, as well as mixed, partial, and allosteric.
Competitive inhibitors often closely resemble the substrates whose reactions they 
inhibit, and therefore compete for the same binding site on the enzyme. The enzyme 
bound inhibitor then either lacks the appropriate reactive group or is held in an 
unsuitable position with respect to the catalytic site. A dead-end complex is formed 
and the inhibitor must dissociate from the enzyme and be replaced by a molecular 
substrate, before a reaction can take place. Uncompetitive inhibitors bind only to the 
enzyme-substrate complex and not to the free enzyme. Substrate binding could cause a 
conformational change to take place and reveal an inhibitor binding site, or the 
inhibitor could bind directly to the enzyme-bound substrate, both resulting in the 
formation of a dead-end complex. Non-competitive inhibitors combine with an 
enzyme molecule to produce a dead-end complex, whether a substrate molecule is 
bound or not. The inhibitor must, by definition, bind to a different site to the substrate, 
destroying the catalytic activity of the enzyme.
Irreversible inhibitors bind to the active site of the enzyme, usually by formation of a 
covalent bond. The inhibitor may act by preventing the substrate binding or it may 
destroy some component of the catalytic site. An inhibitor which shows great affinity 
for the enzyme is regarded as irreversible.
Any data discussed in the text will be associated with enzyme inhibition in vivo by
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various compounds synthesized and will be represented in terms of binding affinities, 
Kis or IC50 values, where IC50 is the concentration required to produce half maximal 
enzyme inhibition.
Peptide Mimetics as Enzyme Inhibitors
In recent years extensive work has been performed on peptide mimetics [278,279]. 
Analogues of natural peptide substrates have been prepared in which conformational 
constraints and non-peptide linkages have been introduced, as well as by changing the 
natural amino acid sequence and making amino acid side chain substitutions.
Structural modifications are introduced into the parent compound to determine the 
resulting biological consequences. This discussion covers peptide backbone 
modifications only. Peptide backbone studies have attempted to identify the 
importance of rigidity, alignment and stereochemistry for biological function and also 
how modification of the backbone affects resistance towards enzymatic degradation.
The introduction of peptide backbone modifications can be used in the design of potent 
peptide analogues or, conversely, peptide antagonists. An antagonist is a compound 
that binds to a receptor but elicits no response. The peptide backbone is made up of 
three repeat elements; the amide N, a-C and amide carbonyl. These have all been 
subject to replacement in the course of new analogue design, either individually or in 
various combinations. The amide group represents a single replaceable unit. The 
symbol \|f[ ] is used to show that the natural peptide unit has been replaced by the unit 
inside the bracket. Refer to Table 8 .
As with side-chain modifications, structural similarity to the natural peptide is not 
necessarily essential for biological potency. Subtle changes in bond length and angles 
could improve receptor interactions. In addition to possessing enhanced resistance to 
biodegradation, many amide bond surrogates possess lipophilic, electronic and
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hydrogen-bonding properties which can affect transport, receptor binding or membrane 
interactions. In the search for potent enzyme inhibitors, requirements are for receptor 
selective antagonists with a prolonged activity profile. Potency and selectivity vary 
with the peptide backbone modification and its position within the peptide chain.
Every enzyme receptor is specific, demanding agonists and antagonists with varying 
structural and electronic properties for strong coordination and resistance to 
biodegradation.
In order to confer stability to a hormone analogue against rapid degradation, scissile 
bonds are identified in the parent molecule and then replaced by a surrogate offering 
greater resistance. A scissile bond is the bond in a substrate subject to enzymatic 
cleavage. The introduction of D-amino acids, N-methyl amino acids, a-substituted 
amino acids into peptides gives mimetics with partial or full enzymatic resistance. This 
effect must be due to altered conformational or electronic properties that decrease the 
fit of the modified analogue, since the cleavage link is still present. A common 
mechanistic feature of many proteolytic enzymes appears to be polarization of the 
amide carbonyl, followed by nucleophilic attack on the weakened scissile bond. A 
proteolytic enzyme catalyses the hydrolysis of peptide bonds. In principle, any 
backbone modification which removes the polarizable group, alters the geometrical 
requirements and/or otherwise increases the strength of the vulnerable link, will tend to 
reduce or eliminate the possibility of proteolytic degradation.
Linear peptides usually assume multiple low-energy conformers. Conformation 
induction and selection have been recognised as being important in hormone receptor 
binding. It has been proposed that conformational changes take place during or after 
the binding event. This is supported by the finding that relatively rigid analogues often 
prove to be good antagonists. Conformationally constrained analogues have been 
designed by the use of peptide backbone modifications, from which it is evident that
7 5
conformational effects are important in the design of potent agonists.
Table 8











dehydro amino acids -CH(R)CONHC(=CR2)-
a-bora -CH(R)CX)NHCB(R1)-
cyclopropylogs C H (R )C O N H O ^
Also invertion of the natural amino acid residue stereochemistry at a-C
Modifications of the Peptide Backbone Involving the Amide Carbonyl 
reduced carbonyl \|/[CH(R)NH]
thioamide Y[CSNH]
sulphonamide y [S 0 2NH]
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Molecular Dynamics procedure is a deterministic simulation process wherein the 
positions and velocities of atoms in a molecule are integrated forward in time, using 
Newton’s laws of motion. The initial velocities are randomly ascribed to atoms via a 
Maxwellian distribution consistent with the temperature at which the simulation is 
being performed. The movement of the atoms is then governed by the kinetic energy 
input into the system and the restoring forces that act on the molecule when its position 
from a minimum energy conformation is disturbed. The latter term is a forcefield term 
from which the potential energy of the system can be determined. This term consists 
of strain energies like bond length, bond angle deformations, torsional components etc. 
and interaction terms like van der Waals, non-bonded interactions and electrostatic 
terms. In this thesis, the Valence Force Field (VFF) is used to compute potential energy 
and the expression is given below (Eq.l). The potential energy of the compound 
studied is represented by the full valence force Field (VFF).
V = X{Db[l-e'“(b'bo)]2-Db) (Eq.l)
+ l/2EHe(e-e0)2







+ Xf[r*/r)12-(r*/r)6] + Xq^j/r
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The first four terms define the energy required to distort the internal from their ideal 
values, (b, e, (J) and % are the bonds, valence angles, torsion angles and out of plane 
angles, respectively; bG and 0 O are the ideal bond lengths and valence angles and the H 
terms are the force constants for distoring the internals). The last three terms represent 
the interactions between non~bonded atoms (r* is the most favourable interatomic 
distance and e the energy of interaction at that distance, q^ are the partial atomic 
charges). Cross terms representing coupling between two or more internals are also 
included. These are required for reproducing experimental vibrational data and will 
affect the shape of the energy surface in non-equilibrium regions. The parameters in the 
equation 1 [280] were derived by fitting experimental data for small model compounds 
including functional groups that occur in amino acids. The non-bond parameters were 
obtained by fitting crystal structure sublimation energies and dipole moments 
[281,282]. These parameters were validated against high grade quantum mechanical 
calculations [283] and tested for conformation dependent properties in solution [284]. 
The valence parameters were obtained by fitting vibrational spectra, molecular 
structures and rotational barriers [285].
The flexible geometry <|>,y energy maps were calculated using the full VFF expression 
and adding two forcing terms:
E<}>=k<j)(<Mo)2 (Eq.2)
Ev=kv(y-y0)2
A force constant of lOOOkcal/mol was used in order to force the angles <j) and y  to adopt 
conformation (<J>0,y0)> while minimising the total energy to relax all other degrees of 
freedom. The values of <J>0 and y 0 were incremented by steps of 10-20°, to produce the 
complete <J>,y map. The minimisation for each map point was carried out in two stages: 
first a steepest descent minimisation was carried out to relieve initial clashes and then a
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quasi Newton method [286] was used to achieve convergence. (Achieved when the 
largest derivative of the energy with respect to any Cartesian coordinates was smaller 
than 0.0001 kcal/A). Grid points that correspond to local minima were subject to 
further minimisation, without the torsion constraints, to reveal the exact location and 
energy of the minima.
Isolated p sheets and turns do not always correspond to a local minimum. Thus in 
addition to the full VFF expression two types of forcing terms were added, one of 
which ensures the backbone conformation is not changed drastically by applying 
torsion forcing terms (Eq. 2). In addition the typical hydrogen bonding pattern is 
preserved by adding a small penalty function:
Ehb^hbOij-ry0)2 (Eq.3)
Where r^ is the distance between a pair of hydrogen bonded atoms. A force constant of 
5kcal/mol was used in order to force the angles <J> and y  to adopt conformation (<J>0,y0), 
and a force constant of 2kcal/mol was used to preserve the hydrogen bonds, while 
minimising the total energy to relax all other degrees of freedom.
The software packages DISCOVER and INSIGHT (BIOSYM Inc. USA) were used to 
perform molecular dynamics simulations and energy minimisation studies. Plots of 
molecular conformations were done by ORTEP [287].
Accessible conformations of AzPhe and V2^  peptides were obtained by performing 
constrained molecular dynamic simulations using types, I, I’, and II’ p turns as four 
starting points in the search. The simulation periods were over 50ps each for the AzPhe 
peptide and 25 ps each for the peptide. Thus a total of 300 ps of simulations were
8 0
performed. The resulting conformations were minimised without any constraints. For 
the VZ* peptide, proper minimisation was found possible only when a harmonic 
potential was used to describe the bond lengths and the cross terms were turned off in 
the energy function.
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1.7 Cholecystokinin and Cholecystokinin Antagonists
Cholecystokinin (CCK) is found in several peripheral sites where it acts as hormonal 
regulator of gut function, digestion and feeding [288,289]. It is also found in the 
nervous system where it functions as a neurotransmitter and a neuromodulator 
[290,291]. Several biologically active forms of cholecystokinin exist, the prevalent 
forms in the periphery being CCK-58, CCK-33, CCK-8
(H-Asp-Tyr(SC>3H)-Met-Gly-Trp-Met-Asp-Phe-NH2) CCK-4
(H-Trp-Met-Asp-Phe-NH^. CCK is found in the central nervous system (CNS) 
predominandy as CCK-8 . The cerebral cortex, the limbic system, midbrain and spinal 
cord neurons contain high levels of CCK peptides relative to other neuropeptides. 
CCK-8 coexists with dopamine in mesolimbic and mesocortical pathways and with 
Met-enkephalin in hypothalmic, hippocampal and periaqueductal regions, CCK’s role 
in satiety and feeding behaviours, its coexistence with other neurotransmitters and 
neuropeptides, and its relative abundance in the CNS compared to other neuropeptides, 
has made it the focus of considerable research effort over the past decade.
The CCK receptor family has been subdivided into two types. Namely the CCK-A 
(alimentary) receptors which predominate in the periphery and are characterised by the 
CCK receptors in the gall bladder, pancreas and ileum; and CCK-B (brain) receptors 
that predominate in the CNS and are typically characterised by receptors in the cerebral 
cortex [292]. CCK-A receptors have been identifed in the CNS in several discrete 
brain regions such as the nucleus tractus solitarius and the dorsomedial caudate [293]. 
The role of CCK-A receptors in the CNS is presently unknown although preliminary 
evidence indicates that a possible role is in the modulation of dopaminergic function 
[294,295]. Similary, the functional significance of brain CCK-B receptors is unclear; 
although recent data suggests a role in the modulation of pain [296], anxiety [297],
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cognition [298] and perhaps the regulation of certain feeding behaviours [299]. The 
CCK-B receptors have also been reported in peripheral sites [300] but controversy 
remains over whether these receptors are indeed of CCK-B type or gastrin receptors. 
The structural similarity of gastrin and CCK peptides, and the inability of ligands, 
either peptidic or non-peptidic, to differentiate gastrin from CCK-B receptors warrants 
the inclusion of gastrin and its receptors into this discussion. Before the existence of 
receptor subtype specific probes, these two classes were differentiated by their relative 
affinities for CCK-4, CCK-8 and its desulphated form (CCK-8(DS)). The 
CCK-B/gastrin receptors recognise all of these with comparable affinity, whereas only 
CCK-8 is bound with high affinity by the CCK-A receptor.




Prior to the recent advances in CCK research, a number of weaker and non-selective 
CCK antagonists such as proglumide (192), benzotript (193), and dibutyryl-cyclic GMP
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(194) were utilised to elucidate CCK pharmacology.
These antagonists have been well studied and previously reviewed [301,302]. The 
discovery of asperlicin (195), a fermentation product from Aspergillus alliaceus [303], 
initiated the synthesis of similar benzodiazepine derivatives, This resulted in the 
discovery of the potent CCK-A selective agent devazepide (196), also known as 
MK-329 [304], which has an affinity for CCK-A receptor comparable to CCK itself 
(IC50 = 10'10M) in a variety of animal models [305]. Further efforts provided the 




The enantiomer of 197 displays selectivity for the CCK-A receptor just as devazepide 
does. In fact the stereoinversion of the chiral centre in these benzodiazepines was
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found to be crucial to the strategy for developing a CCK-B/gastrin selective agent.
Both devazepide and (R)-L-365,260 represented major advances in the CCK antagonist 
field in that they were both potent and selective with good oral bioavailibility.
Peptide Antagonists
A  considerable amount of research within the CCK field has centred on analogues of 
the parent peptides CCK-8 and CCK-4. It should be noted, however, that within this 
subclass the difference between agonism and antagonism is sometimes not well defined 
owing to some entities possessing mixed functional responses, or showing species 
dependent pharmacology.
The general strategies involved in the preparation of peptide antagonists have 
included:-
(a) Amino acid replacement [307]
(b) Substitution of the amide bond (CONH) by isosteric equivalents, e.g. 
ketomethylene (COCH2) [308], aminomethylene (CH2NH) [309], carba 
(CH2CH2) [310], ethylene (CH=CH) [311,312] and retro-inverso amides 
(NHCO) [313,314]
(c) The cyclisation of linear peptides [315]
(d) The incorporation of conformationally restricted amino acids [316].
These efforts have resulted in some ligands with veiy high affinities for either CCK-A 
or CCK-B/gastrin receptors. One of the earliest findings [317] was that deletion of the 





Although it was shown that the antagonism of 198 was species dependent [318], the 
removal and/or modification of the C-terminal portion of CCK peptides has remained a 
viable approach to pharmacologically interesting agents [319]. The des-carboxamide 
CCK analogue JMV-180 (199), for example, was found to act as an agonist at high 
affinity rat pancretic CCK receptors where it stimulates amylase release.
CCK antibodies, being peptidic in nature, represent a further approach to achieve CCK 
antagonism. Their use is of current interest in the promotion of weight gain in 
livestock. A recent study has appeared describing the immunisation of livestock with 
CCK for this purpose [320].
Peptoid Antagonists
200, R= 1 -Adamantyloxycarbonyl (1-Adoc) 201, R= 2-Adoc
202 , R= 1(S) - Endobomyloxycarbonyl
A number of research groups have used CCK-4 as the basis for further exploration of 
high affinity CCK-B ligands. Utilising a deletion approach Horwell and co-workers 
[321] initially evolved a series of "dipeptoids" represented by the tryptophan analogue 





This approach addressed two of the major problems associated with peptide- based 
therapeutic agents. First, by decreasing the overall molecular size it allowed the 
possibility of better adsorption, and second, by specifically using 
a-methyl-D-tryptophan it greatly enhanced metabolic stability. Further research aimed 
at re-incorporating functional groups from CCK-4 led to the discovery of the novel 
dipeptoids PD-134308 (Cl-988) (201) possessing a greatly enhanced potency at CCK-B 





2.1 Aims and Objectives
The objective of this project was as follows
a, the preparation of dehydrophenylalanine mimetics (203) for CCK-4
[H-Trp-Met-Asp-Phe-NHJ
2-Adoc-R-a-M e-TrpNH C 0 2R 1
Ph 
203
b, the diastereoselective synthesis of 2,3-methanophenylalanine esters
(204)
204




The strategy employed in the preparation of the dehydropeptides (203) would involve 
the coupling of an N-blocked tryptophan (206) to the (RS)-r/ireo-3-phenylserine ester
8 8
(207) followed by dehydration of the alcohol(208) (Scheme 55).
Scheme 55
Ph C02R1 




2 - Adoc-R-a-Me-Trp NH C 02R
208 HO Ph
203
For the synthesis of 2,3-methanophenylalanine ester (204) a chiral diketopiperazine 
template (209) would be employed, which once modified to the benzylidene (210) via 
condensation with benzaldehyde would induce selective cyclopropanation. Then on 
suitable modification of the diastereomerically pure cyclopropanes (211) would allow 

















The esters (204) would then be similarly coupled to the N-blocked tryptophan (206) to
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generate the cyclopropyl dipeptide analogues (205).
2.2 Preparation of dehydrophenylalanine dipeptide derivatives
Preparation o f (RS)-threo-3-phenylserine methyl ester (214)
The esterification of the acid, (RS)-r/ire<9-3-phenylserine hydrate (213), to the methyl 
ester (214) employed conventional esterification techniques [324]. Thus, the treatment 
of 213 with methanolic thionyl chloride gave, after basic work-up, the ester (214) 
uneventfully in 80% yield (Scheme 57).
Scheme 57
Ph COoH Ph COoMe
HO NH2 HO NH2
213 214
Reagents : (a) i) SOCl2 , MeOH , 0°C, ii) 1M NaOH , 
pH 7 , 0°C .
Preparation o f N0,-(2-adamantyloxycarbonyl)-a-methyl-R-tryptophanyl-RS- 
threo-3-phenylserine methyl ester (215)
The coupling of the N-protected tryptophan (206) with the C-protected 
RS-f/ireo-3-phenylserine (214) was performed by prior activation of the acid using 
HOBt/DCC. These coupling agents were chosen since they have been reported to give 
good ester yields, but more importantly, with the minimal occurence of racemisation 
[325,326]. The desired dipeptide ester (215) was successfully prepared in 83% yield 
as a mixture of RS-f/im?-enantiomers (Scheme 58).
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Scheme 58
a ^ 2  - Adoc-R-a
2 - Adoc-R-a-Me-Trp - OH
206
Reagents : (a) i) DCC , HOBT, EtOAc ; ii) 206 , EtOAc .
Dehydration o f the alcohol (215) to yield the dehydroamino acid 
Na -(2-adamantyloxycarbonyl-a-methyl-R-tryptophanyl-dehydrophenylalanine methyl 
ester (219)
As was discussed in Section 1.3, various dehydrating reagents have been employed 
successfully for the preparation of dehydroamino acids from p-hydroxy-a-amino acids, 
via p-elimination reactions.
(Diethylamino)sulphur trifluoride (DAST) is generally used in the fluorination of 
alcohols [327], however, there have been a few reports of dehydration products being 
isolated [328,329]. In 1983, Somekh and Shanzer reported [330] the steresospecific 
dehydration of derivatives of serine, threonine (threo and erythro) and leucine (threo 
and erythro) using DAST in the presence of pyridine. They found that threo-hydroxy 
amino acids (216) gave (Z)-dehydroamino acids whilst their erythro isomers gave the
NHCOXHoPh
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corresponding (E)-adducts. These results being compatible with an E2 elimination 
process.
As a result of which we applied these conditions to our system (215). Unfortunately no 
desired dehydroamino ester (219) was isolated. The brown colouration of the solution 
observed, indicated that the reaction conditions were too harsh, so milder conditions 
were then sought. The treatment of a serine moiety with N,N'-carbonyldiimidazole in 
the presence of triethylamine was originally employed by Andruszkiewicz and 
Czerwinski [58] in their preparation of the corresponding dehydroamino esters. These 
conditions were undertaken on the alcohol (215) but this time no colour change was 
observed and t.l.c. indicated no new product had been formed.
In 1986, Kato et al reported [59] the isolation of dehydroserine derivative (217) in 90% 
yield from the (3-phenylserine monohydrate via treatment with sodium acetate in acetic 
anhydride (Scheme 59).
Scheme 59
Phx  ,C° 2 »  a C 02H
y  (   ► P h -C H = C
HO NH2 SNH
217 Ac
Reagents : (a) AcONa, Ac20  , 15 - 45°C , 5h
These conditions were then applied to our analogous system. This generated a pale 
yellow solid 218 in quantitative yield. The *11 NMR spectrum of 218 showed the 
desired olefin had not been formed but that the intermediate O-acetate had been 




Previously, Ogura et al reported [331] that N,N'-disuccinimiydl carbonate (DSC) could 
be used as a coupling reagent in peptide synthesis instead of DCC. Taking advantage 
of the dehydrating properties of this reagent he later announced [56] that DSC could be 
used to prepare dehydroalanine and (Z)-dehydroaminobutyric acid from 
N-blocked-serine and threonine residues, respectively, in good yield. So, to a solution 
of the alcohol (215) in dry acetonitrile was added DSC at room temperature under an 
atmosphere of nitrogen. After work-up and purification by flash chromatography a 
new product was isolated as a white foam in 49% yield. This was shown to be the 
desired dehydroaminodipeptide (219) by NMR studies and microanalysis (Scheme 
60).
Scheme 60





Reagents : (a) DSC , Et3N , CH3CN , room temp
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The stereochemistry of the alkene was determined by n.O.e. experiments. Irradiation 
of the enamine NH (2-NH.2) at 8 8.20 ppm gave no enhancement of the vinyl proton 
whilst irradiation of the vinyl proton (3-H.2) at 5 7.33 ppm gave the same result. Thus 
indicating a resultant (Z)-stereochemistry of the phenyl group with respect to the 
enamine NH as expected.
COoMe
219Z
Attempted hydrolysis o f the dehydrodipeptide ester (219Z)
Typical hydrolysis reagents were employed in the hydrolysis of the dehydrodipeptide 
ester (219Z). Firstly, dilute lithium hydroxide was attempted. A 0 .1M lithium 
hydroxide solution was added to a solution of the ester (219Z) in THF at room 
temperature. After stirring for a few hours no desired acid was observed. Even 
refluxing for 12h gave no change (Scheme 61).
Scheme 61
2 - Adoc-R-a-Me-TrpNH ^___^  C 02Me




Reagents : (a) 0.1M LiOH, TH F, A , 12h
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The saponification process was repeated using a different base - 0.1M sodium 
hydroxide - and to aid solubility a more polar solvent, ethanol, was used. After 2h 
stirring at room temperature the solution was brought to reflux and after a further 3h 
complete hydrolysis had been achieved. Purification of the residue by reverse-phase 
chromatography gave the acid (220Z) as a white foam in 30% yield. The NMR 
spectrum of 220Z confirmed the structure (Scheme 62)
Scheme 62





Reagents : (a) 0.1M NaOH , EtOH , A
The overall forcing conditions were necessary owing to the reduced electrophilicity of 
the carboxyl carbonyl group as a result of the conjugation to the alkene. The use of a 
more polar solvent, meanwhile, aided the solubility of the carboxylate salt formed 
(Scheme 62).
Attempted cyclopropanation o f the dehydropeptide ester (219Z)
Considerable research has been achieved in the cyclopropanation of derivatised 
dehydroamino acids and peptides containing them (see Section 1.4). It was felt 
worthwhile in attempting to produce cyclopropyl dipeptides by this approach.
To a solution of the dehydrodipeptide ester (219Z) was added an ethereal solution of 
diazomethane at room temperature. After stirring for one day a considerable amount of 
starting material remained and so an excess of diazomethane was added. The reaction
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was worked up after a further day. ]H NMR spectrum of the residue revealed a 
multicomponent mix, none of which corresponded to the desired cyclopropyl dipeptide.
2.3 Preparation of 2,3-methanophenylalanine derivatives
A diastereoselective synthesis of 2,3-methanophenylalanine derivatives was proposed 
and, the methodology of which, was based on Schollkopf s bislactim ether approach 
[332], whereby we utilised his procedure in the formation of a chiral 
piperazin-2,5-dione template (222) (see Scheme 63).










Reagents : (a) COCl2 ,(20% toluene solution ) ,  THF ,40°C; (b) H2NCH2CO2ELHCI, 
Et3N , THF ,CHC13 , -78°C ; (c) toluene , A
The oxazolidine (221) was prepared in quantitative yield by the treatment of a 
suspension of L-valine in THF. The suspension was heated at 40°C until the solution 
was clear. The careful removal of the solvent, after purging with nitrogen, gave the 
desired product (221) as a white pungent solid (Scheme 63). This unstable compound
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was then converted directly into the stable piperazin-2,5-dione via the addition of a 
solution of 221 in THF into a suspension of glycine ethyl ester hydrochloride and 
triethylamine in chloroform at -78°C with overhead stirring. This gave the desired 
product (222) as a white powder in 60% yield.
Preparation o f 6-(S)-l ,4-diacetyl-6-isopropylpiperazin-2,5-dione (226)
To establish the condensation of the piperazin-2,5-dione (222) with an aldehyde to 
generate the desired alkene (223) the piperazin-2,5-dione (222 ) had to be suitably 
protected and activated.
In 1973, Gallina et al [109] reported the use of the bis-acylated piperazin-2,5-dione 






where R= Ac , R1=Ar
Reagents : (a) i) t - BuOK , t - BuOH , 0°C ; ii) R ^ H O  , DMF , 12h , 
RT
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This procedure not only solves the problem of activation of the piperazin-2,5-dione 
(222) but provides us with suitable conditions for the condensation process to afford the 
benzylidene products (223).
The bis-acetylated piperazin-2,5-dione (226) was prepared by heating a suspension of 
the highly insoluble piperazin-2,5-dione (222) in acetic anhydride to 110°C until all the 
starting material (222) had dissolved. The brown residue was purified by flash 
chromatography to yield a pale yellow crystalline solid in 78% yield. The NMR 







Reagents : (a) Ac20  , 1 10°C
Despite the severe conditions no evidence of racemisation of the L-valine residue was 
detected. This was also verified by Kanmera et al [110] in a similar cyclo 
(L-Ala-L-Gly) system. Unfortunately under these conditions polymerisation is 
significant. So other acylation techniques [333] were tried. One of the major hurdles 
to overcome in the acylation of piperazin-2,5-diones was their insolubility in many 
polar solvents.
The acylation step was repeated using DMF as solvent, while maintaining acetic 
anhydride as the acylating source. After refluxing for 4h the solution was worked up
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and purified in the usual manner to yield 226 in 45% yield.
The introduction of a base was then considered. Pyridine was added to a suspension of 
222 in acetic anhydride . This was brought to reflux for 7h and after purification 
yielded 226 in a reasonable yield (57%). A repeat of the latter step using 
ultrasonification instead of heat gave poor yields of 226 (29%).
The replacement of the acylating source was then employed. Acetyl chloride was 
added to a suspension of 222 in DMF. After refluxing for 6h purification of the residue 
gave 226 in only 43% yield.
The generation of the more reactive ketene, in situ, in the presence of the reacting 
substrate has been reported [334] by the treatment of acetyl chloride with a tertiary 
amine. This was considered a viable method of imide formation. The treatment of the 
piperazin-2,5-dione with DBU in the presence of acetyl chloride at room temperature, 
however, gave poor yields of the desired product (226) (33%). Again polymerisation 
was suspected as the main source of trouble.
Condensation o f the bis-acetylated piperazin-2,5-dione (226) to afford the benzylidene 
(227)
Condensation of the bis-acetylated piperazin-2,5-dione (226) was achieved by the 
procedure described by Gallina et al [109]. The treatment of 226 with a solution of 
potassium-f-butoxide in THF in the presence of benzaldehyde gave mainly the 
monoacetylated (Z)-benzylidene (2212) (Z:E, 8:1) in good yield (83%). The two 




Reagents : (a) PhCHO , D M F; (b) t - BuOK, THF , 0°C, 4 h
The !H NMR spectra of both alkenes (227Z and 227E) showed the presence of a 
phenyl multiplet and an alkene singlet indicating the addition-elimination had been 
successful. It also showed that one of the acetyl groups had been removed in the 
process. The overall structure of 227Z and 227E were proved by difference n.O.e. 
experiments.
In the case of 227Z the N-H signal (8 8.0 ppm) was enhanced when the phenyl group (5 
7.44 ppm) was irradiated whilst no N-H enhancement was observed when the vinyl 
proton (5 7.15 ppm) was irradiated. Thus indicating, a (Z)-stereochemistry about the 
C=C bond.
For compound 227E, however, only the vinyl proton was enhanced (8 6.65 ppm) when 
the N-H signal (8 9.65 ppm) was irradiated. Thus indicating an (E)-stereochemistry 
about the C=C bond.
The major product was thus confirmed as the kinetic and more thermodynamically 
stable Z-isomer (227Z) arriving through the p-elimination of acetic acid after an N-Ac 
to O-Ac transfer.
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Photoequilibration o f the (Z)-benzylidene (227Z) into its (E)-geometrical isomer 
(227E).
It was noticed that when the (Z)-benzylidene (227Z) was left for any period of time in 
daylight that it partially converted into its isomeric (E)-form (227E) i.e. 227Z and 









This has been reported in other unsaturated systems [335]. The irradiation of a solution 
of 227Z in chloroform with L-W U.V. light (X =370nm) for 24h reaffirmed this 
observation in converting 35% of the original (Z)-component into its (E)-form. Thus, 
here lies a technique for the generation of the (E)-isomer which allows access to the 
synthesis of (E)-2,3-methanophenylalanine (228E).
Ac _






There are three major techniques which can be employed in the preparation of a 
cyclopropane from a a,p-unsaturated amide:-
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(i) the Simmons-Smith reaction
(ii) the addition of a diazoalkane
and (iii) the addition of a sulphoxonium ylide
Simmons-Smith reaction
The Simmons-Smith reaction is a method of preparation of cyclopropanes from alkenes 
without the isolation of insertion side-products typical of free carbene intermediate 
processes [336]. This procedure involves the treatment of C=C containing compounds 
with methylene diiodide and a Zn/Cu couple leading to cyclopropanes in good yields 
[337] (Scheme 68).
Scheme 68
Reagents : (a) CH2l2 , Zn(Cu), Et20  , A
The Zn/Cu couple can be prepared in several ways [338], of which heating zinc dust 
with copper(I)chloride in ether under nitrogen [339] is particularly convenient. The 
actual attacking species is an organozinc intermediate and thought to be (ICH2)2 
Zn.ZnI2. The addition of this intermediate to C=C bond is stereospecifically syn and is 
thought to go via a concerted mechanism [340] (Scheme 69).
The Simmons-Smith conditions described by Simmons, Mash et al [341,342] were 
applied to our (Z)-benzylidene (227Z) having previously prepared the Zn-Cu couple by 












No carbene insertion resulted, with the majority of the starting material (227Z) being 
recovered (95%). The reason was thought to be the overall deactivation of the alkene 
by the electron withdrawing ester function, since Simmons and Smith reported low 
yielding in a,p-unsaturated esters containing P-substituted electron withdrawing groups 
[341].
More recently a modified Simmons-Smith procedure using a Zn-Ag couple has been 
established [343]. This method when applied to the benzylidine (227Z) gave no 
desired product (228Z).
Addition of a diazoalkane
Diazomethane is an important method for the generation of cyclopropanes from 
alkenes. If the free carbene is required the diazomethane is initially photolysed [344]
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or pyrolysed [345] before the addition of the alkene substrate (Scheme 71) otherwise it 
is added directly.
Scheme 71
r -u /*■+__  hv
2 N —  N -------------------- ^  : CH2 + N2
or pyrolysis
Normally direct addition of diazomethane to an alkene results in the formation of a 
pyrazoline intermediate (229) probably via a 2+3 cycloaddition mechanism (Scheme 
72).
Scheme 72
£ r > v <
230
Often these intermediates are stable and can be isolated [249, 253] or require photolysis 
[344] or pyrolysis [345] for their conversion into the cyclopropane derivatives (230).
If the free carbene is generated it is usually formed as a high energy singlet species and 
is so reactive that it reacts before it has chance to decay into the triplet state [346]. As 
a consequence the reaction is stereospecific and syn products are formed [347] 
probably via one step mechanism [348] (Scheme 73).
> \




Whereas for carbenes generated in the lower energy triplet state [349] have been found 
to react non-stereospecifically with alkenes [350] probably by a diradical mechanism 
(Scheme 74).
Scheme 74
A disadvantage in the use of diazomethane is its tendency to insert into other 
functionalities, if present, such as oxygen e.g. carbonyl group, and nitrogen e.g. amine 
or amide groups. Although it has been shown [351] that diazomethane reacts 
preferentially towards carbon-carbon double bonds when both alkenes and amides, in 
conjugation, are present within a molecule. Thus the cyclopropane product (232) was 





Reagents : (a) CH2N2 , ether
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The reaction was thus attempted with our intermediates. The diazomethane was 
generated [352] by the treatment of N-nitroso-N-methyl-/?-methyltoluenesulphonamide 
with KOH (Scheme 76).
Scheme 76
p - Me - C6H4S0 2N(N0)Me + ROH ---- -— ► CH2N2 + p - Me - C6H4S 03R
Reagents : (a) KOH , H20  , Et20 ,70  - 75°C
In the presence o f light
On the addition of 1.25 mole equivalents of diazomethane to the (Z)-benzylidene 
(227Z) at room temperature two major products were formed, neither of which 










Reagents : (a) CH2N2 , ether, room temp . ,  Id
These compounds, 233 and 234, occurred as a result of N- and O-methylation, 
respectively. The reaction was then repeated using an excess of diazomethane. It was 
found that on allowing the solution to stir at room temperature for 2 days the desired 
cyclopropane (235) was formed as a mix of two diastereomers (4:1) together with the 








Ph Ph CH3 Ph 
233227Z 235
Reagents : (a) CH2N2 (10 mol e q .) ,  ether , RT , 2d
It is interesting to note that no pyrazoline intermediate (236) was isolated as a 
consequence of alkene insertion of diazomethane.
This indicated the intermediate (236) was sufficiently unstable to collapse directly to 
the cyclopropane without the need of photolytic or pyrolytic techniques.
The two cyclopropyl diastereomers were separable by flash chromatography to give the 
major compound (237) as a white solid in 30% yield.
The absolute stereochemistry of 237 was determined by NMR studies. The NMR 








This is in following with the proposed structure since the coupling constants (7) agree 
with the ruling that / syn^anri-^gem- The chemical shifts and coupling constants were 
found to be similar to that of a (Z)-phenyl substituted spirocyclopropane (238) [173].
Ph
238




Si 2.38 J 12-5.5
s2 2.24 ^23 8.7
s3 3.20 J\3 9.7
A crystal structure of the N-tosyl derivative of (2S,3S)-2,3-methanophenylalanine later 
derived from the (Z)-cyclopropane (237) concluded that the proposed structure was 
indeed correct (See Appendix for X-ray structure).
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Catalysed carbene transfer
Methods were now sought to improve the diastereoselectivity of the carbene transfer 
and to improve the overall yield of cyclopropane. The addition of diazomethane to the 
benzylidene (227Z) was repeated in the absence of light but gave a similar ratio of 
diasteromers (235) (3:1) with the (lS,3S)-configuration as the major diasteromer, as 
before.
Use o f silica template
In 1979, Ohno et al reported the synthesis of the caprolactim (240) from the 
caprolactam (239) via treatment with diazomethane in the presence of a silica gel 





Reagents : (a) CH2N2 , ether, silica g e l, NaHC03
The use of a silica gel template to bind the substrate was considered a plausible method 
to obtain selective cyclopropanation once the alkene (227Z) had been bound to the 
template. On treatment with diazomethane, however, no desired O-methylated 
cyclopropane was obtained.
Use o f transition metal complexes
The generation of cyclopropanes via catalytic transformation of diazo compounds with 
olefins is generally attributed to occur by the interaction of an electrophilic metal
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carbene with an olefin. However the specific details of that interaction remains 
unresolved [354]. A broad selection of catalysts for cyclopropanation have been 
identified. Originally copper complexes were the main source of catalysis within this 
field [355], but more recently this has been strongly challenged by some group VIII 
metals e.g. palladium, rhodium, etc. [356].
Initially palladium (II) acetate was selected as a suitable catalyst to use after claims of 
near quantitative cyclopropanation were reported for a,(3-unsaturated ketones on 
treatment with catalysed diazomethane [357]. The addition of an ethereal solution of 
diazomethane to a suspension of the benzylidene (227Z) and palladium (II) acetate in 
ether afforded, after work-up, a 3.5:1 mix of the O-methylated cyclopropanes (235) in 
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235
Ph
Reagents : (a) CH2N2 , Pd(OAc)2 c a t., ether
The use of palladium (II) chloride gave similar diastereoselectivity (4:1) and yield 
(23%). In both cases NMR studies indicated the major diastereomer to have the 
same configuration as for the uncatalysed diazomethane reaction i.e. the 
(Z)-(lS,3S)-configuration.
The low yields obtained during the cyclopropane formation, from the alkene (227Z), 
clearly indicated that the amide function would have to be protected as to inhibit the
competitive N- and O-methylation during carbene transfer. Acylation seemed the 
natural choice since by using the same amide protecting group, as already present, 
deprotection at a later stage would be simplified.
Acylation was achieved by heating the (Z)-benzylidene (227Z) in acetic anhydride in 








Reagents : (a) Ac20 , pyridine, 70°C , 7h
The treatment of 241 with an excess of ethereal diazomethane, in daylight, afforded an 
mix of the desired cyclopropane (242) and the vinyl methyl adduct (243) (1:1.5) in 13% 














Reagents : (a) CH2N2 , ether, RT
I l l
The protection of the amide nitrogen in the alkene (227Z) with a silyl group was then 
attempted. The treatment of 227Z with trimethylsilyl chloride and base gave the 







Reagents : (a) i) t - BuOK , THF , 0°C , ii) TMS - Cl
Separation of the geometrical isomers of 244E/Z via flash chromatography 
unfortunately resulted in deprotection to yield the starting material (227E/Z).
The next strategy for cyclopropane construction was via the addition of a 
sulphoxonium ylide to the bis-acylated alkene (241).
Addition o f a sulphoxonium ylide
In 1965, Corey and Chaykovsky showed that dimethylsulphoxonium ylide (245) reacts 
with unsaturated conjugated ketones by a Michael addition to give cyclopropyl ketones 
(247) [358]. A two step mechanism involving the dipolar intermediate (246) and 















Since then other sulphur ylides e.g. 248 (A=acyl [359], carbethoxy [360], 249 [361], 
and 250 [362], which transfer CHA, CH-vinyl, and CMe2 respectively, have been used.
CH3
J  .
CH3-±S — CH-A 
248
The addition of a sulphoxonium ylide was then applied to our system. The 
dimethylsulphoxonium ylide was prepared following Trosts procedure [363]. To this 
was added a solution of the bisacylated benzylidene (241) in DMF. After the 
application of heat and work-up a NMR study of the residue revealed a 
multicomponent mix of products together with unreacted starting material (Scheme 
85).
CH, Ph




















Reagents : (a) CH2S(0 )Me2 , DMF, 0 - 100°C
Overall the direct use of diazomethane with the benzyldine (227Z) was found to give 
the best results. Despite the low yield of cyclopropane (235) a 4:1 diastereoselectivity 
was obtained of which a single diastereomer could be obtained in pure form. In 
addition, the cyclopropane (235) contained an imine ether moiety as a result of
O-methylation. This is fortunate since the amide bonds will later require suitable 
modification to allow hydrolysis to be achieved, and provided access to the preparation 
of the VPhe-Val dipeptides.
Deprotection o f the cyclopropane (237)
The deprotection of 237 was achieved quite cleanly by the treatment with potassium 
carbonate in methanol at room temperature to give the desired amide (251) in 




Reagents : (a) K2C 03 , MeOH , RT , 15 mins
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Preparation o f (Z)-(2S,3S)-2,3-methanophenylalanine methyl ester (253).
The procedures of Schollkopf [332] were employed in the conversion of the amide 
(251) to the desired 2,3-methanophenylalanine methyl ester (253).
To a solution of the amide (251) in DCM was added
trimethyloxoniumtetrafluoroborate. After two days, work-up yielded the desired 
bislactim ether (252) as a colourless oil in 71% yield (Scheme 87).
Scheme 87
Reagents : (a) Me3 0 BF4 ,DCM ,RT , 2d
The hydrolysis of the bislactim ether (252) under mild acidic conditions afforded, after 






Reagents : (a) i) 0.25M HC1,ether, R T , 24h , ii) NH3(aq), pH9 , 0°C
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These were found to be easily separated via flash chromatography on silica gel to give 
the 2,3-methanophenylalanine methyl ester (253) in 58% yield as a colourless oil.
The absolute stereochemistry of 253 had yet to be proven. The treatment of
2,3-methanophenylalanine with triethylamine and tosyl chloride generated the N-tosyl 
derivatives (254) in 78% yield as a colourless solid (Scheme 89).
Scheme 89
H2N .  ^ C 0 2Me TsNH ^ C 0 2Me> —^  >
Ph Ph
253 254
Reagents : (a) TSC1 , Et3N , THF , A , 2 h
Recrystallisation of (254) from ethyl acetate-petrol provided crystals suitable for an 
X-ray crystallographic determination, which duly confirmed our assignment of this 















Fig 4. X-ray plot of (2S,3S)-N-tosylamino-VzPhe-OMe(ORTEP plot).
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Having successfully found a diastereomeric synthesis for (Z)-2,3-methano- 
phenylalanine methyl ester (253), their (E)-analogues were then prepared following the 
same synthetic pathway.
Preparation o f (E)-2,3-methanophenylalanine methyl ester (259)
The (E)-benzylidene (227E), prepared through photoequilibration of the (Z)-isomer 
(227Z), was treated with ethereal diazomethane to afford the desired cyclopropane 








MeO N ^ \ L - ph
255
Reagents : (a) CH2N2 , ether, RT , 2d
The major isomer (256) was separated by flash chromatography and isolated as a 




Deprotection o f the cyclopropane (256)
The desired amide (257) was prepared uneventfully by treating the cyclopropane (256) 








NX L - Ph
257
Reagents : (a) K2C 0 3 , DCM , R T , 2h
Preparation o f the (E)-(2S,3R)-2,3-methanophenylalanine methyl ester (258).
The treatment of the amide (257) with Meerwein’s reagent gave the (E)-bislactim ether 





MeOX ^ , n X X - -
Ph
258
Reagents : (a) Me3OBF4 , DCM , RT , 2d
The hydrolysis of (258) under mild acidic conditions gave a mixture of L-valine methyl 
ester and (E)-2,3-phenylalanine methyl ester (259) after basification. (Scheme 93).
These were readily separated by flash chromatography on silica gel to afford the 
desired (E)-2,3-methanophenylalanine (259) in low yield (22%).
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Scheme 93






Reagents : (a) i) 0.25M HC1, ether, R T , 24h , ii) 2M NH4OH , pH6 , 0°C
2.4 Preparation of 2,3-methanophenylalanine dipeptide derivatives
Coupling of(Z)- and (E)-2,3-methanophenylalanine ester (253 and 259) with an 
N-protected tryptophan (206)
Preparation o f the (Z)-dipeptide ester (260)
The coupling conditions used for the preparation of the dehydrophenylalanine dipeptide 
series (Section 1.3) were initially employed. The N-protected tryptophan (206) was 
initially activated by the addition of HOBt/DCC and to this was added (Z)-amino ester 
(253) at room temperature. After work up only unreacted starting material was 
recovered in 80% yield (Scheme 94).
Scheme 94
Reagents : (a) i) HOBT, DCC , EtOAc , ii) (2S,3S)-VzPhe-OMe , EtOAc , RT
Clearly the activated ester generated in situ was insufficient to favour attack by the 
hindered amine of the amino ester (253). It was noticed that Stammer et al had 
previously reported [364] the preparation of peptides containing (Z)-2,3-methano- 




no desired dipeptide 
formed
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enkephalin analogues (Scheme 95).
Scheme 95
BO C-Tyr- D-Ala-Gly-OH -----------------► BOC - Tyr - D - Aia - Gly - (-)-Vz Phe - OMe
Reagents : (a) i) NMM , isobutyl chloroformate , TH F, -10°C , 30 m ins., 
ii) (-)-VzPhe - O M e. HC1, NM M , CHCI3 , 0°C
These conditions were applied to our system and afforded the desired dipeptide (260) 
as a yellow foam in 40% yield.
O CH;x„>
260
This procedure was successful owing to the anhydride (261) generated being highly 
















+ C 0 2 + OH
Reagents : (a) NMM , TH F, 0°C .
An adapted DCC coupling procedure was then tried whereby
l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) was used 
instead of DCC for ease of removal of the urea by-product (EDU) on work-up. This 
gave no desired dipeptide (260) at room temperature but under more forcing conditions 
260 was achieved but in low yield (31%) (Scheme 97).
Scheme 97
2-Adoc-R-a-Me-T rp-OH 2-Adoc-R-a-Me-Trp N H ^ _ / C 02Me>
Ph
260
Reagents : (a) i) NM M , HOBT, EDC , THF , 0°C , lh , ii) (2S,3S)VzPhe - OMe , 
THF , A , l d
Preparation o f the (E)-dipeptide ester (262)
The mixed anhydride approach was applied to the coupling of the (E)-amino ester (259) 
with the N-protected tryptophan (206). On employing the same conditions, as for the
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It was noticed during these mixed anhydride couplings that several by-products were 
obtained. These were not isolated but were likely to be acyl and anhydride derivatives 
(264) and (265) of the starting amino esters (263) formed as a result of competing 






HoN ^ C 0 2Me
Ph 263
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R-NHC(Me) O w COoMeY Y >









These side reactions would account for the low yield of the desired (Z)- and
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(E)-dipeptide esters (260) and (262).
Hydrolysis o f the dipeptide ester (260)
The same hydrolysis techniques were employed as for the dehydrodipeptide ester 
(219Z). The use of lithium hydroxide similarly gave no desired acid even after reflux 
(Scheme 99), unreacted starting material was recovered in 85% yield.
Scheme 99
Reagents : (a) 0.1M LiOH (aq), TH F, A , 3h
The use of 0.1 M sodium hydroxide with the ester (260) in ethanol was attempted, 
which after reflux for 2h afforded the desired acid (266) in crude form (88% yield).
The product was then further purified by reverse-phase chromatography to give the acid 













Reagents : (a) 0.1M NaOH (aq), EtOH tA , 3h
Insufficient material of the (E)-dipeptide ester (262) and time prevented the
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corresponding acid (267) from being made by these techniques.
2-Adoc-R-a-Me-T rp NH
267
Attempted hydrolysis o f the imine ether (237)
As a result of treatment of the (Z)-benzylidene (227Z) with an excess of diazomethane 
it was found that methylene not only inserted into the carbon-carbon double bond to 
form the cyclopropane, as desired, but also added into the amide carbonyl oxygen to 
give the imine ether adduct (237) (See Section 2.3).





The obvious choice of hydrolysis reagent was mild acidic conditions since this was 
successfully employed in the hydrolysis of the bismine ether (252) to afford the






O ^  OMe
253
Reagents : (a) i) 0.25M HC1, ether , RT, 24h , ii) NH3(aq), pH9 , 0°C
These conditions were applied to the imine ether (237). After 2h at room temperature 
normal-phase tic indicated that all the starting material had been transformed into the 












Reagents : (a) 0.25M HC1, ether , RT, 2d
After work-up NMR of the organic phase verified that the deacylated product (251) 
had been formed. Reverse-phase tic on the remaining aqueous phase indicated an 




Clearly hydrolysis of the imine ether was being achieved, however, the hydrolysed 
product (268) was recyclising and/or undergoing further hydrolysis. To overcome 
these problems hydrolysis using an ammonium hydroxide source was considered a 
good alternative since the amide (270) formed upon hydrolysis would be more stable to 
recyclisation than the corresponding ester.
HoN> H CONH,
270
An aqueous ammonia solution was added to the imine ether (237) at room temperature 
and the reaction was monitored by tic. No baseline products were evident after 2 days.










Reagents : (a) 33% w/w NH3 (aq), TH F, R T , 2d
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In 1990 Schollkopf reported [366] the isolation of a dipeptide ester (272) via the 
hydrolysis of an imine ether (271) in an analogous system (Scheme 104).
Scheme 104
NH2 R3 R2





R*= 1-8C alkyl, phenyl or benzyl 
R2= 1-8C alkyl (opt. interupted by 0,S 
or COO), phenyl or benzyl.
R3= H
R2+R3= (CH2)3 , (CH2)4 or CH2CH=CHCH2
Reagents : (a) 0.1N HC1, CH3CN , R T , 24h
Using mild acidic conditions and high dilution. These conditions were applied to the 








H,N N ^  COoMe
y >  h
Reagents : (a) i) 0.1M HC1, CH3CN , RT, 21h , ii) NaHC03 (aq) ,pH7
The compound 268 was confirmed by NMR and tic (ninhydrin active). The same 
conditions were applied to the (E)-imine ether (257) and the (E)-2,3-methano-
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1 ■ N C 02Me
""/// Ph
257 273
Reagents : (a) i) 0.1M HC1, CH3CN , room temperature , 15h , ii) NaHC03 (aq), 
pH7
128
2.5 Structure Activity Relationships
In 1990 Horwell et al reported the design of novel a-methyl-Trp dipeptide analogues of 
CCK (30-33) which possessed micromolar CCK-B receptor affinity [321]. For 




274A(R=Trichloro-fbutyloxycarbonyl (TcBoc), R!=H, Ar= 2-Pyr) 
B(R= 1-Adamantyloxycarbonyl (1-Adoc), R1= H, Ar= Ph)
It was suggested that the minimum fragment of CCK (30-33) can be read by the 
receptor as the continuous message Trp-Phe, corresponding to the non-continuous 
message of CCK (30-33) (Trp-Met-Asp-Phe-amide) (Fig. 5).
Fine tuning of the N- and C-terminus groups of these dipeptide analogues(274) 
indicated that the C-terminus could tolerate many changes to the a-Phe side chain, e.g. 
(S)-Phe-CONH2 (274C, R^CONHj), (S)-Phe-CH2OH (274D, R'=CH2OH) and 
(S)-Phe-piperidide (274E, R’=CON-piperidine), without loss in binding affinity [321]. 
Whilst the N-terminus required bulky substituents rather than a straight chain or an 



















Boc-NH — C H - CO-NH — CH- CONH
Fig.5 Model of the non-continuous Trp-Phe-message of CCK-4 mimicked by the 
continuous Trp-Phe-message of the dipeptide Boc-Trp-Phe-amide.
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Table 10. Physical data binding affinities for a-Me-Trp-Phe and 




Entry R R1 Configuration
MeTrp Phe Ar
274A TcBoc H RS 2-Pyr 10
B 1-Adoc H RS - Ph 5
C Boc c o n h 2 R S Ph 35
D Amoc c h 2o h RS S Ph 9
E Amoc CON Q RS s Ph 23
The 2-adamantyl group was later found to be the superior choice of N-substituent and 
when present in a-methyl-(R)-tryptophan derivative, for example compound 275, Table 
11, these compounds were found to have nanomolar CCK-B binding affinities [322].
1 3 1
In most instances these compounds possessed binding affinities comparable to CCK 
(30-33) itself [367].




Entry R1 R2 ICjo (nM)
CCK-B CCK-A
275A CH2OH H 6.3 (4.2-8.9) 780 (690-850)
275B CH2OCO(CH2)2-
c o 2h
H 3.4 (2.5-5.8) 740 (690-790)
275C c h 2n h c o c h = c h -
c o 2h
H 0.8 (0.4-1.2) 440 (430-440)
275D H NHCOCH=CH-
c o 2h
0.7 (0.5-1.0) 790 (680-1000)
275E H NHCO(CH2)2-
c o 2h
1.7 (1.3-2.7) 4300 (1200-8500)
276, Devazepide (MK329) 31 (18-43) 0.1 (0.03-0.2)
277, L-365,260 5.1 (4.6-5.4) 230 (170-380)
278, CCK-8S 0.3 (0.2-0.3) 0.1 (0.08-0.2)
279, Pentagastrin 0.8 (0.5-0.9) 600 (500-660)
* IC50 represents the concentration (nM) producing half maximal inhibition of specific 
binding of [125I] Bolton Hunter CCK-8 to CCK receptors in the mouse cerebral cortex 
(CCK-B) or the rat pancreas (CCK-A). The values given are the geometric mean and the 
range from at least three separate experiments.
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This data indicates that the Tip and Phe residues are necessary to impart micromolar 
affinity but molecular recognition information in the Met and Asp residues of CCK 
(30-33) enhances affinity a further 1000-fold. Conformational energy minimisation 
studies of CCK(30-33) have shown a preferred helical stucture [368], in which the Trp 
and Phe residues are within close proximity of one another, which is in agreement with 
ORD data [369]. As a consequence of this, the Asp residue is readily available as an 
necessary binding group in which the terminal COOH group is free to explore a large 
volume of space [368-370]. These compounds, containing a C-terminal carboxyl 
group, are expected to be good candidates for CCK-4 dipeptide surrogates. If the 
carboxyl moiety is conformationally restricted and if its conformation, together with 
those of the Trp and Phe moieties, are correct to fit the receptor in the active site then, 
as a result of the molecules reduced degrees of freedom, the gain in entropy should 
cause the substrate to bind more strongly to the receptor and thus be a better agonist/ 
antagonist. The conformationally restricted dehydrophenylalanine and 2,3-methano­
phenylalanine derivative (280 and 281) were seen as ideal candidates for this purpose 











The binding affinities of the a-Me-(R)-Tip dipeptide derivatives prepared are given in 
Table 12.
1 3 3
Table 12 - CCK receptor binding affinities*
Substrate IC50 (nM)
CCK-B CCK-A
R,S Threo 2-Adoc-R-a-Me-Trp-NHC(C02Me)CHPh(OAc) (218) 13 -
2-Adoc-R-a-Me-Trp-AzPhe-OMe (219Z) 270 -
2-Adoc-R-a-Me-Trp-AzPhe-OH (220Z) 54 60
2-Adoc-R-a-Me-Trp-(2S,3S)-VzPhe-OMe (260) 595 720
2-Adoc-R-a-Me-Trp-(2S,3S)-VzPhe-OH (266) 126 84
2-Adoc-R-a-Me-Trp-(2S,3R)-VEPhe-OMe (262) 6.5 -
• Binding affinities defined in footnote a, Table 11
It can be seen from Table 12 that with respect to CCK-B receptor binding the 
introduction of a carbon-carbon double bond to the Phe residue with Z-stereochemistry 
gives reasonable binding of which the acid form (220) has a 5-fold increased activity 
over its ester counterpart (219). This, latter feature is likely to be due to the presence of 
H-bonding of the carboxyl group with the enzyme receptor site. Whilst the presence of 
a cyclopropyl group gives slightly worse binding in both ester and acid forms, (260) 
and (266), when present with Z-configuration than the corresponding (Z)-dehydro Phe 
analogues (219) and (220) respectively. The ester (262), however, with 
E-configuration exhibits excellent CCK-B binding affinity with an IC50 = 6.5nM. The 
corresponding acid form of (267) would thus be expected to have a binding affinity 
similar to the parent substrate CCK-4 (Kj = 3nM) [367].




Molecular dynamic studies were performed upon the three peptides
2-Adoc-a-Me-(R)-VzPhe-OMe(260), 2-Adoc-a-Me-(R)-VEPhe-OMe(262) and
2-Adoc-a-Me-(R)-AzPhe-OMe(219Z) in an attempt to elucidate their preferred 
conformations. Prior to this, the effect of the a-Me-(R)-Trp residue ;which is common 
to all three peptides; on the overall peptide conformation was looked at in detail by 
determining its (<j>,y) energy contour map. The model chosen to study this was the 
dipeptide N-Ac-a-Me-(R)-Trp-N-Me.
The <j),y energy map of N-Ac-a-Me(R)-Trp-N-Me indicates two main low energy 
regions, one on the right hand side of the map at <J), 30 to 100°, y , -80° to 60° and a 
similar region on the left hand side of the map at <j>, -80° to -50°, y , -50° to 100° (Fig.
6). The rotational energy barrier between these two conformationally favoured regions 
being b-Skcalmol"1. The lowest energy conformation is indicated on the map by an X. 
It can also be seen that a negative (j) value prefers a positive y  value, whilst for a 
positive <J> value there is no preference in the sign of the y  value.
The ten lowest energy minima calculated for the dehydro- and 2,3-methano­
phenylalanine derivatives (219Z, 260 and 262) are shown in Tables 13-15. In each 
case the p-tum type stated represents the initial conformation of the dipeptide before 
minimisation studies were applied; and not the resultant dipeptide conformation, which 
is defined by the calculated <J>, y  and % values.
IK)
/ 2.0
Fig6. A (<J>,y) energy contour 
map for the dipeptide 
N-Ac-a-Me-(R)-Trp-N-Me
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For 2-Adoc-a-Me-(R)-Trp-AzPhe-OMe (219) the ten calculated minimum energy 
conformations (Table 13) all possessed a (3-tum, but there was no preference in type.










1 I ’ 45 23 -65 93 43 2 0
2 r 42 29 -66 94 -72 2 0
3 i -72 67 53 -81 -26 0 0.6
4 ii -68 73 -178 94 31 0 0.6
5 ii -62 40 -70 96 37 2 1.4
6 r 53 24 -64 95 40 2 1.5
7 ii -72 32 48 97 30 4 1.8
8 r 51 24 -70 99 37 2 1.8
9 i -72 62 54 -93 32 0 1.9
10 i -72 60 54 -89 -27 -1 1.9
The majority of the conformations favoured the indole and phenyl rings on the same 
side of the peptide chain, with the adamantyl group on the opposite side (Fig.7).
Structure 1. Structure
Fig 7. Two minimum energy conformations of 2-Adoc-a-Me-R-Trp-Az
(Structures 1 and 4)
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In one particular case, Structure 4, there is clearly n stacking occuring between the 
phenyl and indole rings, the inter-ring distance being 4-6A.
Similarly for the VzPhe-OMe derivative (260) there was no preference in p-tum type 
[Table 14].










1 I -60 57 -76 -55 -58 8 0
2 n -67 30 47 71 59 18 1.3
3 r 40 36 -65 68 59 18 1.8
4 n -69 25 47 72 59 18 2.5
5 i -72 56 53 -66 -62 6 2.5
6 i 72 48 160 -84 -72 6 2.7
7 n -72 55 57 76 60 18 3.1
8 n -71 58 59 77 59 18 3.6
9 i -56 4 -73 -67 -65 4 4.1
10 IT 54 20 59 -69 -62 4 4.3
The four lowest energy conformations (Structures 1-4) (Fig.8) have the phenyl and 
indole rings on the same side of the peptide chain, whilst the remainder had phenyl and 
indole rings on opposite sides. In all these examples the adamantyl group tends to be in 
close proximity to either phenyl or indole ring
Structure 1. Structure 2.
Fig 8. Two minimum energy conformations of 2-Adoc-a-Me-R-Trp-VzPhe-OMe (Structures
1 and 2)
In the case of the VEPhe-OMe derivative (262) the two lowest energy conformations 
(Structures 1 and 2) (Fig.9) have the phenyl and indole rings approximately orthogonal 
to one another. It is interesting to note that energies of structures (1) and (2) are similar 
even though the relative disposition of the rings are quite different in the two cases.
For the remainder of the examples (Structures 3-10) all possess the indole and phenyl 
groups on the same side of the peptide chain. Once again all p-tum types are 
favoured. (Table 15).










1 II -65 61 174 86 -87 150 0
2 II’ 54 -13 -71 -75 -57 141 0.3
3 I -66 71 -111 -54 -56 144 0.4
4 II -68 59 111 85 -86 150 0.8
5 II -66 61 176 85 74 151 1.0
6 II -72 51 53 85 -86 150 2.0
7 II -68 59 178 84 80 151 2.2
8 I -70 45 162 -88 -62 141 2.8
9 II’ 61 -9 -68 -75 -60 143 2.9
10 I -54 -6 -75 -76 -63 142 2.9
Structure 2.Structure 1
Fig 9. Two minimum energy conformations of 2-Adoc-a-Me-R-Trp-VEPhe-OMe
(Structures 1 and 2)
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2.6 Conclusion
The amino acids VPhe, APhe and a-Me-(R)-Trp are all highly constrained residues 
and as a consequence the overall conformation appears to be governed by the 
constraints imposed by the individual residues present. As a result, the allowed low 
energy conformations of VPhe, APhe and a-Me-(R)-Trp are conducive to all p-tum 
types. The type of p-tum present may therefore be unimportant but the presence of a 
P-tum appears to be important.
The majority of low energy conformations, in all three dipeptides, indicated the 
preference of both indole and phenyl rings to lie on the same side of the peptide chain, 
and thus be available for receptor binding at the active site. This is in accordance with 
the CCK-B receptor site model proposed by Horwell et al [321].
Future work should be directed towards the synthesis of the remaining diastereomers of 
VPhe and APhe analogues of a-Me-(R)-Trp-Phe especially the E-forms which indicate 





3.1 Instrumentation and experimental techniques
3.1.1 Solvents and reagents
All solvents were dried and distilled before use. Petrol refers to petroleum ether 
boiling in the range 60-80°C. Tetrahydrofuran was pre-dried over sodium wire and 
then refluxed over sodium benzophenone ketyl under a nitrogen atmosphere until 
anhydrous. This was redistilled immediately prior to use. All other solvents and 
reagents were purified using the procedures described in Purification o f laboratory 
chemicals [371].
3.1.2 Chromatography
Thin layer chromatography (tic) was used extensively as a qualitative guide during 
reactions and for assessing the purity of compounds. Merck DC-alufolien Kieselgel 60 
F254 sheets and Whatman Reverse Phase KCjgF octadecylsilane bonded plates (both 
containing fluorescent indicator) were used for this purpose. Visualisation of 
compounds was achieved by illumination under short wavelength (254nm) ultraviolet 
light (when possible). Plates were developed by treatment with either a 0.5% (w/v) 
aqueous solution of potassium permanganate or a 7% (w/v) methanolic solution of 
phosphomolydbic acid or a 0.3% (w/v) solution of ninhydrin in butanol or a 3% (v/v) 
solution of anisaldehyde in ethanol, normally followed by warming of the tic plate.
Normal phase medium pressure flash chromatography was routinely employed using 
Amicon Matrex or Merck 9385 silica gel whilst LiChroprep RP-18 reverse phase silica 
gel was used for reverse phase chromatograhy. Columns were packed as a slurry in the 
eluting solvent and the material to be chromatographed introduced directly as a solution
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in the eluting solvent or preabsorbed onto silica and then applied as a thin layer to the 
top of the column. A pressure gradient was developed using a small hand bellow.
3.1.3 General
Glassware used for moisture sensitve reactions was heated in an oven at 120°C 
overnight and then allowed to cool in a desicator over calcium chloride. Flasks and 
stirrer bars were additionally flame dried under a stream of dry nitrogen prior to use.
Solvents were evaporated with a Buchi rotary evaporator using a water aspirator or a 
vacuum pump as required and a water bath temperature <40°C to avoid unnecessary 
heating.
3.1.4 Analysis and spectroscopy
Melting points (m.p.) were determined on commercially available apparatus 
(electrothermal M KII or Gallenkamp) and are uncorrected. Elemental micro-analyses 
were carried out using a Carlo Erba 1106 Elemental Analyser. Optical rotations were 
measured using a Perkin-Elmer 141 polarimeter with concentrations expressed in 
g/100cm3.
Infrared spectra were recorded in the range 4000-600cm'1 using a Perkin-Elmer 1310 
spectrophotometer and peaks are reported (vmax) in wave numbers (cm-1) and the 
abbreviations br (broad), s (strong) and vs (very strong) were used to describe the 
peaks. Samples were prepared as liquid films, nujol mulls or chloroform solutions as 
indicated.
Proton magnetic resonance spectra were recorded on a Jeol GX FT 270 (270MHz) 
spectrometer, although where indicated a Jeol GX FT 400 (400MHz) instrument was
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used. Carbon-13 magnetic resonance spectra were recorded on a Jeol GX FT 270 
spectrometer operating at 67.8MHz and using 90 and 135 DEPT pulse sequences to aid 
multiplicity determination. Chemical shifts (8) are expressed in parts per million 
downfield from internal tetramethylsilane. The multiplicities of the resonances are 
denoted by s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet) and m 
(multiplet). The abbreviation br (broadened) is used to indicate significant broadening, 
whether due to rapid exchange or unresolved fine coupling. Homonuclear decoupling 
experiments and 2D homonuclear shift correlated (COSY) spectra were used to confirm 
proton assignments when required.
Mass spectra were recorded using a VG Analytical 7070E instrument with a VG 2000 
data system. Electron ionisation (E.I.) spectra were produced using an ionising 
potential of 70eV. Chemical ionisation (C.I.) was employed using wo-butane as the 
reagent gas.
3.2 Experimental procedure 
Preparation of dehydropeptides
Preparation o f (RS)-threo-3-phenylserine methyl ester (214).
To methanol (100cm3) in 250cm3 rbf was added dropwise neat thionyl chloride (23ml, 
275mmol) with stirring at 0°C. To this was added RS-r/zreo-3-phenylserine hydrate 
(lOg, 55mmol) in solid form. After allowing to warm to room temperature the 
suspension was stirred overnight. The clear solution was neutralised with 1M sodium 
hydroxide solution, extracted with DCM (3x75cm3) and the combined organic extracts 
dried (sodium sulphate), filtered and the solvent was removed in vacuo to yield a 
yellow oil (214), (8 .6g, 80%) (Rf=0.58, methanol-DCM (15:85)); t)max (CHC13) 3373
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and 3200 (NH2and OH), 1739 (C02Me), 1670 (Ar C=C), 1216 (C-N); 8H (CDC13) 2.44 
(3H, s, NH2 and OH), 3.62 (1H, d, / 3,24.6, 3-H); 3.67 (3H, s, C 02Me), 4.90 (1H, d, 
72>34.6, 2-H), 7.33 (5H, s, Ph).
N a -(2 -Adamantyloxy carbonyl)-a-methyl-R-tryptophanyl-R,S-threo-3 -phenylserine 
methyl ester (215)
To a solution of the acid (206) (lg, 2.5mmol) in ethyl acetate (50cm3) was added
1-hydroxybenzotriazole (0.42g, 2.8mmol) in solid form. This was followed by the 
dropwise addition of a solution of N,N'-dicyclohexylcarbodiimide (0.62g, 3.0mmol) in 
ethyl acetate (5cm3) at room temperature. The suspension was stirred for one hour.
The precipitate which had formed (dicyclohexylurea) was filtered off and a solution of
3-phenylserine methyl ester (214) in ethyl acetate (10cm3) was added dropwise to the 
filtrate. After 23h the solution was worked up by washing with 5% aqueous citric acid 
solution (25cm3), saturated aqueous sodium bicarbonate solution (25cm3) and brine 
(30cm3). The organic phase was dried over anhydrous magnesium sulphate and 
reduced in vacuo to yield a yellow oil. After purification via flash chromatography on 
silica gel by elution with methanol-DCM (1:19), the desired product (215) was isolated 
as a white foam (1.2g, 83%); (Rf=0.69, methanol-DCM (15:85), umax (CHC13) 3395 br 
(OH and NH2), 1734 (C02Me), 1670 (CONH), 1496 (Ar C=C), 1215 (C-N); 8H 
(CDC13), 1.45 (3H, s, R-a-Me), 1.46-1.96 (14H, m, adamantyl), 3.23 (1H, d , / gem 15,
3-H.l), 3.41 (1H, d, / gem 15, 3-H.l), 3.61 (3H, s, C 02Me), 4.82 (1H, br s, adamantyl
2-H), 4.92 (1H, m, 2-H.2), 5.09 (1H, d, J  4.4, 3-H.2), 5.28 (1H, br s, 2-NH.2), 5.32 (1H, 
s, 2-NH.l), 6.80-7.57 (10H, m, Indole, Ph Ar), 8.34 (1H, s, Indole NH); 8C (CDC13) 
14.14 (R-a-Me), 21.02 (Ad), 23.71 (Ad), 24.55 (Ad), 25.23 (Ad), 26.86 (Ad), 27.05 
(Ad), 31.66 (C-3.1), 31.98 (Ad), 33.12 (Ad), 36.26 (Ad), 37.27 (Ad), 52.35 (C-2.2), 
58.64 (MeO), 60.45 (C-2.1), 74.30 (C-3.2), 109.57 (Ar), 111.09 (Ar), 118.88 (Ar), 
119.52 (Ar), 121.83 (Ar), 123.87 (Ar), 124.03 (Ar), 125.91 (Ar), 127.89 (Ar), 128.33
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(Ar), 135.87 (Ar), 139.53(AR), 155.4(CONH), 170.80(OCONH), 174.3l(C 02Me); m/z 
(+FAB), 574(MH+,27%), 444(17), 378(20),135(100).
Attempted dehydration o f the alcohol (215) to yield the dehydroamino acid,
2-adamantyloxycarbonyl)-a-methyl-R-tryptophanyl-dehydro phenylalanine methyl 
ester (219Z)
Method 1.
To a solution of the alcohol (215) (lOOmg, 0.17mmol) in dry THF (5cm3) was added 
pyridine (14jxl, 0.17mmol) followed by diethylaminosulphur trifluoride (23pl, 
0.17mmol) with stirring under nitrogen at 0°C. After stirring overnight the solution had 
turned a light brown colour, however no presence of the dehydrated product was 
observed except baseline material by tic, solvent methanol-DCM (1:9). After a further 
24 hours the solution was worked up by washing with water (5cm3) and extracting with 
DCM (3x10cm3). The combined organic extracts were dried over sodium sulphate and 
reduced in vacuo yielding a dark brown oil. Purification via flash chromatography on 
silica gel gave only recovered starting material (215) (20mg, 20%).
Method 2.
To a solution of the alcohol (215) (lOOmg, 0.17mmol) in THF (3cm3) was added 
triethylamine (24pl, 0.17mmol) followed by N,N'-carbonyldiimidazole (28mg, 
0.17mmol) with stirring under nitrogen at room temperature. After 3h no product had 
been formed. The solution was refluxed for 24h and worked up by washing with water 
(5cm3) and extracting into DCM (3x10cm3). The combined extracts were dried over 
anhydrous sodium sulphate and reduced in vacuo to give a pale yellow oil. *H NMR 
spectroscopy revealed only the presence of recovered starting material (Yield 80%).
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Method 3.
To the alcohol (215) (lOOmg, 0.17mmol) and dried sodium acetate (anhydrous) (28mg, 
0.34mmol) was added acetic anhydride (3cm3) with stirring at 30°C. The solution 
immediately turned from colourless through orange to red. After 12h the reaction was 
complete. The solution was washed with water (5cm3) and extracted with DCM 
(3x30cm3). The combined organic extracts were dried over anhydrous magnesium 
sulphate and the solvent removed in vacuo. The residue was purified by flash 
chromatography on silica gel eluting with methanol-DCM (2:98). No dehydroamino 
acid was generated but instead (218) (O-acetylated product) was isolated as a pale 
yellow foam (104mg, 100%), (RpO.61 (methanol-DCM (1:9)); (Found C, 66.14; N, 
6.61, H, 6.77 C35H41N307 . H20  required C, 66.2; N, 6.23; N, 6.92). umax (CHC13) 
3395 (amide NH), 1747 vs br (C02Me and CH3CO), 1496 (Ar C=C), 1232 (C-O and 
C-N); 5h (CDC13) 1.38-2.10 (17H, m, adamantyl and R-a-Me), 2.10 (3H, d, acetyl),
3.20 (1H, d, / gem 15, 3-H.2), 3.51 (1H, d, 7gem 15, 3-H.2), 3.61 (3H, d, C 02Me), 4.84 
(1H, s, adamantyl 2-H), 5.02 (1H, m, 2-H.2), 5.08 (1H, s, 2-NH.2), 5.18 (1H, s,
2-NH.l), 6.24 (1H, m, 3-H.2), 6.80-7.57 (10H, m, Ph, indole Ar), 8.75 (1H, d, indole 
NH); 5C (CDC13) 13.82 (R-a-Me), 20.40 (Ac Me), 23.22 (Ad), 23.58 (Ad), 24.59 (Ad),
25.20 (Ad), 26.60 (Ad), 26.79 (Ad),31.36 (C-3.1), 31.69 (Ad), 33.34 (Ad), 36.00 (Ad),
36.98 (Ad), 48.78 (A d),52.22 (C-2.2), 56.55 (MeO), 60.30 (C-2.1), 74.26 (C-3.2), 
108.79 (Ar), 111.09(Ar), 118.39 (Ar), 119.04 (Ar), 121.34 (Ar), 124.00 (Ar), 126.08 
(Ar),128.12 (Ar), 135.61 (Ar), 135.84 (Ar), 155.20 (CONH), 169.44 (OC=0),174.47 
(C02Me), 174.63 (Ac C=0); m/z (-FAB) 635 (M+, missing), 614 (M-H30 +, 90%), 402 
(100), 314 (40), 273 (38).
Method 4.
To a mixture of the alcohol (215) (lOOmg, 0.17mmol) and N,N'-disuccinimidyl 
carbonate (44mg, 0.17mmol) under nitrogen was added dry acetonitrile (3cm3)
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followed by triethylamine (24jxl, 0.17mmol) with stirring at room temperature. After 
2d the suspension was worked up by washing with water (5cm3) and extracting into 
DCM (3x1 Ocm3). The combined organic extracts were dried over sodium sulphate and 
concentrated in vacuo. The residue was purified by flash chromatography eluting with 
methanol-DCM (2:98) to give the desired dehydroamino acid (219Z) (46mg, 49%) as a 
white foam, m.p. 177-182°C (Rf=0.64) Methanol-DCM (1:9), (Found C, 70.76; H,
6.83; N, 7.29. C33H37N30 5 . 0.25 H20  requires C, 70.84; H, 6.71; N, 7.51), [<x]22D +26° 
(c 3.6 in CHC13). a)max (CHCI3) 3366 (amide NH), 1713 vs br (C02Me, CONH, and 
conj. C=C) 1490 (Ar, C=C), 1214 (C-N); 5H (CDC13) 1.48-1.95 (17H, m, adamantyl 
and R-a-Me), 3.33 (1H, d, 7gem 15, 3-H.l), 3.68 (1H, d, / gem 15, 3-H.l), 3.83 (3H, s, 
C 02Me), 4.86 (1H, s, adamantyl 2-H), 5.14 (1H, s, 2-NH.l), 7.05-7.64 (11H, m, Ph, 
indole Ar, and 3-H.2 (7.33)), 8.20 (1H, s, 2-NH.2), 8.24 (1H, s, indole NH); 8C 
(CDC13)24.00 (Ad), 26.89 (Ad), 27.08 (Ad), 31.33 (Ad), 31.69 (C-3.1), 32.01 (Ad), 
32.08 (Ad), 36.33 (Ad), 37.30 (Ad), 52.58 (MeO), 61.11 (C-2.1), 109.86 (Ar), 111.12 
(Ar), 119.04 (Ar), 119.82 (Ar), 122.12 (Ar), 124.13 (Ar), 124.36 (Ar), 128.41 (Ar), 
129.16 (Ar), 129.81 (Ar), 131.13 (Ar), 133.76 (Ar), 155.00 (CONH), 165.00 (0C=0), 
173.00 (C02Me); m/z (C.I., /^-butane) 636 (MH+ missing) (MH+ - 0.25 H20 , 18%), 
524 (8), 468 (7), 404 (79), 135 (100).
Attempted hydrolysis o f the ester (219Z)
Method 1.
To a solution of the ester (219Z) (lOOmg, 0.18mmol) in THF (3cm3) was added a 0.1M 
lithium hydroxide solution (2cm3, 0.2mmol) with stirring at room temperature. The 
suspension was then refluxed overnight, however tic indicated that no hydrolysis had 




To a solution of the ester (219Z) (78mg, 0.14mmol) in ethanol (10cm3) was added a 
0.1M sodium hydroxide solution (1.5cm3, 0.15mmol) with stirring at room temperature. 
After 5h reflux, complete hydrolysis had been achieved (as determined by tic). The 
solution was then neutralised with 0.1M hydrochloric acid, washed with water (5cm3) 
and extracted into ethyl acetate (3x5cm3). The combined organic extracts were dried 
over anhydrous magnesium sulphate and concentrated in vacuo. The residue was 
purified by reverse-phase chromatography using methanol-water (3:1) as eluant to give 
the acid (220Z) (30mg, 40%) as a white foam ; (Rf=0.14, methanol-DCM (1:9)), [a]22!) 
+34° (c 3.6 in CHC13); \)max (Nujol) 3265 (OH), 1715 s (C02H, CONH, C=C), 1240 
(C-N); 5h (CDC13), 1.38-1.87 (17H, m, adamantyl, R-a-Me), 3.24 (1H, d, / gem 14.8,
3-H.l), 3.53 (1H, d, / gem 14.8, 3-H.l), 4.77 (1H, s, adamantyl 2-H), 5.06 (2H, br s, 
C 02H, 2-NH.l), 6.98-7.52 (11H, m, Ph, indole and 3-H.2), 8.15 (1H, s, 2-NH.2), 8.52 
(1H, s, indole NH); 6C (CDC13) 14.04 (R-a-Me), 22.96 (Ad), 23.68 (Ad), 24.78 (A d), 
26.86 (A d), 27.05 (Ad), 28.90 (Ad), 29.68 (Ad), 30.33 (A d), 30.97 (Ad), 31.66 
(C-3.1), 31.98 (A d), 36.26 (Ad), 37.27 (Ad), 37.53 (Ad), 61.20 (C-2.1), 88.15 (C-2.2), 
109.11 (Ar), 111.35 (Ar), 118.78 (Ar), 119.69 (Ar), 121.96 (Ar), 123.93 (Ar), 124.49 
(Ar), 128.35 (Ar), 128.48 (Ar), 129.55 (Ar), 129.93 (Ar), 130.88 (Ar), 133.47 (Ar),
136.03 (Ar), 155.00 (CONH), 168.73 (OC=0 ), 173.24 (C02H); m/z (+FAB) 542 
(MH+, 10%), 412 (8), 391 (20).
Attempted cyclopropanation of the dehydropeptide (219Z)
To a solution of the dehydroamino ester (219Z) (50mg, 0.09mmol) in ether (5cm3) was 
added an ethereal solution of diazomethane (5cm3, 0.09mmol, lmol eqXprepared by 
method 2, described on page 156) with stirring at room temperature. After Id, some 
starting material was still present (as determined by tic) and so an excess of ethereal
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diazomethane (0.45mmol, 5mol eq) was added. The solution was stirred for one day 
and worked up by quenching the excess diazomethane with glacial acetic acid and 
subsequent concentration in vacuo. *H NMR of the resultant residue showed a 
multicomponent mix, of which none corresponded to the desired cyclopropyl 
dipeptide.
Preparation of 2,3-methanophenylalanine derivatives
(4S)-iso-Propyl-l ,3-oxazolidin-2,5-dione (221) [372]
To a suspension of L-valine (5.85g, 0.05mol) in dry THF (75cm3) was added a 20% 
phosgene/toluene solution (54.9cm3, 0.1 mol) whilst under an atmosphere of nitrogen. 
The solution was stirred at 40°C until clear, the solution was purged with dry nitrogen 
for 2h and the solvent removed in vacuo. The residue was taken up in a little dry THF 
and the solvent once again removed in vacuo (removal of hydrogen chloride). A white, 
pungent solid (221)(7.21g, 99.3%) resulted after drying under vacuum for 3h; \>max 
(liquid film) 3290 s (NH), 1751 (C=0), 1620-1670 (C=0); 6H (CDC13) 1.03 (3H, d, / 7 ,  
/-Pr Me), 1.09 (3H, d, J  7, i-Pr Me), 2.26 (1H, m, /-Pr CH), 4.25 (1H, d, J4t6 4.2,4-H ), 
7.25 (1H, s, NH).
(6S)-iso-Propylpiperazin-2,5-dione (222).
A solution of (221) (18.4g, 0.13mol) in dry THF (130cm3) was added dropwise to a 
stirring mixture of glycine ethyl ester hydrochloride (18.0g, 0.13mol), triethylamine 
(38cm3,0.39mol) and dry chloroform (210cm3) (in a 500cm3 2-necked rbf) at -78°C. 
After 3h stirring, the mixture was allowed to warm to room temperature, the 
triethylamine hydrochloride salt was filtered off under vacuum and the solvent was 
evaporated in vacuo. Toluene (210cm3) was added to the residue, the resulting 
suspension was heated for 12h under reflux with mechanical stirring, and then cooled
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to 0°C. (222) was removed by suction filtration, washed several times with ether and 
then dried in vacuo at 100°C. (222) (12.2g, 60%) was a white solid; m.p. 253°C (from 
water) (lit.[372], 254°C); \)max (nujol) 3360 (amide NH), 1670 (CONH), 1215 (C-N);
8h (d6-DMSO) 0.86 (3H, d, /  7, /-Pr Me), 0.93 (3H, d, J  7, /-Pr Me), 2.11 (1H, m, /-Pr 
CH), 3.54 (1H, d, J6J 3.7, 6-H), 3.63 (1H, d, / 3>3 18, 3a-H), 3.83 (1H, d, / 3>3 18, 3P-H),
8.03 (1H, s, NH), 8.21 (1H, s, NH).
Acylation o f the piperazin-2,5 -dione (222)
Preparation o f (6S)-1,4-diacetyl-6-iso-propylpiperazin-2,5-dione (226)
Method 1.
To the piperazin-2,5-dione (222) (1.56g, lOmmol), previously dried in vacuo at 120°C 
for one day, was added acetic anhydride (60cm3). The suspension was heated, with 
stirring, to 110°C for 7h. The solvent was removed in vacuo and the product (226) was 
isolated via column chromatography on silica gel by elution with ethyl acetate-petrol 
(1.5:8.5). The desired product (226) was isolated as a pale yellow solid (1.86g, 78%); 
m.p. 73-4°C (ethyl acetate-petrol) (Rf=0.36 ethyl acetate-petrol (2:8)). (Found C, 55.3; 
H, 6.87; N, 11.7. Cn H16N20 4  requires C, 55.00; H, 6.67; N, 11.67); v max (liquid film) 
2870-2960,1690 (C=0), 1370; 5H (CDC13) 0.99 (3H, d, J  6 .8 , /-Pr Me), 1.11 (3H, d, /  
6 .8 , /-Pr Me), 2.05 (1H, m, /-Pr CH), 2.57 (3H, s, N-Ac), 2.60 (3H, s, N-Ac), 4.11 (1H, 
d, J3t3 19.1, 3a-H), 5.01 (1H, d, J6J 9.7, 6-H), 5.10 (1H, d, JX3 19.1, 3P-H); 8C (CDC13) 
19.27 (2 x /-Pr M e), 26.53 (Ac Me ), 26.99 (Ac Me ), 31.43 (C-7), 46.84 (C-3), 62.44 
(C-6), 166.52 (CONH), 167.14 (CONH), 170.84 (Ac C=0), 171.29 (Ac C=0); m/z 
(E.I.) 240 (M+, 40%), 198 (100, M-C2H20), 156 (90, 198-C2H20), 114 (20).
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Method 2.
To a suspension of the piperazin-2,5-dione (222) (lg, 6.4mmol) in DMF (15cm3) was 
added acetic anhydride (1.3cm3, 14.1mmol, 2.2mol eq) with stirring. The suspension 
was refluxed for 4h, the solvent was removed in vacuo and the brown residue was 
purified by flash chromatography on silica in the usual manner (method 1) to yield 226 
as a pale yellow solid (0.7g, 45%). (Previously characterised).
Method 3.
To a suspension of the piperazin-2,5-dione (222) (20.lg, 0.13mol) in acetic anhydride 
(200cm3) was added pyridine (23.1cm3, 0.29mol, 2.2mol eq) with stirring. The 
suspension was refluxed for 7h, the solvent was removed in vacuo to yield a brown 
residue. This was purified in the usual manner to yield 226 (17.8g, 57%). (Previously 
characterised).
Method 4.
To a suspension of the piperazin-2,5-dione (222) (lg, 6.4mmol) in acetic anhydride 
(10cm3) was added pyridine (1cm3, 12.8mmol, 2mol eq) followed by ultrasonification 
for 3d. The solvent was then removed in vacuo and the residue purified by flash 
chromatography in the usual manner. The diacylpiperazin-2,5-dione (226) was isolated 
in low yield (0.44g, 29%). (Characterised previously).
Method 5.
To a suspension of the piperazin-2,5-dione (222) (lg, 6.4mmol) in dry DMF (15cm3) 
was added acetyl chloride (1cm3,14.2mmol, 2.2mol eq) with stirring. The suspension 
was refluxed for 6h, the solvent was reduced in vacuo and the residue purified by flash 




To a suspension of the piperazin-2,5-dione (222) (lg, 6.4mmol) in acetyl chloride 
(10cm3) was added DBU (2.1g, 14.1mmol, 2.2mol eq) with stirring at 0°C. The 
suspension instantly turned pale green on the additon of DBU, the intensity of which 
increased as the reaction progressed. After lh the solvent was removed in vacuo and 
the pale brown residue was purified by flash chromatography in the usual manner to 
yield 226 (0.48g, 33%) as a yellow solid (previously characterised).
Preparation o f
(6S)-N(l)-acetyl-3-benzylidene-6-iso-propylpiperazin- 2,5-dione (227)
A solution of potassium r-butoxide (1.3g, 11.5mmol, l.lm ol eq) in dry THF (20cm3) 
was added dropwise to a stirred solution of 226 (2.40g, lOmmol), benzaldehyde (1.06g, 
lOmmol) and dry DMF (125cm3) at 0°C. After one hour the solution was allowed to 
warm to room temperature and stirred for a further 14h at which point the solution was 
quenched with water (300cm3) and extracted with DCM (3x 100cm3). The solvent was 
removed in vacuo and the residue was purified via column chromatography on silica 
gel with ethyl acetate-petrol (1:9) as eluent. The major component 227Z (Z-isomer) 
(2.35g, 82%) was obtained as a colourless oil (Rf=0.24, ethyl acetate-petrol (2:8)): 
(Found C, 67.2; H, 6.72; N, 9.69. C16H18N20 3 requires C, 67.13; H, 6.29; N, 9.79);
Umax (liquid film) 3365 (NH), 1670 (C=0), 1628 (C=C), 1445 ; 5H (CDC13) 1.05 (3H, d, 
J  1.3, /-Pr Me), 1.07 (3H, d, J  1.3, /-Pr Me), 2.14 (1H, m, /-Pr CH), 2.59 (3H, s, N-Ac),
4.98 (1H, d, J6t7 7, 6-H), 7.15 (1H, s, vinyl H), 7.44 (5H, m, Ph), 8.00 (1H, s, NH); 8C 
(CDC13) 18.42 (/-Pr Me), 19.17 (/-Pr Me), 26.40 (Ac Me), 33.76 (C-7), 61.17 (C-6),
119.69 (C-9), 126.33 (C-3), 128.80 (Ph), 129.32 (Ph), 129.42 (Ph), 132.66 (Ph), 161.69 
(CONH), 165.48 (CONH), 171.65 (Ac C=0); m/z (E.I.) 286 (M+, 70%), 244 (15,
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M-C2H20), 202 (100, 244 - C3H6), 201 (45), 45 (100).
A second product was isolated in a very low yield (30mg, 1%) as a colourless oil 
(Rf=0.12, ethyl acetate-petrol (2:8)), this was assigned to the E-isomer (227E); vmax 
(liquid film) 3465 (NH), 1670 vs (0=0), 1620 s (C=C); 5H (CDC13) 1.08 (3H, d, / 6 .8 ,
i-Pr Me), 1.11 (3H, d, /  6 .8 , /-Pr Me), 2.19 (1H, m /-Pr CH), 2.52 (3H, s, N-Ac), 4.98 
(1H, d, J6t7 7.5, 6-H), 6.65 (1H, s, vinyl H), 7.49 (5H, m, Ph), 9.65 (1H, s, NH); 5C 
(CDC13) 18.49 (/-Pr Me), 18.97 (/-Pr Me), 26.73 (Ac Me), 33.38 (C-7), 60.88 (C-6), 
125.91 (C-3), 126.98 (C-9), 128.12 (Ph), 128.93 (Ph), 129.81 (Ph), 133.08 (Ph), 160.91 
(CONH), 168.21 (CONH), 171.84 (Ac C=0); m/z (E.I.) 286 (M+, 100%), 244 (15, 
M-C2H20), 202 (70, 244-C3H6), 201 (25).
Photoequlibration o f the (Z)-benzylidene (227Z) into its (E)-geometrical isomer 
(227E).
Into a quartz test tube was placed a solution of the (Z)-benzylidene (227Z) (3g, 
10.5mmol) in freshly distilled chloroform (30cm3). The sample was irradiated with 
L-W U.V. light (X=370nm) with stirring for 2 days. The solution was then reduced in 
vacuo to yield a 2:1 mix of Z/E isomers. The two components were separated via flash 
chromatography on silica eluting with ethyl acetate-petrol (1:9).
Attempted cyclopropane construction via the Simmons-Smith reaction
Method 1. Using ZnlCu couple.
To a solution of the (Z)- benzylidene (227Z) (1.28g, 4.5mmol) in ether (30cm3) 
containing Zn/Cu powder (0.45g, 6.3mmol of Zn), was added methylene diiodide 
(3.7cm3,45mmol, lOmol eq) and one small crystal of iodine. The reaction mixture was 
gently heated to reflux for 6h yielding no apparent change by tic; therefore it was
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transferred to an ultrasound bath for a further 3h but still no change was observed, as 
determined by tic. The solvent was removed in vacuo and the residue was taken up in 
DCM (30cm3), the couple filtered off and the filtrate was dried over anhydrous 
Na2S 04. The filtrate was reduced in vacuo and starting material (1.21g, 95%) was 
recovered.
Method 2. Using Zn/Ag couple.
To a Zn/Ag couple (0.34g, 4.9mmol of Zn) in dry ether (10cm3) was added a solution 
of the (Z)-benzylidene (227Z) (lg, 3.5mmol) in dry ether (20cm3) with overhead 
mechanical stirring. To this was added dropwise methylene diiodide (1.3g, 4.9mmol, 
1.4mol eq). The mixture was stirred overnight at room temperature and then brought to 
reflux. After 12h the Zn/Ag couple was filtred whilst hot and the filtrate cooled to 0°C, 
to which was added ether (20cm3) and pyridine (3cm3). The white precipitate 
generated (pyridine salts) was filtered through celite and more pyridine was added to 
the filtrate with refiltration, until all of the iodide salts were removed. The remaining 
filtrate was reduced in vacuo and the residue was purified by flash chromatography on 
silica eluting with ethyl acetate-petrol (2:8). No desired cyclopropane was isolated. 
Unreacted starting material (0.6g, 60%) was retrieved.
Preparation o f diazomethane
Method 1.
Using the Aldrich mini diazald kit an ethereal diazomethane solution was prepared as 
follows:
Into a 250cm3 rbf, fitted with distillation head, water condenser, receiver adaptor and 
collecting rbf, was placed potassium hydroxide (6 .2g, O.llmol), water (10.5cm3), ether
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(10.5cm3) and ethanol (37cm3). The distilling flask was heated in a water bath at 
70-75°C with stirring ("Teflon" coated stirrer bar) and a solution of N-nitroso- 
N ’-methyl-p-methyltoluene sulphonamide in ether (200cm3) was added at a rate 
approximately equivalent to the rate of condensing distillate. Once all the nitrosamide 
solution had been added, additional ether was placed in the dropping funnel and added 
at the same rate until the distillate was colourless. The distillate contained 2.8-3.0g 
(64-69%) of diazomethane. For safety purposes see De Boer and Backer [352].
Method 2.
To a solution of N-methyl-N'-nitroso urea (2.5g, 24mmol)[373] in ether (25cm3) in a 
non-quickfit conical flask was slowly added a 40% potassium hydroxide solution 
(7.5cm3) with cooling to 0/-5°C (ice-salt bath). On addition of all the potassium 
hydroxide solution the sample was allowed to warm until all the urea dissolved giving a 
clear yellow solution. If any urea remained, further potassium hydroxide solution was 
added until dissolution resulted. The ethereal layer was then decanted into a second 
flask containing potassium hydroxide pellets (~12). This was repeated into a third 
flask. The resultant solution contained approximately 0.7g (17mmol) of diazomethane.
Direct addition in the light
Attempted cyclopropane construction via the addition o f diazomethane to the 
benzylidene (227)
To a solution of the (Z)-benzylidene (227Z) (2.0g, 7mmol) in dry ether (60cm3) was 
added a freshly distilled ethereal solution of diazomethane (8.75mmol, 1.1 mol eq, 
method 1, page 156) whilst stirring under nitrogen at RT. After 22h the excess 
diazomethane was quenched via the addition of glacial acetic acid (3cm3). The solvent
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was then removed in vacuo and the residue was purified by column chromatography on 
silica gel with ethyl acetate-petrol (0.3:9.7) as eluant. No cyclopropane was generated, 
but instead (2 3 4 ) (O-methylated product) (0.34g, 16%) was isolated as a colourless oil 
(Rf=0.61, ethyl acetate-petrol (3:97) (Found C, 67.9; H, 6.72; N, 9.25. C17H20N2O3 
requires C, 68.00; H, 6 .66 ; N, 9.33); [a]20D +258° (c 0.69 in CHC13); a)max (liquid film) 
1680 s (C=0), 1640 (C=N), 1605 (C=C); 8H (CDC13) 0.88 (3H, d ,/6 .9 , /-PrMe), 0.98 
(3H, d, J  6.9, /-Pr Me), 2.08 (1H, m, i-Pr CH), 2.61 (3H, s, N-Ac), 3.97 (3H, s, MeO), 
5.02 (1H, d, Jg 9 6.1, 6-H), 7.27 (1H, s, vinyl H), 8.06-7.33 (5H, m, Ph); 8C (CDC13) 
18.33 (/-Pr Me), 19.46 (/-Pr Me), 26.73 (Ac Me), 34.11 (C-7), 54.10 (MeO), 58.32 
(C-6), 127.99 (Ph), 128.38 (Ph), 129.06 (Ph), 131.78 (C-9), 132.66 (C-3), 135.06 
(Ph),163.86 (CONH),164.54 (C-5), 172.30 (Ac C=0); m/z (E.I.) 300 (M+, 100%), 258 
(20, M-C2H20), 216 (8), 215 (25, 258-C3H7).
A second product was also isolated (2 3 3 ) (0.68g, 32%) (Rf=0.43 (ethyl acetate-petrol 
(2:8)) as a white crystalline solid corresponding to the N-methylated product; m.p. 
110-14°C; (Found C, 67.7; H, 6 .66 ; N, 9.33. C17H20N2O3 requires C, 68.00; H, 6.67; N, 
9.33); [oc]20d -5 5 9 °  ( c  1.16 in EtOH); umax (liquid film ) 1700 vs (C=0), 1666, 1615 
(C=C), 1350 vs (C-N); 8H (CDC13) 0.98 (3H, d, J 6 .8 , /-Pr Me), 1.13 (3H, d, /  6 .8 , /-Pr 
Me), 2.07 (1H, m, /-Pr CH), 2.62 (3H, s, N-Ac), 2.91 (3H, s, N-Me), 5.01 (1H, d, J6J
9.9, 6-H), 7.28-7.43 (6H, m, Ph and vinyl H); Sc (CDC13) 19.46 (2 x /-Pr Me), 26.56 
(Ac Me), 32.53 (C-7), 34.48 (N-Me), 61.66 (C-6), 124.26 (C-9), 128.74 (Ph), 129.38 
(Ph), 129.55 (Ph), 132.00(C-3), 133.05 (Ph), 163.96 (CONH), 167.07 (CONH), 171.42 
(Ac-C=0); m/z (E.I.) 300 (M+, 100%), 258 (20, M-C2H20 ) 243 (8 , 258-CH3), 216 
(60), 215 (50).
Preparation of(Z)-(lS, 3S, 6S)-N(7)-acetyl-6-iso-propyl-5-methoxy-l-phenyl-4,7- 
diazaspiro[2£]oct-4-en-8-one (2 3 7 )
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To a solution of the Z-benzylidene (227Z) (4.28g, 15mmol) in dry ether (40cm3) was 
added a freshly distilled ethereal solution of diazomethane (105mmol, 7mol eq, method 
1, page 156) with stirring, under nitrogen at RT. After 19h, the excess diazomethane 
was quenched via the addition of glacial acetic acid (5cm3). The solvent was removed 
in vacuo and the residue was purified via column chromatography on silica gel using 
ethyl acetate-petrol (0.5:9.5) as eluant. The desired product (237) was isolated as a 
white solid (1.41g, 30%) m.p.62-3°C, (Rf=0.66 ethyl acetate-petrol (2:8)) (Found C, 
68.50; H, 6.91; N, 9.19. C18H22N20 3 requires C, 68.79; H, 7.01; N, 8.92), [a]20D -177° 
(c 1.46 in CHC13); umax (liquid film) 1720-1600 vs br (C=N and C=0); 8H (CDC13)
0.57 (3H, d, J  6 .8 , i-Pr Me), 0.84 (3H, d, /7 .0 , i-Pr Me), 1.88 (1H, m, i-Pr CH), 1.89 
(1H, dd, J224.8, / 2B, 1 8.4, 2B-H), 2.38 (1H, dd, J22 4.8, / 2A?1 9.9, 2A-H), 2.53 (3H, s, 
N-Ac), 2.88 (1H, dd, / 1?2B 8.4, / lj2A 9.9, 1-H), 3.50 (3H, s, MeO), 4.88 (1H, d, /  6.2, 
6-H), 7.22 (5H, m, Ph); 5C (CDC13) 18.03 (i-Pr Me), 19.36 (i-Pr Me), 25.40 (C-2),
26.40 (Ac Me), 32.86 (C-9), 38.66 (C-l), 48.62 (C-3), 53.00 (MeO), 58.03 (C-6),
126.56 (Ph), 127.50 (Ph), 128.80 (Ph), 135.19 (C-5), 163.05 (C=0), 171.26 (Ac C=0).
A second product was obtained (233), (1.46g, 32%) corresponding to the N-methylated 
product (previously characterised).
Direct diazomethane addition in the dark
To a solution of the (Z)- benzylidene (227Z) (3g, 10.5mmol) in ether (10cm3) was 
added ethereal diazomethane (105mmol, lOmol eq, method 1, page 156) with stirring at 
room temperature in the absence of light. After 2 days the excess diazomethane was 
quenched by the addition of glacial acetic acid. The solution was reduced in vacuo and 
the residue was purified by flash chromatography, to yield a 3:1 mix of diasteromeric
O-methylated cyclopropanes (235) (0.75g, 23%). Previously characterised.
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Attempted carbene insertion using a silica gel template
To a solution of the (Z)-benzylidene (227Z) (lOOmg, 0.35mmol) in ether (10cm3) was 
added pre-dried silica gel (2.9g, 190°C) and sodium bicarbonate (lOOmg, 1.2mmol, 
3.5mol eq). To this was added ethereal diazomethane (3,5mmol, lOmol eq, method 2, 
page 157) at room temperature with stirring. Instantaneously the yellow colouration of 
the diazomethane disappeared. The silica was filtered off and the solution was worked 
up as normal. No cyclopropane product was isolated, just unreacted starting material 
(95mg, 95%).
Catalysed cryclopropanations
i. To a solution of the (Z)-benzylidene (227Z) (lOOmg, 0.35mmol) in ether (10cm3) 
was added palladium (II) acetate (8mg, 0.035mmol) followed by an ethereal 
solution of diazomethane (3.5mmol, lOmol eq, method 1, page 156) with stirring at 
room temperature. After stirring for 15h the diazomethane was quenched with 
glacial acetic acid. The palladium salts were then filtered off and the filtrate was 
worked up as usual. The residue was purified by flash chromatography to yield a 
4:1 mix of diastereomeric O-methylated cyclopropanes (235) (30mg, 27%). 
Previously characterised.
ii. To a solution of the (Z)-benzylidene (227Z) (lOOmg, 0.35mmol) in ether (10cm3) 
was added palladium(II) chloride (6mg, 0.035mmol) followed by an ethereal 
solution of diazomethane (3.5mmol, lOmol eq, method 1, page 156) with stirring at 
room temperature. After stirring for 12h, the excess diazomethane was removed in 
the usual manner, the palladium salts filtered, and the filtrate worked up as normal. 
The residue was purified by flash chromatography yielding a 3.5:1 mix of 
diastereomeric O-methylated cyclopropanes (235) (25mg, 23%). Previously
1 6 1
characterised.
Preparation of (6S)-l ,4-diacetyl-3-benzylidene-6-iso-propylpiperazin-2,5-dione (241) 
To a solution of the (Z)-benzylidene (227Z) (2g, 7mmol) in acetic anhydride (20cm3) 
was added pyridine (0.6cm3, 7mmol) with stirring at room temperature. The solution 
was heated to 70°C for 7h, the solvent removed in vacuo and the residue purified by 
flash chromatography using ethyl acetate-petrol (15:85) as eluant. The desired product 
was isolated as a white solid (1.2g, 52%) m.p.l58-9°C, (Rf=0.37, ethyl acetate-petrol 
(2:8)); (Found C, 66.0; H, 6.19; N, 8.61. C18H20N2O4 requires C, 65.85; H, 6.10; N, 
8.54). 5h (CDC13) 0.96 (3H, d, J  6 , /-Pr Me), 1.17 (3H, d, J  6 , /-Pr-Me), 2.19 (1H, m,
i-Pr CH), 2.47 (3H, s, N-Ac), 2.58 (3H, s, N-Ac), 5.09 (1H, d, /  11, 6-H), 7.38 (5H, m, 
Ar), 7.57 (1H, s, vinyl H); 5C (CDC13) 19.20 (/-Pr Me), 19.53 (/-Pr Me), 25.95 (Ac Me),
27.47 (Ac Me), 31.46 (C-7), 65.20 (C-6), 124.36 (C-3), 128.67 (Ph),128.96 (Ph),
130.23 (Ph), 133.15 (Ph), 134.22 (C-9), 163.93 (CONH), 167.53 (CONH), 168.37 (Ac 
O O ), 171.13 (Ac C=0); m/z (C.I.) 329 (MH+, 100%), 287 (MH+-Ac, 95%).
Attempted preparation of(Z)-(6S )-l-acetyl-3-benzylidene-6-iso-propyl-4 - 
trimethylsilylpiperazin-2,5-dione (244Z)
To a solution of (Z)-benzylidene (227Z) (lOOmg, 0.35mmol) in dry THF (3cm3) was 
added a solution of potassium r-butoxide (43mg, 0.38mmol) in THF (3cm3) of 0°C with 
stirring. To the yellow solution that formed was added neat trimethylsilyl chloride 
(44pl, 0.35mmol). After stirring for 1 day the solution was worked up by pouring onto 
ice and extracted into ethyl acetate (3x10cm3). The combined organic extracts were 
dried over anhydrous sodium sulphate and the solvent reduced in vacuo. The residue 
was purified by flash chromatography on silica gel using ethyl acetate-petrol (3:7) as 
eluant. Only starting material (227Z) was recovered (60mg, 60%).
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Attempted cyclopropane construction via the additon o f diazomethane to the 
bis-acetylated benzylidene (241)
To a solution of the bis-acylated benzylidene (241) (0.5g, 1.5mmol) in ether (10cm3) 
was added an ethereal diazomethane solution (15mmol, lOmol eq, method 1, page 156 
) with stirring at room temperature in the presence of day light. After 1 day the excess 
diazomethane was quenched with glacial acetic acid and the solvent removed in vacuo. 
The residue was purified by flash chromatography on silica gel using ethyl 
acetate-petrol (6:94) as eluant; to yield an inseparable mix of the desired product (242) 
and the vinyl methyl adduct (243) (1:1.5) in 80mg (13%) yield.
Attempted cyclopropane construction via the addition o f a sulphoxonium ylide to the 
bis-acetylated benzylidene (241).
To a 50cm3 one-neck rbf containing trimethylsulphoxonium iodide (242mg, l.lmmol) 
and sodium hydride (26mg, l.lmmol) was added DMSO (10cm3) whilst stirring under 
argon at 0°C. The mixture was then stirred until all the trimethylsulphoxonium iodide 
had disappeared. Then a solution of bis-acetylated benzylidene (241) (0.33g, lmmol) 
in DMSO (2cm3) was added dropwise and the reaction was followed by tic. After 5h at 
room temperature, lOh at 80°C and lh at 100°C, the reaction mixture was poured into 
water (80cm3), extracted with ether (3x20cm3) and the collected organic fractions were 
dried over anhydrous Na2S 04. After filtration the solvent was reduced in vacuo. A 




To a solution of (237) (0.67g, 2.lmmol) in methanol (20cm3) was added potassium
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carbonate (0.29g, 2.1mol) with stirring at 0°C. After 0.5h the solvent was removed in 
vacuo. The residue was taken up in DCM (20cm3) and the potassium salts were 
removed via filtration. The filtrate was reduced in vacuo, to yield a colourless oil 
(0.57g, 100%) (Rf=0.12 ethyl acetate-petrol (2:8)); [a]20D -260°(c 1.63 in CHC13); a)max 
(CHC13) 3390 (NH), 1650 (C=N); SH (CDC13) 0.68 (3H, d, J  6 .8 , i-Pr Me), 0.92 (3H, d, 
J  7.0, z-Pr Me), 1.65 (1H, dd, J12 4.7, / 2B>1 8.0, 2B-H), 2.03 (1H, m, z-Pr CH), 2.19 (1H, 
dd, J22 4.7, J2A,i 9.5, 2A-H), 2.86 (1H, dd, / 1>2B 8.0, / 1>2A 9.5, 1-H), 3.43 (3H, s, MeO), 
3.99 (1H, d, /  5.5, 6 -H), 7.16-7.27 (5H, m, Ph), 7.62 (1H, s, NH); 8C (CDC13) 15.86 
(z-Pr Me), 18.33 (z-Pr Me), 23.32 (C-2), 31.88 (C-9), 35.19 (C-l), 45.51 (C-3), 53.00 
(MeO), 58.00 (C-6), 126.01 (Ph), 127.34 (Ph), 128.93 (Ph), 136.29 (Ph), 159.45 (C-5), 
171.74 (CONH); m/z(E.l.) 272 (M+, 272.15765 C16H20N2O2 requires 272.15248 29%), 
229 (160, M-C3H7).
(Z)-(1S, 3S, 6S)-6-iso-propyl-5,8-dimethoxy-1 -phenyl-4,7-diazospiro[2,5] 
octa-4,7-diene (252)
To a solution of (251) (1.22g, 4.5mmol) in dry DCM (30cm3) was added 
trimethyloxoniumtetrafluoroborate (2.0g, 13.5mmol) with stirring at 0°C. After 2 days 
the reaction mix was washed with phosphate buffer solution (sodium phosphate, 
monobasic (21.6g, 0.2mmol) and sodium phosphate, dibasic (85.2g, 0.5mmol) in water 
(500cm3) and extracted into DCM (3x30cm3). The combined organic extracts were 
dried over anhydrous sodium sulphate, filtered, and reduced in vacuo. The residue was 
purified via column chromatography on silica gel using ethyl acetate-petrol (1:9) as 
eluant. The desired product (252) (0.9 lg, 71%) was isolated as a colourless oil. 
(Rf=0.72 ethyl acetate-petrol): [a]20D -185°(c 1.62 in CHC13); umax (CHC13) 1655 vs 
(C=N), 1435 and 1320; 8H (CDC13) 0.58 (3H, d, J  6 .8 , z-Pr Me), 0.94 (3H, d, J  7.0, z-Pr 
Me), 1.55 (1H, dd, J22 5.0, / 2Btl 7.7, 2B-H), 2.05 (1H, dd, J22 5.0, / 2A>1 9.5, 2A-H),
2.06 (1H, m, z-Pr CH), 2.70 (1H, dd, / 1>2B 7.7, / 1>2A 9.5, 1-H), 3.41 (3H, s, MeO), 3.71
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(3H, s, MeO), 4.12 (1H, d, / 6>9 3.3, 6-H), 7.11-7.23 (5H, m, Ph); 8C (CDC13) 16.83 (/-Pr 
Me), 19.04 (/-Pr Me), 21.83 (C-2), 31.98 (C-9), 32.66 (C-l), 44.11 (C-3), 52.35 (MeO), 
52.67 (MeO), 61.79 (C-6), 125.72 (Ph), 127.24 (Ph), 128.93 (Ph), 136.81 (Ph), 163.34 
(C-8), 164.32 (C-5); mtz (E.I.) 286 (M+, 286.16268 C17H22N20 2 requires 286.16813, 
11%), 243 (100, M-C3H7).
(Z)-(2S, 3S)-2,3-methanophenylalanine methyl ester((2S,3S) VzPhe-OMe) (253)
To neat bis imine ether (252) (0.86g, 3mmol) was added 0.25M hydrochloric acid 
(24cm3, 6mmol) with stirring at RT. After 1 day ether (5cm3) was added and stirred for 
a further 24h. The reaction mix was partitioned between ether (5cm3) and water (5cm3) 
to remove any unreacted 252. The aqueous phase was basified to pH 9 with 33% w/w 
aqueous ammonia solution and extracted with ether (3x30cm3). The combined organic 
extracts were dried over anhydrous sodium sulphate and reduced in vacuo. The crude 
residue was purified by column chromatography on silica gel using ethyl acetate-petrol 
(4:6) as eluant. The title compound (253) was isolated as a colourless oil (0.33g, 58%) 
(Rf=0.15 ethyl acetate-petrol (2:8)) (Found C, 69.30; H, 7.10; N, 7.25. Cn H 13N 02 
requires C, 69.11; H, 6.81; N, 7.33); umax (CHC13) 3510 and 3385 (NH2), 1710 (ester 
C=0); 5h (CDC13) 1.43 (1H, dd, J22 4.9, / 2B 3 7.6, 2B-H), 1.56 (2H, s, 2xNH), 1.82 
(1H, dd, J22 4.9, / 2A>3 9.5, 2A-H), 2.81 (1H, dd, / 3>2B 7.6, / 3>2A 9.5, 3-H), 3.75 (3H, s, 
MeO), 7.20-7.34 (5H, m, Ph); 8C (CDC13) 21.93 (C-2’), 33.05 (C-3), 40.90 (C-2), 52.28 
(MeO), 126.69 (Ph), 128.02 (Ph), 129.06 (Ph), 135.55 (Ph), 175.73 (C=0). m/z (E.I.) 
191 (M+, 8%), 176 (13, M-CH3), 159 (72, M-CH3OH), 132 (92, M-C02Me).
(Z)-(2S,3S)-N-(tosylamino)methanophenylalanine methyl ester (254)
To a solution of VzPhe-OMe (253) (47mg, 0.25mmol) in dry THF (4cm3) was added a 
solution of tosyl chloride (47mg, 0.25mmol) in THF (4cm3) and neat triethylamine 
(34fil, 0.25mmol) with stirring at RT. The reaction mixture was refluxed for 2h and the
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solvent was then removed in vacuo. The residue was purified by column 
chromatography on silica gel using ethyl acetate-petrol (1:9) to yield a colourless 
crystalline solid (67mg, 78%) m.p.l41-2°C; (Rf=0.38 ethyl acetate-petrol (3:7));
(Found C, 62,30; H, 5.50; N, 3.94. C18H 19N 04S requires C, 62.58; H, 5,50; N, 4.06); 
[a]22D -47° (c 3.05 in CHC13); \)max (CHC13) 3271 (NH), 1729 vs (C02Me), 1333 
(S02NH); 5h (CDC13) 2.14 (1H, dd, J22 6.3, / 2A>3 9.8, 2A-H), 2.24 (1H, dd, J22 6.3, 
/ 2B3 8.0, 2B-H), 2.43 (3H, s, Tosyl Me), 2.67 (1H, dd, / 3>2B 8.0, / 3 2A 9.8, 3-H), 3.41 
(3H, s, MeO), 4.85 (1H, s, NH), 7.08-7.11 (2H, m, 2x o-Tosyl), 7.26-7.31 (5H, m, Ph),
7.69 (2H, d, J  8.3, 2x m-Tosyl); 5C (CDC13) 18.42 (C-2’), 21.54 (Me), 34.12 (C-3), 
41.13 (C-2), 52.51 (MeO), 127.53 (Ph), 128.28 (Ph), 128.83 (Ph), 129.42 (Ph), 133.34 
(Ph), 137.07 (Ph), 143.65 (Ph),171.65 (C=0); m/z (C.I., iso-butane) 346 (MH+, 100%), 
326 (8), 314 (5, M-CH40), 286 (30).
(E)-(1R, 3S,6S)-N(7)-acetyl-6-iso-propyl-5-methoxy-1 -phenyl-4,7- 
diazaspiro[2,5]oct-4-en-8-one (256)
To a solution of (E)-benzylidene (227E) (1.6g, 5.6mmol) in dry ether (20cm3) was 
added a freshly distilled ethereal solution of diazomethane (56mmol, lOmol eq, method 
1, page 156) with stirring, under nitrogen at room temperature. After 2 days, the excess 
diazomethane was removed via the addition of glacial acetic acid (3cm3). The solvent 
was removed in vacuo and the residue was purified via column chromatography on 
silica gel using ethyl acetate-petrol (6:94) as eluant. The desired product (256) was 
isolated as a colourless oil (0.24g, 14%) (Rf^O.59 ethyl acetate-petrol (2:8)); [a]22D 
+170° (c 3.0 in CHC13); umax (CHC13) 1697 (amide C=0, acyl C=0 and C=N), 1215 
(C-N); §H (CDC13), 0.74 (3H, d, J  7.0, i-Pr Me), 0.97 (3H, d, J  7.0, z-Pr Me), 1.83 (1H, 
dd, J22 4.5, / 2B)1 9.2, 2B-H), 1.89 (1H, m, i-Pr CH), 2.40 (3H, s, N-Ac), 2.50 (1H, dd, 
J22 4.5, / 2AJ 9.2, 2A-H), 2.77 (1H, t, / lj2B 9.2, / 1>2A 9.2, 1-H), 3.74 (3H, s, MeO), 4.86 
(1H, d, / 6>9 7.9, 6-H), 7.26 (5H, m, Ph); 5C (CDC13) 19.17 (2 x z-Pr Me), 23.94 (C-2),
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26.56 (Ac Me), 32.95 (C-9), 40.19 (C-l), 50.73 (C-3), 53.32 (MeO), 58.25 (C-6),
126.95 (Ph), 127.79 (Ph), 129.09 (Ph), 133.73 (Ph), 164.71 (C-5), 169.25 (C-8), 171.58 
(Ac C=0); m/z (E.I.) 314 (M+, 314.16643 C18H22N20 3  requires 314.16304,10%), 272 
(8 , M-CH2CO), 229 (66 , 272-C3H7).
(E)-(1R,3S,6S)-7(H)-6-iso-propyl-5-methoxy-l-phenyl-4,7-diazaspiro[2,5]oct-4-en-8-one
(257)
To a solution of (256) (0.24g, 0.76mmol) in DCM (20cm3) was added potassium 
carbonate (0.12g, 0.84mmol) with stirring at 0°C. After stirring for 4h the potassium 
salts were removed via filtration. The filtrate was reduced in vacuo to yield a pale 
yellow oil (0.21g, 100%) (Rf=0.08 ethyl acetate-petrol (2:8)); [a]20D +227°(c 1.85 in 
CHC13); umax (CHCI3) 3412 (NH), 1668 (amide C=0 and C=N), 1224 (C-N); 8H 
(CDCI3) 0.81 (3H, d, J  4.0, i-Pr Me), 0.83 (3H, d, J  4.0, i-Pr Me), 1.61 (1H, dd, / 2B, 1
8.9, J22 4.5, 2B-H), 2.05 (1H, m, /-Pr CH), 2.35 (1H, dd, / 2Ajl 8.9, / 22 4.5, 2A-H), 2.64 
(1H, t, Jh2A 8.9, / 1>2B 8.9, 1-H), 3.70 (3H, s, MeO), 3.93 (1H, t, / 6>9 7.0, 6-H), 6.39 (1H, 
s, NH), 7.14-7.55 (5H, m, Ph); 5C (CDC13) 16.44 (/-Pr Me), 18.36 (/-Pr Me), 21.96 
(C-2), 31.72 (C-9), 37.98 (C-l), 47.29 (C-3), 53.19 (MeO), 59.36 (C-6), 126.37 (Ph),
127.53 (Ph), 129.22 (Ph), 135.09 (Ph), 160.00 (C-5), 168.05 (C-8); m/z (E.I.) 272 (M+, 
12%), 229 (62, M-C3H7), 43 (30), 28 (100).
(E)-( 1R,3S ,6S)-6-iso-propyl-5,8-dimethoxy-l -phenyl-4,7-diazaspiro [2$ ]octa-4,7-diene
(258)
To a solution of (257) (0.21g, 0.76mmol) in DCM (15cm3) was added 
trimethyloxoniumtetrafluoroborate (0.23g, 1.5mmol) with stirring at RT. After 2 days 
the reaction mix was washed with phosphate buffer solution and extracted into DCM 
(3x15cm3). The combined organic extracts were dried over anhydrous sodium 
sulphate, filtered, and reduced in vacuo. The residue was purified via column
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chromatography on silica gel using ethyl acetate-petrol (1:9) as eluent. The desired 
product (258) was isolated as a pale yellow oil (140mg, 65%) (Rf=0.64 ethyl 
acetate-petrol (2:8); [oc]20D +259°(c 2.02 in CHC13); umax (CHC13) 1670 (C=N), 1218 
(C-N and C-O); 5h (CDC13) 0.82 (3H, d, J  6 .8 , /-Pr Me), 1.00 (3H, d, /7 .0 , /-Pr Me),
1.53 (1H, dd, J22 5.0, / 2b,i 9.4, 2B-H), 2.13 (1H, m, /-Pr CH), 2.21 (1H, dd, J12 5.0, 
/ 2a,i 9.4, 2A-H), 2.54 (1H, t, / lj2A 9.4, / lj2B 9.4, 1-H), 3.22 (3H, s, MeO), 3.68 (3H, s, 
MeO), 4.11 (1H, d, / 6>9 4.0, 6-H), 7.16-7.25 (5H, m, Ph); 8C (CDC13) 17.71 (/-Pr Me), 
19.20 (/-Pr Me), 20.21 (C-2), 32.17 (C-9), 35.65 (C-l), 45.90 (C-3), 51.70 (MeO),
52.64 (MeO), 62.44 (C-6), 125.98 (Ph), 127.44 (Ph), 129.06 (Ph), 136.32 (Ph), 163.15 
(C-8), 166.30 (C-5); m/z (E.I.) 286 (M+, 286.16540 C17H22N20 2 requires 286.16813, 
3%) 243 (100, M-C3H7), 228 (15), 105 (12).
(E)-(2S,3R)-2,3-methanophenylalanine methyl ester((2S,3R) VEPhe-OMe) (259)
To neat bis imine ether (258) (260mg, 0.9lmmol) was added 0.25M hydrochloric acid 
(7.3cm3, 1.82mmol) with stirring at room temperature. After 1 day, ether (5cm3) was 
added and stirred for a further 24h. The reaction mix was partitioned between ether 
(5cm3) and water (5cm3), the aqueous phase was basified to pH8 with 1M ammonium 
hydroxide and extracted with ether (3x15cm3). The combined organic extracts were 
dried over anhydrous sodium sulphate and reduced in vacuo. The crude residue was 
purified by column chromatography on silica gel using ethyl acetate-petrol (4:6) as 
eluant. The title compound (259) was isolated as a pale yellow oil (39mg, 22%) 
(Rf=0.26 ethyl acetate-petrol (3:7)); \)max (CHC13) 3380 (NH2), 1710 (C02Me), 1215 
(C-N); 8H (CDC13) 1.47 (1H, dd, J22 5.3, / 2B>1 8 .6 , 2B-H), 1.99 (1H, dd, J22 5.3,
8 .6 , 2A-H), 2.43 (2H, s, NH^, 2.67 (1H, t, J h2A 8 .6 , / li2B 8 .6 , 1-H), 3.30 (3H, s, MeO), 
7.22-7.34 (5H, m, Ph); 8C (CDC13) 19.98 (C-2’), 36.26 (C-3), 43.20 (C-2), 51.51 (MeO),
126.56 (Ph), 127.86 (Ph), 128.99 (Ph), 136.39 (Ph), 173.69 (C=0); m/z (E.I.) 191 (M+, 
4%),. 190 (M-H, 190.08665 Cn H12N 02 requires 190.08680, 3%), 176 (27, M-CH3),
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159 (6 8 ,M-CH3OH), 132 (94,M-C02Me), 115 (34).
Coupling of (Z)- and (E)-2,3-methanophenyIalanine methyl ester (253) and (259) 
with an N-protected trytophan (206).
Preparation o fN a -(2-adamantyloxycarbonyl)-a-methyl-R-tryptophanyl-(Z)~ 
(2S,3S)-2,3-methanophenylalanine (260)
Method 1.
To a solution of 2-Adoc-R-a-Me-Trp-OH (206) (104mg, 0.26mmol) in ethyl acetate 
(5cm3) was added HOBt (44mg, 0.29mmol) in solid form followed by a solution of 
DCC (65mg, 0.3lmmol) in ethyl acetate (2cm3) with stirring at room temperature.
After lh  the precipitated dicyclohexylurea (DCU) was filtered and to the filtrate was 
added a solution of(Z)-(2S,3S)-2,3-methanophenylalanine methyl ester (253) (50mg, 
0.26mmol) in ethyl acetate (1cm3) at 0°C. After 4h the solution was brought to reflux. 
The solution was worked up after a further 6h by washing with water and extracting 
into ethyl acetate (3x10cm3). The combined organic extracts were dried over sodium 
sulphate and reduced in vacuo to yield a pale yellow oil. The residue was purified by 
flash chromatography to yield no desired dipeptide (260). Only the starting material 
(253) (40mg, 80%) was recovered.
Method 2.
To a solution of 2-Adoc-R-a-Me-Trp-OH (247mg, 0.62mmol) in dry THF (5cm3) was 
added NMM (68pl, 0.62mmol) and wo-butyl chloroformate (81 pi, 0.62mmol) 
successively with stirring at RT. After 30 min a solution of (2S, 3S) VzPhe-OMe (253) 
(lOOmg, 0.52mmol) in dry THF (5cm3) was added and stirred for 1 day. The solvent 
was then worked up by washing with water (5cm3) extracting into DCM (3x5cm3) and
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drying the combined organic extracts over anhydrous sodium sulphate. The solvent 
removed in vacuo and the residue was purified by column chromatography on silica gel 
by using ethyl acetate-petrol (1:9) as eluant. The title compound (260) was isolated as 
a yellow foam (118mg, 40%) (Rf=0.13 ethyl acetate-petrol (3:7); [a]20D +6° (c 1.35 in 
CHC13); Dmax (CHCI3) 3418 (amide NH), 1718 vs (C02Me), 1686 vs (CONH), 1491 
(Ar. C=C), 1215 (C-N); 5H (CDC13) 1.39 (3H, s, R-oc-Me), 1.44-1.93 (15H, m, 
adamantyl and 2'B-H.2), 2.18 (1H, dd, JT1' 5.8, J2'A,3 9.8, 2'A-H.2), 2.95 (1H, dd,
/ 3>2'B 8.0, / 3>2'A 9.8, 3-H.2), 3.13 (1H, d, / gem 15, 3-H.l) 3.37 (1H, d, / gem 15, 3-H.l), 
3.73 (3H, s, MeO), 4.61 (1H, s, adamantyl 2-H), 5.02 (1H, s, 2-NH.l), 6.87-7.56 (11H, 
m, Ph and indole Ar, 2-NH.2), 8.29 (1H, s, indole NH); 5C (CDC13) 14.17 (R-oc-Me),
20.98 (C-2’.2), 23.09 (Ad), 26.92 (Ad), 27.08 (Ad), 31.62 (C-3.1), 31.88 (Ad), 31.95 
(Ad), 32.14 (Ad), 32.37 (C-3.2), 36.29 (Ad), 37.30 (Ad), 39.08 (Ad), 52.64 (C-2.2), 
60.39 (MeO), 60.72 (C-2.1), 109.76 (Ar), 111.09 (Ar), 119.10 (Ar), 119.65 (Ar), 122.02 
(Ar), 123.90 (Ar), 127.18 (Ar), 128.25 (Ar), 128.77 (Ar), 134.18 (Ar), 135.87 (Ar), 
155.27 (C=0), 172.13 (0C=0), 175.70 (C02Me); mlz (E.I.) 569 (M+, 5%), 440 (5),
417 (6), 395 (2), 379 (3), 130 (100).
Method 3.
To a solution of 2-Adoc-R-a-Me-Tro-OH (206) (125mg, 0.3mmol) in dry THF (3cm3) 
was added NMM (35|xl, 0.3mmol), HOBt (48mg, 0.3mmol) and EDC (60mg, 0.3mmol) 
successively with stirring at 0°C for 1 hour. To this was added a solution of (2S,3S) 
VzPhe-OMe (253) (60mg, 0.3mmol) in dry THF (3cm3). After stirring for 3 days at 
room temperature, no desired product was observed. The solution was brought to 
reflux. After 3h no starting material was detected by tic. The solvent was removed in 
vacuo and the residue taken up in ethyl acetate (5cm3) and washed with water (5cm3). 
The organic layer was dried over sodium sulphate and reduced in vacuo. The 
remaining residue was purified via column chromatography on silica gel using ethyl
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acetate-petrol (2:8) as eluant. The desired product (260) was isolated as a pale yellow 
foam (53mg, 31%). Previously characterised.
Preparation o fN a -(2-adamantyloxycarbonyl)-a-methyl-R~trypophanyl-(E)~ 
(2S,3R)-2,3-methanophenylalanine methyl ester (262)
To a solution of 2-Adoc-R-a-Me-Trp-OH (206) (162mg, 0.41mmol) in dry THF 
(10cm3) was added successively NMM (45pl, 0.4lmmol) and then /so-butyl 
chloroformate (54pl, 0.42mmol) with stirring at 0°C. After 30min a solution of (2S,3R) 
VEPhe-OMe (259) (52mg, 0.27mmol) in THF (5cm3) was added. After stirring for 1 
day the reaction was worked up in the usual manner and the residue was purified by 
column chromatography on silica by using ethyl acetate-petrol (2:8). The title 
compound (262) was isolated as a pale yellow foam (74mg, 32%); [a]22D +68° (c 2.92 
in CHC13); umax (CHCI3) 3390 (amide NH), 1717 (C02Me), 1686 (CONH), 1492 (Ar 
C=C); 5h (CDCI3, ) 1.13-2.01 (18H, m, adamantyl, R-a-Me and 2'B-H.2), 2.18 (1H, 
dd, J2y  5.7, J2'At3 8 .6 , 2'A-H.2), 2.81 (1H, dd, JX2'A 9.7, / 3>2'B 8 .6 , 3-H.2), 3.32 (3H, s, 
C 0 2Me), 3.41 (1H, d, / gem 14.8, 3-H.l), 3.61 (1H, d, / gem 14.8, 3-H.l), 4.85 (1H, br s, 
adamantyl 2-H), 5.24 (1H, br s, 2-NH.l), 7.08-7.66 (11H, m, Ph and indole Ar,
2-NH.2), 8.32 (1H, br s, indole NH); 6C (CDC13) 15.05 (R-a-Me), 20.40 (C-2’.2), 24.10 
(Ad), 24.78 (Ad), 25.43 (Ad), 26.89 (Ad), 27.12 (Ad), 29.68 (Ad), 31.49 (C-3.1), 31.75 
(Ad), 32.14 (Ad), 33.60 (Ad), 34.96 (C-3.2), 36.29 (Ad), 37.30 (Ad), 49.30 (C-2.2), 
51.86 (OMe), 60.75 (C-2.1), 109.99 (Ar), 111.19 (Ar), 118.94 (Ar), 119.72 (Ar), 122.05 
(Ar), 124.03 (Ar), 126.92 (Ar), 127.89 (Ar), 128.41 (Ar), 129.32 (Ar), 135.35 (Ar),
135.96 (Ar), 155.08 (C=0), 169.99 (OC=0), 175.34 (C02Me); m/z (+FAB) 570 
(MH+, 52%), 379 (12), 225 (36), 135 (100).
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Hydrolysis o f the (Z)- dipeptide ester (260)
Method 1.
To a solution of the dipeptide (260) (26mg, 0.046mmol) in THF (2cm3) was added
0.1M lithium hydroxide solution (aq) (0.5cm3,0.05mmol) with stirring at RT. After 2h 
no change had been observed and so the solution was refluxed for a further 3h the 
reaction was then worked up by washing with 0.1M hydrochloric acid (5cm3) and 
extracted into ethyl acetate (2x5cm3). The combined organic extracts were dried over 
anhydrous sodium sulphate and reduced in vacuo. No dipeptide acid was isolated, only 
starting material (260) was recovered (22mg, 85%).
Method 2.
To a solution of the dipeptide ester (260) (58mg, 0. lmmol) in ethanol (2cm3) was 
added 0.1M sodium hydroxide solution (aq) (1.1cm3, 0.1 lmmol) with stirring at RT. 
After lh no change had been observed. The solution was refluxed for 2h when no 
starting material was detected by tic. The reaction was worked up by washing with
0.1M hydrochloric acid (10cm3) and extracted into ethyl acetate (2x10cm3). The 
combined organic extracts were dried over anhydrous sodium sulphate, and reduced in 
vacuo. This generated the desired carboxylic acid (266) (50 mg, 88%) as a colourless 
oil (Rf = 0.49 methanol-DCM (1:9)). The product was further purified via 
reverse-phase column chromatography using methanol-water (3:1) as eluant. This 
yielded a white foam. [a]22D +23° (c 0.77 in CHC13); umax 3405 (NH), 1695 (C02H, 
CONH), 1498 (ArC=C), 1216 (C-N); 8H (CDC13) 1.26 (3H, s, R-a-Me), 1.38-1.93 
(15H, m, adamantyl and 2'B-H.2), 2.20 (1H, dd, J2'T 6 , h ’k t  9, 2'A-H.2), 3.03 (1H, t, 
^3,2'a 9, /3,2'B 9, 3-H.2), 3.21 (2H, s, 3-H.l), 4.71 (1H, s, C 02H), 5.12 (1H, s, 
adamantyl 2-H), 6.22 (1H, s, 2-NH.l), 6.88-7.50 (11H, m, Ph and indole Ar and
2-NH.2), 8.56 (1H, s, indole NH); 5C (CDC13) 21.60 (C-2\2), 22.90 (Ad), 26.82 (Ad),
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27.05 (Ad), 31.62 (C-3.1), 31.88 (Ad), 32.63 (Ad), 32.95 (C-3.2), 36.20 (Ad), 37.23 
(Ad), 60.62 (C-2.2), 108.92 (Ar), 111.35 (Ar), 118.87 (Ar), 119.72 (Ar), 122.02 (Ar), 
124.65 (Ar), 127.40 (Ar), 128.15 (Ar), 128.38 (Ar), 128.60 (Ar), 133.76 (Ar), 136.03 
(Ar), 155.95 (C=0), 173.24 (0C=0), 175.51 (C02Me); mJz 556 (M+, 85%), 512 (3), 
392 (8), 130(100).
Attempted hydrolysis o f the (Z)-imine ether (237) to give the cyclopropyldipeptide 
(268)
Method 1.
To the neat imine ether (237) (lOOmg, 0.32mmol) was added 0.25M hydrochloric acid 
(2.6cm3, 0.64mmol) with stirring at room temperature. After 1 day, ether (3cm3) was 
added and the solution was stirred for a further 2 hours. Tic indicated that all the 
starting material had been converted into two products, both more polar than the 
starting material, one of which was baseline (ethyl acetate-petrol(l:l)). The reaction 
was worked up by washing with water (5cm3) and extracting into DCM (3x5cm3). The 
combined organic extracts were dried over anhydrous sodium sulphate and reduced in 
vacuo to give a colourless oil (70mg, 80%) corresponding to the deacylated 
cyclopropane (251)(previously characterised). Reverse-phase tic on the remaining 
aqueous phase indicated an unseparable mixture of ninhydrin active components.
Method 2.
To a solution of the imine ether (237) (23mg, 0.07mmol) in THF (3cm3) was added a 
33% w/w aqueous ammonia solution (43jil, 0.7mmol) with stirring at room 
temperature. The reaction was monitored by tic. After two days no baseline material 
was evident by tic (ethyl acetate-petrol (1:1)). The solution was then worked up by
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neutralising with 0.1M hydrochloric acid and extracting into DCM (3x5cm3). The 
combined organic extracts were dried over anhydrous sodium sulphate to give an oil 
(20mg,10%). NMR indicated a 10:1 mix of deacylated cyclopropane (251) to 
starting material (237).
Preparation o f the dipeptide (Z)-(2S,3S)-2,3-methanophenylalanyl-S-valine methyl 
ester (268)
To a solution of the (Z)-imine ether (251) (205mg, 0.75mmol) in acetonitrile (30cm3) 
was added 0.1M hydrochloric acid (30cm3, 3.0mmol) with stirring at room 
temperature. After stirring for 21h the solution was neutralised with sodium 
bicarbonate and extracted with DCM (3x20cm3). The combined organic extracts were 
dried over anhydrous sodium sulphate and reduced in vacuo. The residue was purified 
by flash chromtography using ethyl acetate-petrol (3:7) as eluant to yield the desired 
compound (268) as a colourless oil (178mg, 82%). (Rf=0.28, ethyl acetate-petrol (3:7)); 
[a]22D -149° (c 3.13 in CHC13) umax (CHC13) 3377 br (amide NH and NH2), 1739 
(C02Me), 1665 (CONH), 1215 (C-N); 5H (CDC13) 0.94 (3H, d, /7 .0 , i-Pr Me), 0.98 
(3H, d, J  7.0, i-Pr Me), 1.26 (1H, dd, / 2y  5.0, / 2'B>3 7.4, 2'B-H.l), 1.58 (2H, s, NH2),
1.98 (1H, dd, J2y  5.0, / 2'Aj3 9.5, 2'A-H.l), 2.21 (1H, m, 3-H.2), 2.94 (1H, dd, / 3>2'B
7.4, / 3i2'A 9.5, 3-H.l), 3.75 (3H, s, MeO), 4.53 (1H, dd, / 2<2N 5.1, J2t3 9.2, 2-H.2), 
7.18-7.38 (5H, m, Ph), 8.30 (1H, d, / 2N>2 9.2, 2-NH.2); 5C (CDC13) 17.87 (C-4.2), 19.04 
(C-4.2), 22.51 (C-2M), 31.23 (C-3.2), 32.56 (C-3.1), 40.28 (C-2.1), 51.99 (C-2.2),
57.47 (MeO), 127.05 (Ph), 128.60 (Ph), 129.03 (Ph), 135.58 (Ph), 172.68 (CONH),
174.47 (C02Me); m/z (+FAB) 291 (MH+, 100%), 258 (3), 231 (10), 132 (70).
174
Preparation o f the dipeptide (E)-(2S,3S)-2,3-methanophenylalanyl-S-valine methyl 
ester (273)
To a solution of the (E)-imine ether (257) (105mg, 0.39mmol) in acetonitrile (15cm3) 
was added 0.1M hydrochloric acid (15cm3,1.5mmol) with stirring at room 
temperature. After stirring for 15h the solution was neutralised with sodium 
bicarbonate and extracted with DCM (3x30cm3). The combined organic extracts wre 
dried over anhydrous sodium sulphate and reduced in vacuo. The residue was purified 
by flash chromatography using ethyl acetate-petrol (4:6) as eluant. This yielded the 
desired compound (273) as a colourless oil (89mg, 79%). (Rf=0.2 ethyl acetate-petrol 
(1:1)); (Found C, 66.00; H, 7.73; N, 9.30. C ^ H ^ N ^  requires C, 66.21; H, 7.59; N, 
9.66); omax (CHC13) 3370 br (amide NH and NH2), 1736 (C02Me), 1665 (CONH); 8H 
(CDCI3), 0.65 (3H, d, J  6 .8 , /-Pr Me), 0.75 (3H, d, J  6 .8 , /-Pr Me), 1.31 (1H, dd, JTT 
5.1, / 2>B>3 9.5, 2'B-H.l), 1.96 (1H, m, 3-H.2), 2.17 (3H, m, NH2 and 2'A-H.l), 2.55 
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18.62 (C-4.2), 21.34 (C-2’.l), 30.91 (C-3.2), 31.10 (C-3.1), 36.46 (C-2.1), 51.93 
(C-2.2), 56.99 (MeO), 126.59 (Ph), 127.83 (Ph), 128.96 (Ph), 135.97 (Ph), 171.20 
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APPENDIX
2 0 0
X-ray crystallographic data for 254
TsNH **C 0 2Me>
Ph
254
Compound 254 was crystallised from petrol-ethyl acetate.
A crystal of approximate dimensions 0.3 x 0.4 x 0.4 mm was used for data collection.
Crystal data: C18H190 4NS, M  = 339.4 monoclinic, a = 10.335(1), b = 9.066(2), c = 
10.371(2)A, |3 =109.94(1), 17 = 913.5 A3, space group P2h Z = 2  , Dc = 1.23 
gem'3, |x(Mo-A'a ) = 1.50 cm '1, F(000) = 358. Data were measured at room 
temperature on a Hilger and Watts Y290 four-circle diffractometer in the range
o
2<0<22 . 1171 reflections were collected of which 616 were unique with I > 3 g ( I ) .  Data 
were corrected for Lorentz and polarization effects and the structure was solved by 
Direct methods and refined using the SHELX [1,2] suite of programs. In the final least 
squares cycles the sulphur and oxygen atoms along with carbons 11-12 were allowed to 
vibrate anisotropically. All other atoms were treated isotropically. Hydrogen atoms 
were included at calculated positions. Final residuals after 10 cycles of least squares 
were R = R W = 0.0876, for unit weights. Max. final shift/esd was 0.010. The max. and 
min. residual densities were 0.13 and -0.14 eA'3 respectively. Final fractional atomic 
coordinates and anisotropic thermal parameters, bond distances and angles are given in 
Tables 16-17, 18 and 19-22 respectively. Tables of anisotropic temperature factors and 
hydrogen atom positions are available as supplementary data. The asymmetric unit is 
shown in Fig. 10, along with the labelling scheme used.
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1. Sheldrick G.M., SHELX86, a computer program for crystal structure determination, 
University of Gottingen, 1986.
2. Sheldrick G.M., SHELX76, a computer program for crystal structure determination, 


















Fig 10. X-ray structure of (Z)-(2S,3S)-N-(tosylamino)-2,3-methanophenylalanine 
methyl ester (254).
Table 16 Fractional atomic coordinates and thermal 
parameters for 254 (A)
Atom X y z Uiso or Ueq
SI -0.7766 6) -0.4666 -0.7164 6) 0.062 4)
01 -0.8645 16) -0.5514 (39) -0.6680 17) 0.150 22)
02 -0.7528 18) -0.3202 (22) -0.6823 17) 0.077 14)
03 -0.6113 16) -0.8810 (30) -0.4784 18) 0.079 14)
04 -0.6102 15) -0.6406(25) -0.4251 16) 0.060 11)
Cll -0.6094 23) -0.7524 (40) -0.5021 26) 0.053 17)
C12 -0.6181 32) -0.6592 (55) -0.2898 23) 0.154 36)
N1 -0.6269 16) -0.5506 (24) -0.6701 16) 0.039 4)
Cl -0.6057 20) -0.6950 (28) -0.6435 23) 0.047 6)
C2 -0.4982 24) -0.7771 (36) -0.6834 24) 0.069 8)
C3 -0.6518 23) -0.8064 (35) -0.7543 24) 0.070 7)
C4 -0.8432 20) -0 .4800 (36) -0.8965 20) 0.057 6)
C5 -0.7832 22) -0.4023 (34) -0.9766 22) 0.059 7)
C6 -0.8377 23) -0.4021 (38) -1.1158 23) 0.071 7)
Cl -0.9453 21) -0.5054 (33) -1.1781 22) 0.058 7)
C8 -1.0056 26) -0.5804(35) -1.1063 24) 0.074 8)
C9 -0.9544 21) -0.5739 (31) -0.9603 21) 0.054 6)
CIO -1.0024 29) -0.5144 (43) -1.3379 25) 0.102 10)
C13 -0.4173 21) -0 . 6804 (28) -0.7536 23) 0.048 6)
C14 -0.2847 22) -0.6462(34) -0.6702 24) 0.065 7)
C15 -0.2019 26) -0.5612 (33) -0.7183 24) 0.066 7)
Cl 6 -0.2552 27) -0.5045 (38) -0.8509 26) 0.091 9)
C17 -0.3835 25) -0.5382 (37) -0.9297 27) 0.075 8)
C18 -0.4680 25) -0.6299(35) -0.8819 24) 0.070 7)
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Table 17 Fractional atomic coordinates for the hydrogen 
atoms
Atom X y z
Hll -0.6227 -0.6786 -0.5474
H21 -0.4081 -0.8445 -0.6374
H31 -0.6920 -0.9100 -0.7330
H32 -0.7067 -0.7742 -0.8591
H51 -0.6960 -0.3316 -0.9283
H61 -0.7956 -0.3353 -1.1782
H81 -1.0849 -0.6596 -1.1564
H91 -1.0049 -0.6332 -0.9006
H101 -0.9454 -0.4397 -1.3797
HI 02 -1.1100 -0.4845 -1.3755
H103 -0.9907 -0.6258 -1.3692
H121 -0.6177 -0.5517 -0.2448
H122 -0.5307 -0.7219 -0.2265
H123 -0.7119 -0.7164 -0.2969
H141 -0.2430 -0.6905 -0.5676
H151 -0.0990 -0.5323 -0.6531
HI 61 -0.1923 -0.4376 -0.8924
H171 -0.4227 -0.4975 -1.0338
H181 -0.5732 -0.6509 -0.9459
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Table 18 Anisotropic thermal parameters (A)
Atom Ull U22 U33 U23 U13 U12
SI 0.052 (3) 0.085 (7) 0.051 (3) 0.009 (5) 0.019 (3) 0.039 (5)
01 0.041(10) 0.340 (45) 0.069 (12) 0. 062 (18) 0.022 (10) 0.038(16)
02 0.115(16) 0.050 (14) 0.067 (12) 0.013 (13) 0.028 (11) 0.055 (11)
03 0.059(12) 0.078(16) 0.101 (14) 0.027 (15) 0.030 (10) 0.005 (12)
04 0.081 (12) 0.054 (13) 0 .046 (9) 0.013 (12) 0.021 (8) 0 . 009 (10)
Cll 0.062(16) 0.036 (17) 0.062 (17) 0.022 (17) 0.025 (14) -0.014 (15)
C12 0.135(29) 0.299 (62) 0.028 (16) 0.035 (26) 0.028 (16) -0.031 (37)
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Table 19 Bond lengths (A)
SI -01 1.407 (24) SI -02 1.374 (21)
SI -N1 1.642 (17) SI -C4 1.761 (20)
03 -Cll 1.19(3) 04 -Cll 1.29 (3)
04 -C12 1.44 (3) N1 -Cl 1.34 (3)
Cl -C2 1.51 (3) Cl -C3 1.48 (3)
Cl -Cll 1.57 (3) C2 -C3 1.53 (3)
C2 -C13 1.55 (3) C4 -C5 1.39 (3)
C4 -C9 1.40 (3) C5 -C6 1.36(3)
C6 -Cl 1.43 (3) Cl -C8 1.31 (3)
C7 -CIO 1.56 (3) C8 -C9 1.42 (3)
C13 -C14 1.38 (3) C13 -Cl 8 1.33 (3)
C14 -C15 1.37 (3) C15 -Cl 6 1.39 (3)
Cl 6 -C17 1.34 (3) C17 -Cl 8 1.41(3)
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Table 20 Bond angles (°)
02 -SI -01 121 1)
N1 -SI -02 108 1)
C4 -SI -02 108 1)
C12 -04 -Cll 122 3)
C2 -Cl -N1 121 2)
C3 -Cl -C2 61 2)
Cll -Cl -C2 110 2)
C3 -C2 -Cl 58 1)
C13 -C2 -C3 121 2)
C5 -C4 -SI 120 2)
C9 -C4 -C5 119 2)
C7 -C6 -C5 117 3)
CIO -Cl -C6 118 2)
C9 -C8 -Cl 120 2)
04 -Cll -03 129 3)
Cl -Cll -04 109 2)
C18 -C13 -C2 125 2)
C15 -C14 -C13 120 2)
C17 -Cl 6 -C15 120 3)
C17 -C18 -C13 118 2)
N1 -SI -01 107 1)
C4 -SI -01 106 1)
C4 -SI -N1 105 1)
Cl -N1 -SI 126 2)
C3 -Cl -N1 121 2)
Cll -Cl -N1 117 2)
Cll -Cl -C3 113 2)
C13 -C2 -Cl 114 2)
C2 -C3 -Cl 60 1)
C9 -C4 -SI 120 2)
C6 -C5 -C4 122 2)
C8 -Cl -C6 122 2)
CIO -Cl -C8 120 2)
C8 -C9 -C4 118 2)
Cl -Cll -03 122 3)
C14 -C13 -C2 114 2)
C18 -C13 -C14 121 2)
Cl 6 -C15 -C14 119 3)
C18 -C17 -Cl 6 122 3)
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Table 21 Intermolecular distances (A)
01 ...H151 2.49 1 1.0
o•o 0 .
01 ...H151 2.49 1 1.0 0.0 0 .
02 . . .H81 2.41 2 -2.0 -1.0 -2.
02 ...H141 2.86 2 -1.0 -1.0 - 1 .
03 . . . N1 2.87 2 -1.0 0.0 - 1 .
03 . . . H102 2.91 2 -2.0 0 . 0 - 2 .
04 ...H21 2.75 2 -1.0 -1.0 - 1 .
C2 ...H121 2.97 2 -1.0 0 . 0 - 1 .
H2 1 ...C12 2.99 2 -1.0 0 . 0 - 1 .
C6 ...H91 2.97 2 -2.0 -1.0 - 2 .
H61 ...014 2.64 2 -1.0 -1.0 - 2 .













Table 22 Intramolecular distances (A)
SI .. .Cl 2.66 SI ...Hll 2.
SI . . C5 2.74 SI ...H51 2.
SI .. . C9 2.75 SI ...H91 2.
01 .. .02 2.42 01 . . . N1 2.
01 .. .Cl 2.91 01 ...Hll 2.
01 .. . C4 2.54 01 . . .C9 2.
01 .. . H91 2.47 02 . . . N1 2.
02 .. . C4 2.55 02 ...H51 2.
03 .. .04 2.25 03 . . .Cl 2.
03 .. .Hll 1.96 03 . . .C2 2.
03 .. . C3 2.83 03 ...H31 2.
03 .. . C12 2.82 03 ...H122 2.
03 ...H123 2.86 04 . . . N1 2.
04 . .Cl 2.33 04 ...H121 2.
04 ...H122 2.08 04 ...H123 2.
N1 . .Hll 1.71 N1 . . .C2 2.
N1 .. . C3 2.46 N1 ...H32 2.
N1 . . C4 2.71 N1 ...Cll 2.
N1 . . C13 2.85 Cl ...H21 2.
Cl .. . H31 2.21 Cl ...H32 2.
Cl .. . C13 2.57 Hll . . .C2 2.
Hll .. . C3 2.37 Hll ...C12 2.
C2 .. . H31 2.24 C2 ...H32 2.
C2 .. .Cll 2.53 C2 ...C14 2.
C2 ...H141 2.62 C2 ...C18 2.




























H21 . . .Cll 3.00 H21 ...C13 1.
H21 . . . C14 2.30 C3 ...Cll 2.
C3 . . . C13 2.68 C3 ...H181 2.
H31 . . .Cll 2.67 H32 . . . C4 2.
H32 . ..C13 2.94 H32 ...Cl 8 2.
C4 . ..H51 2.14 C4 . . .C6 2 .
C4 . . .Cl 2.76 C4 . . .C8 2 .
C4 ...H91 2.16 C5 ...H61 2 .
C5 . . . C7 2.38 C5 . . . C8 2 .
C5 . . .C9 2.40 H51 . . .C6 2 .
C6 . . . C8 2.40 C6 . . . C9 2 .
C6 . . .CIO 2.56 C6 . ..H101 2 .
H61 . . .Cl 2.19 H61 ...CIO 2 .
Cl . . . H81 2.07 Cl . . . C9 2 .
Cl ...HI 01 2.17 Cl ...H102 2 .
Cl . . .H103 2.17 C8 ...H91 2 .
C8 ...CIO 2.49 C8 ...HI02 2 .
C8 . . .HI03 2.81 H81 . . .C9 2 .
H81 ...CIO 2.66 Cll ...C12 2 .
Cll . . .H122 2.71 Cll ...H123 2 .
C13 ...H141 2.15 C13 ...C15 2 .
C13 . . . Cl 6 2.74 C13 ...C17 2 .
C13 ...H181 2.11 C14 ...H151 2 .
C14 ...Cl 6 2.38 C14 ...C17 2 .
C14 ...Cl 8 2.36 HI 41 ...C15 2 .
C15 ...HI 61 2.15 C15 ...C17 2 .
C15 . ..C18 2.77 H151 ...Cl 6 2 .






























H161...C17 2.09 C17 ...H181 2.17
H171...C18 2.15
